WO2016100568A1 - Fungal genome modification systems and methods of use - Google Patents

Abstract

Compositions and methods are provided for genome modification at a target site in the genome of a filamentous fungal cell. The methods and compositions are drawn to a guide polynucleotide/ Cas endonuclease system for promoting modification of the DNA sequence at a target site in a filamentous fungal host cell genome.

Description

FUNGAL GENOME MODIFICATION SYSTEMS AND METHODS OF USE

CROSS-REFERENCE TO RELATED APPLICATIONS [01] The present application claims priority to PCT Patent Appln. Ser. Nos.

PCT/CN2014/093918, PCT/CN2014/093916, and PCT/CN2014/093914, all filed

December 16, 2014, which are hereby incorporated by reference in their entireties.

SEQUENCE LISTING [02] The sequence listing submitted via EFS, in compliance with 37 C.F.R. §1 .52(e), is incorporated herein by reference. The sequence listing text file submitted via EFS contains the file "40532-WO-PCT-6_2015-868_Final_ST25.txt" created on December 13, 2015, which is 151 kilobytes in size.

BACKGROUND

[03] Bacteria and archaea have evolved adaptive immune defenses termed clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) systems that can introduce double strand beaks in DNA in a sequence-specific manner. Cas systems perform their functions through the activity of a ribonucleoprotein complex that includes short RNA sequences (tracrRNA and crRNA) and an RNA dependent endonuclease (Cas endonuclease) that targets a specific DNA sequence (through homology to a portion of the crRNA, called the variable targeting domain) and generates double strand breaks in the target. CRISPR loci were first recognized in E. coli (Ishino et al. (1987) J. Bacterial. 169:5429-5433; Nakata et al. (1989) J. Bacterial. 171 :3553-3556), with similar interspersed short sequence repeats being subsequently identified in a number of bacterial species, including but not limited to Haloferax mediterranei, Streptococcus pyogenes, Anabaena, and Mycobacterium tuberculosis (Groenen et al. (1993) Mol. Microbiol. 10:1057-1065; Hoe et al. (1999) Emerg. Infect. Dis. 5:254-263; Masepohl et al. (1996) Biochim. Biophys. Acta 1307:26-30; Mojica et al. (1995) Mol. Microbiol. 17:85-93).

[04] It is well known that inducing cleavage at a specific target site in genomic DNA can be used to introduce modifications at or near that site. For example, homologous recombination for gene targeting has been shown to be enhanced when the targeted DNA site contains a double-strand break (see, e.g., Rudin et al., Genetics 122:519-534; Smih et al., Nucl. Acids Res. 23:5012-5019). Given the site-specific nature of Cas systems, genome modification/engineering technologies based on these systems have been described, including in mammalian cells (see, e.g., Hsu et al.; Cell vol. 157, p1262-1278, 5 June 2014 entitled "Development and Applications of CRISPR-Cas9 for Genome Engineering"). The power of the Cas-based genome engineering comes from the ability to target virtually any specific location within a complex genome by designing a recombinant crRNA (or equivalently functional polynucleotide) in which the DNA- targeting region (variable targeting domain) of the crRNA is homologous to the desired target site in the genome and combining it with a Cas endonuclease (through any convenient means) into a functional complex in a host cell.

[05] Although Cas-based genome engineering technologies have been applied to a number of different host cell types, the efficient use of such systems in fungal cells has proven to be difficult. Thus, there still remains a need for developing efficient and effective Cas-based genome engineering methods and compositions for

modifying/altering a genomic target site in a fungal cell.

BRIEF SUMMARY

[06] Compositions and methods are provided that relate to employing a guide

RNA/Cas endonuclease system for modifying the DNA sequence at a target site in the genome of a fungal cell, e.g., a filamentous fungal cell.

[07] Aspects of the present disclosure are drawn to methods for modifying the DNA sequence at a target site in the genome of a fungal cell. In some embodiments, the method includes: a) introducing into a population of fungal cells a Cas endonuclease and a guide RNA, wherein the Cas endonuclease and guide RNA are capable of forming a complex that enables the Cas endonuclease to introduce a double-strand break at a target site in the genome of the fungal cells; and b) identifying at least one fungal cell from the population that has a modification of the DNA sequence at the target site, where the Cas endonuclease, the guide RNA, or both are introduced transiently into the population of fungal cells.

[08] In one aspect, the present disclosure are drawn to a method for modifying the DNA sequence at a target site in the genome of a fungal cell, the method including: a) introducing into a fungal cell a Cas endonuclease and a guide RNA, wherein the Cas endonuclease and guide RNA are capable of forming a complex that enables the Cas endonuclease to introduce a double-strand break at a target site in the genome of the fungal cell; and b) identifying if a modification of the DNA sequence at the target site has occurred in the fungal cell, where the Cas endonuclease, the guide RNA, or both are introduced transiently into the fungal cell.

[09] In another aspect, the present disclosure is drawn to methods for modifying the DNA sequence at a target site in the genome of a fungal cell. In some embodiments, the method includes: a) introducing into a population of fungal cells a Cas

endonuclease and a guide RNA, wherein the Cas endonuclease and guide RNA are capable of forming a complex that enables the Cas endonuclease to introduce a double-strand break at a target site in the genome of the fungal cells; and b) identifying at least one fungal cell from the population that has a modification of the DNA sequence at the target site, where both the Cas endonuclease and the guide RNA are introduced non-transiently into the population of fungal cells. [010] In yet another aspect, the present disclosure are drawn to a method for modifying the DNA sequence at a target site in the genome of a fungal cell, the method including: a) introducing into a fungal cell a Cas endonuclease and a guide RNA, wherein the Cas endonuclease and guide RNA are capable of forming a complex that enables the Cas endonuclease to introduce a double-strand break at a target site in the genome of the fungal cell; and b) identifying if a modification of the DNA sequence at the target site has occurred in the fungal cell, where both the Cas endonuclease and the guide RNA are introduced non-transiently into the fungal cell.

[011] In certain embodiments of the methods described herein, the modification of the DNA sequence at said target site is selected from the group consisting of a deletion of one or more nucleotides, an insertion of one or more nucleotides, a substitution of one or more nucleotides, and any combination thereof.

[012] In certain embodiments, the identifying step comprises culturing the population of fungal cells or the fungal cell from step (a) under conditions to select for or screen for the modification of the DNA sequence at the target site. In certain embodiments, the identifying step comprises culturing the population of fungal cells or the fungal cell from step (a) under conditions to screen for unstable transformants [013] Several different types of CRISPR-Cas systems have been described and can be classified as Type I, Type II, and Type III CRISPR-Cas systems (see, e.g., the description in Liu and Fan, CRISPR-Cas system: a powerful tool for genome editing. Plant Mol Biol (2014) 85:209-218). In certain embodiments, the Cas endonuclease or variant thereof is a Cas9 endonuclease of the Type II CRISPR-Cas system. The Cas9 endonuclease may be any convenient Cas9 endonuclease, including but not limited to Cas9 endonucleases, and functional fragments thereof, from the following bacterial species: Streptococcus sp. (e.g., S. pyogenes, S. mutans, and S. thermophilus), Campylobacter sp. (e.g., C. jejuni), Neisseria sp. (e.g., N. meningitides), Francisella sp. (e.g., F. novicida), and Pasteurella sp. (e.g., P. multocida). Numerous other species of Cas9 can be used. For example, functional Cas9 endonucleases or variants thereof containing an amino acid sequence that has at least 70% identity to any one of SEQ ID NOs:1 to 7 may be employed, e.g., at least 80% identity, at least 90% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, and including up to 100% identity to any one of SEQ ID NOs:1 to 7. In other embodiments, the Cas endonuclease or variant thereof is a Cpf 1 endonuclease of the Type II CRISPR-Cas system. Cpf1 mediates robust DNA interference with features distinct from Cas9. Cpf1 lacks tracrRNA and utilizes a T-rich protospacer-adjacent motif. It cleaves DNA via a staggered DNA double-stranded break. See, e.g., Zetsche etal., Cell (2015) 163:759-771 .

[014] Introducing the Cas endonuclease or the guide RNA into the population of fungal cells can be achieved using any convenient method, including: transfection,

transduction, transformation, electroporation, particle bombardment (biolistic particle delivery), and cell fusion techniques. [015] In certain embodiments, introducing the Cas endonuclease and/or the guide RNA into the fungal cells includes introducing one or more DNA constructs comprising expression cassettes for the Cas endonuclease, the guide RNA, or both into the fungal cells. The one or more DNA constructs, once in the fungal cells, express the Cas endonuclease and/or the guide RNA. In certain embodiments, the DNA construct is a linear DNA construct. In certain embodiments, the DNA construct is a circular DNA construct. In certain embodiments, the DNA construct is a recombinant DNA construct.

[016] In certain embodiments, the introducing step includes directly introducing a Cas endonuclease polypeptide, a guide RNA, or both into the fungal cells. Any combination of direct introduction and using DNA constructs can be employed (e.g., introducing a DNA construct with an expression cassette for a Cas endonuclease into the fungal cell and directly introducing a guide RNA into the cell, either simultaneously or sequentially as desired). [017] In certain embodiments of the methods described herein, the Cas expression cassette in the DNA construct includes a Cas endonuclease encoding gene that is optimized for expression in the fungal cell. For example, a Cas endonuclease encoding gene that is optimized for expression in filamentous fungal cells includes a sequence that has at least 70% sequence identity to SEQ ID NO:8 (encoding Cas9 from S.

pyogenes; SEQ ID NO: 1 ), e.g., at least 80% identity, at least 90% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, and including up to 100% identity to SEQ ID NO:8.

[018] In some instances, the Cas endonuclease is operably linked to one or more nuclear targeting signal (also referred to as a nuclear localization signal/sequence; NLS). SEQ ID NO:9 and SEQ ID NO:10 provide an example of a filamentous fungal cell optimized Cas9 gene with NLS sequences at the N- and C-termini and the encoded amino acid sequence, respectively. Many different NLSs are known in eukaryotes. They include monopartite, bipartite and tripartite types. Any convenient NLS can be used, the monopartite type being somewhat more convenient with examples including the SV40 NLS, a NLS derived from the T. reesei blr2 (blue light regulator 2) gene, or a combination of both. In some embodiments, the DNA construct is a recombinant one and comprises a promoter operably linked to a filamentous fungal cell optimized polynucleotide sequence encoding a Cas9 endonuclease or variant thereof.

[019] In certain embodiments of the methods described herein, a DNA construct or an expression cassette comprising a guide RNA-encoding sequence and capable of expressing the guide RNA, is introduced into the population of fungal cells or the fungal cell. In some embodiments, the DNA construct or the expression cassette comprises a RNA polymerase III dependent promoter functional in a Euascomycete or

Pezizomycete, wherein the promoter is operably linked to the guide RNA-encoding sequence. In some embodiments, the promoter is derived from a Trichoderma U6 snRNA gene. In certain embodiments, the promoter comprises a nucleotide sequence with at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 11 or 12. In specific embodiments, the promoter comprises the sequence of SEQ ID NO: 11 or 12. In some embodiments, the DNA construct or the expression cassette for the guide RNA comprises a guide RNA-encoding DNA with an intron sequence from a Trichoderma U6 snRNA gene. In some embodiments, the intron sequence derived from Trichoderma U6 snRNA gene comprises a nucleotide sequence with at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 90. In specific embodiments, the intron sequence derived from Trichoderma U6 snRNA gene comprises the sequence of SEQ ID NO: 90.

[020] In certain embodiments, the modification of the DNA sequence at the target site in the genome of the fungal cells or the fungal cell is caused by non-homologous end joining (NHEJ), either without the presence of a donor DNA or in the presence of a donor DNA that is also introduced into the fungal cells or the fungal cell. In certain other embodiments, the modification of the DNA sequence at the target site is caused by homologous recombination, optionally through the presence of a donor DNA that is also introduced into the fungal cell(s). In some embodiments, the modification (e.g., a deletion of one or more nucleotides, an insertion of one or more nucleotides, insertion of an expression cassette encoding a protein of interest, or a substitution of one or more nucleotides) is originally present in the donor DNA. In some embodiments, the donor DNA has a sequence homologous to a region of the chromosomal DNA on each side of, or at or near, the target site of the Cas/guide RNA complex over at least . In some other embodiments, the donor DNA does not have a sequence homologous to a region of the chromosomal DNA on each side of, or at or near, the target site of the Cas/guide RNA complex. In certain embodiments, the donor DNA comprises an expression cassette encoding a protein of interest. In certain embodiments, the protein of interest encoded by the expression cassette is an enzyme. In particular

embodiments, the protein of interest is a hemicellulase, a peroxidase, a protease, a cellulase, a xylanase, a lipase, a phospholipase, an esterase, a cutinase, a pectinase, a keratinase, a reductase, an oxidase, a phenol oxidase, a lipoxygenase, a ligninase, a pullulanase, a tannase, a pentosanase, a mannanase, a beta-glucanase, an

arabinosidase, a hyaluronidase, a chondroitinase, a laccase, an amylase, a

glucoamylase, a variant thereof, a functional fragment thereof, or a hybrid or mixture of two or more thereof. In yet other particular embodiments, the protein of interest is a peptide hormone, a growth factor, a clotting factor, a chemokine, a cytokine, a lymphokine, an antibody, a receptor, an adhesion molecule, a microbial antigen, a variant thereof, a functional fragment thereof, or a hybrid or mixture of two or more thereof.

[021] In certain embodiments where homologous recombination between the donor DNA and the genome of the fungal cell(s) is desired, the NHEJ pathway in the fungal cell(s) is non-functional (inactivated) or reduced, e.g., where one or more components of the NHEJ pathway are inactivated, nonfunctional, or have reduced activity (e.g., ku80, ku70, rad50, mre11 , xrs2, Iig4, xrs, or combinations thereof). For example, the fungal cell can have an inactivated/reduced activity form of ku80. In certain other embodiments, the NHEJ pathway in the fungal cell(s) is functional. [022] Fungal cells that find use in the subject methods can be filamentous fungal cell species. In certain embodiments, the fungal cell is a Eumycotina or Pezizomycotina fungal cell. In some embodiments, the fungal cell is selected from Trichoderma, Penicillium, Aspergillus, Humicola, Chrysosporium, Fusarium, Neurospora,

Myceliophthora, Thermomyces, Hypocrea, and Emericella. The filamentous fungi Trichoderma reesei, P. chrysogenum, M. thermophila, Thermomyces lanuginosus, A. oryzae and A. niger are of particular interest. Other fungal cells, including species of yeast, can also be employed.

[023] The target site selected by a user of the disclosed methods can be located within a region of a gene of interest selected from the group consisting of: an open reading frame, a promoter, a regulatory sequence, a terminator sequence, a regulatory element sequence, a splice site, a coding sequence, a polyubiquitination site, an intron site, and an intron enhancing motif. Examples of genes of interest include genes encoding acetyl esterases, aminopeptidases, amylases, arabinases, arabinofuranosidases, carboxypeptidases, catalases, cellulases, chitinases, cutinase, deoxyribonucleases, epimerases, esterases, a-galactosidases, β-galactosidases, a-glucanases, glucan lysases, endo- β-glucanases, glucoamylases, glucose oxidases, a-glucosidases, β- glucosidases, glucuronidases, hemicellulases, hexose oxidases, hydrolases, invertases, isomerases, laccases, lipases, lyases, mannosidases, oxidases,

oxidoreductases, pectate lyases, pectin acetyl esterases, pectin depolymerases, pectin methyl esterases, pectinolytic enzymes, peroxidases, phenoloxidases, phytases, polygalacturonases, proteases, rhamno-galacturonases, ribonucleases, transferases, transport proteins, transglutaminases, xylanases, hexose oxidases, and combinations thereof. Target genes encoding regulatory proteins such as transcription factors, repressors, proteins that modify other proteins such as kinases, proteins involved in post-translational modification (e.g., glycosylation) can be subjected to Cas mediated editing as well as genes involved in cell signaling, morphology, growth rate, and protein secretion. No limitation in this regard is intended. [024] In some embodiments of the methods, the step of identifying a fungal cell having a genomic modification at the site of interest includes culturing the population of cells from step (a) under conditions to select for or screen for the modification at the target site. Such conditions include antibiotic selection conditions, conditions that select for or screen for auxotrophic cells, and the like. [025] In certain embodiments, the introducing step includes: (i) obtaining a parental fungal cell population that stably expresses the Cas endonuclease, and (ii) transiently introducing the guide RNA into the parental fungal cell population. Conversely, the introducing step can include: (i) obtaining a parental fungal cell population that stably expresses the guide RNA, and (ii) transiently introducing the Cas endonuclease into the parental fungal cell population.

[026] Aspects of the present disclosure are drawn to recombinant fungal cells produced by the methods described above as well as those for use as parental host cells in performing the methods.

[027] Aspects of the present disclosure further include an engineered nucleic acid, e.g., a recombinant DNA construct that can be used in the methods described above or disclosed herein. In one aspect, the engineered nucleic acid encodes a Cas

endonuclease or variant thereof. In some embodiments, the Cas endonuclease or variant thereof encoded by the engineered nucleic acid comprises an amino acid sequence that has at least 70%, 75%, 80%, 85%, 90%, or 95% identity to any one of SEQ ID NOs:1 to 7. In some embodiments, the engineered nucleic acid comprises a polynucleotide sequence that is codon-optimized for expression in filamentous fungi. In some embodiments, the engineered nucleic acid comprises a polynucleotide sequence that is at least 70% 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:8. In a particular embodiment, the nucleic acid comprises the sequence of SEQ ID NO:8. In some embodiments, the engineered nucleic acid comprises a promoter for expression of the Cas endonuclease or variant thereof.

[028] In another aspect, the engineered nucleic acid encodes a guide RNA. In some embodiments, the nucleic acid encoding the guide RNA comprises a RNA polymerase III dependent promoter functional in a filamentous fungal cell, a Euascomycete or a Pezizomycete. In some embodiments, the promoter is derived from a Trichoderma U6 snRNA gene. In particular embodiments, the promoter comprises a nucleotide sequence with at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 1 1 or 12 or a functional fragment thereof. In particular embodiments, the nucleic acid comprises the sequence of SEQ ID NO: 1 1 or 12. In some embodiments, the guide RNA-encoding nucleic acid has a promoter operably linked to at least one heterologous sequence or guide RNA-encoding sequence, where the promoter functions in a filamentous fungal cell as an RNA polymerase III (pol III) dependent promoter to express the heterologous sequence and includes a

polynucleotide sequence that has at least 80% sequence identity to SEQ ID NO:11 or 12 (e.g., 80%, 85%, 90%, 95%, 98%, 99%, 100%, or any value there between) or a functional fragment thereof. In certain embodiments, the heterologous sequence or guide RNA-encoding sequence comprises an intron sequence derived from a

Trichoderma U6 snRNA gene. In particular embodiments, the heterologous sequence or guide RNA-encoding sequence includes an intron that contains a U6 B-Box sequence, e.g., a B-Box sequence having the polynucleotide sequence of

GTTCGTTTC. The intron can have a polynucleotide sequence with at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 90. In particular embodiments, the intron comprises a polynucleotide sequence with at least 80% sequence identity to SEQ ID NO:90. In particular embodiments, the nucleic acid comprises the sequence of SEQ ID NO:90. In some embodiments, the guide RNA- encoding nucleic acid comprises both the RNA polymerase III dependent promoter and the intron sequence derived from Trichoderma U6 snRNA gene as described herein. In some embodiments, the engineered nucleic acid or the recombinant DNA construct further includes a transcriptional terminator sequence downstream of the heterologous sequence, e.g., the sequence set forth in SEQ ID NO:91 or its derivative.

[029] In certain embodiments, the promoter comprised in the Cas endonuclease- encoding engineered nucleic acid and/or the guide RNA-encoding engineered nucleic acid is derived from a filamentous fungal cell. The filamentous fungal cell can be selected from any of a wide variety of filamentous fungal cells, with specific examples including T. reesei and A. niger. In some cases, the promoter is derived from a ribosomal RNA (rRNA) promoter. [030] The recombinant DNA construct operably linked to promoter may encode a functional RNA. In certain aspects, for example, the heterologous sequence encodes a guide RNA polynucleotide, e.g., a guide RNA that includes (i) a first nucleotide sequence domain that is complementary to a polynucleotide sequence in a target DNA (variable targeting domain); and (ii) a second nucleotide sequence domain that interacts with a Cas endonuclease (CER domain).

[031] Aspects of the present disclosure include a vector having the recombinant DNA construct having a promoter operably linked to at least one heterologous sequence as described herein. The vector can further include an expression cassette for a Cas endonuclease.

[032] The present disclosure further provides a filamentous fungal cell containing a recombinant DNA constructs having a promoter operably linked to at least one heterologous sequence as described herein. Methods of expressing a heterologous sequence in a filamentous fungal cell by a) introducing the recombinant DNA construct having a promoter operably linked to at least one heterologous sequence (e.g., as an vector) into a filamentous fungal cell, and b) culturing the filamentous fungal cell of step a) under conditions to allow expression of the heterologous sequence in the

recombinant DNA construct (or vector).

[033] Additional embodiments of the methods and compositions of the present disclosure are shown herein.

BRIEF DESCRIPTION OF THE DRAWINGS

[034] The disclosure can be more fully understood from the following detailed description and the accompanying drawings, which form a part of this application. [035] FIG. 1 depicts the nucleotide sequence of a putative T. reesei U6 gene (SEQ ID NO:22). Elements of interest are indicated, including the TATA box (underlined), the transcriptional start site (downward arrow), the A -box (underlined), the Intron (forward arrow), the B-box (underlined; within the Intron of the gene), the sequences that are identical to the human U6 gene (in bold italics), and the terminator (underlined). [036] FIG. 2 shows a schematic of the pTrex2gHyg-Mo Cas plasmid.

[037] FIG. 3 shows a schematic of the p219M plasmid. [038] FIG. 4 shows a schematic of the T. reesei ad3A gene with PCR primer sites and intronic regions shown.

[039] FIG. 5 shows a schematic of the T. reesei glucoamylase gene (TrGA) with PCR primer and intronic regions shown. [040] FIG. 6 shows a schematic of the pTrex2gHygMoCasgPyr2TS6 plasmid which includes telomere sequences.

[041] FIG. 7. Plasmid map of pET30a-SpyCas9.

[042] FIG. 8A shows a plasmid map for pSM1 guide which is used for flexible cloning of any potential guide RNA variable targeting (VT) domain matching the sequence pattern GGN18NGG or GN19NGG. FIG. 8B is a more detailed map of the single molecule guide RNA expression cassette region of the pSM1 guide plasmid in panel A and shows the configuration of the T7 promoter, the transcriptional start site, the type II restriction endonuclease sites of Bsa1 (used to insert the desired VT domain, e.g., using annealed oligos), the CER domain (which includes the transcriptional terminator sequence TTTTT; not shown), and the full region encoding the single molecule guide RNA . Restriction enzyme DRA1 is used to linearize this plasmid before in vitro transcription. When transcribed, the CER domain of the guide RNA will form a hairpin structure that is able to bind to a cognate Cas9 polypeptide, thus generating a functional Cas9/guide RNA complex that can induce a double strand break at a DNA target site (one having a sequence complementary to the VT domain and the appropriate PAM site).

[043] FIG. 9A shows a map of the pXA3 plasmid which was used for creating linearized DNA substrate. This plasmid contains the coding sequence for the xyrl gene (SEQ ID NO:89) and was linearized by digestion with the restriction enzyme Ndel to produce the DNA substrate.

[044] FIG. 9B shows the results of guide RNA/Cas9 cleavage assay (visualized by ethidium bromide staining). Agarose gel analysis of xyrl -specific in vitro cleavage assay is shown in this figure. Lane 1 shows molecular weight markers; Lane 2 shows linearized plasmid substrate (containing the xyrl gene) in the absence of Cas9 and guide RNA; Lane 3 shows cleavage of the plasmid substrate in the presence of Cas9 and a guide RNA with the xyrl Ta VT domain; Lane 4 shows cleavage of the plasmid substrate in the presence of Cas9 and a guide RNA with the xyrl Tc VT. Positions of the linearized plasmid substrate and the cleaved products are indicated at the right. [045] FIG. 10. Sequence analysis of the of the pyr4 gene from strains that are resistant to FOA and requires uridine for growth. Alignment with the wild type sequence (K21 control T4; SEQ ID NO:68) revealed the presence of sequence modifications at the target site in the pyr4 gene (insertions of a few (1 -2 bps) or many (68bp) nucleotides). SEQ ID NOs: 69 to 77 are the sequences for strains T4 4-3, T4 4-13, T4 4-11 , T4 4-12, T4 4-18, T4 4-20, T4 4-19, T4 4-4, and T4 4-7, respectively. Strains T4 4-13 (SEQ ID NO: 70) and T4 4-12 (SEQ ID NO: 72) have no changes from the wild type sequence at the target site.

[046] FIGS. 11 A and 11 B. DNA sequence modification at a target site by uptake of in vitro formed Cas9/guide RNA complex. FIG. 11 A shows agarose gel analysis of pyr4 specific PCR products (encompassing the target site) of two strains (T4 2.2. and T4 4.1 ) resistant to FOA and that require uridine for growth isolated after direct introduction of in vitro formed Cas9/guide RNA complex followed by growth on Vogel's Uridine/FOA plates. Strain T4 2.2 (Lane 2) showed a PCR product that is of lower molecular weight than the T4 4.1 clone (Lane 3; which is equivalent to the control, shown in Panel B, Lane 2), indicating a large deletion in the pyr4 gene. FIG. 11 B shows a similar

PCR/agarose gel analysis as in FIG. 11 A, but showing T4 strains 4.1 , 4.2, 4.3, and 4.4, all of which are resistant to FOA and that require uridine for growth. Strain 4.3 (Lane 5) showed PCR product of the pyr4 gene that is of lower molecular weight than the control (C+; Lane 2).

[047] FIG. 12. Sequence analysis of the pyr4 genes derived from clones T4 2.2

(shown in FIG. 11 A) and T4 2.4. Sequence analysis shows that the T4 2.2 clone (top alignment) has a deletion of 611 base pairs at the target site of the introduced

Cas9/guide RNA complex. The sequence corresponding to the VT domain sequence of the guide RNA is boxed and the PAM site is circled. The bottom alignment shows a 1 base pair insertion in the pyr4 gene at the target site of the isolated T4 2.4 strain (a "G" residue). The sequence corresponding to the VT domain sequence of the guide RNA is indicated with a line over the alignment and the PAM site is circled. SEQ ID NOs:78 to 81 are the sequences for 9-96 (T4 2.2 strain), Pyr Tr (wild type sequence), Query (wild type sequence), and Sbjct (T4 2.4 strain), respectively.

[048] FIG. 13. Sequence analysis of the pyr4 genes derived from clones T4 4.1 and 4.2 (top alignment), 4.3 (bottom alignment) and 4.4 (middle alignment) (which are shown in FIG. 11 B). The wild type pyr4 sequence is the first sequence (top) in all alignments and a consensus is shown on the bottom of all alignments (SEQ ID NO:82). The top alignment shows that the T4 4.1 clone (third sequence in the alignment; SEQ ID NO:84) has an insertion of a T nucleotide while the T4 4.2 clone (second sequence in the alignment; SEQ ID NO:83) has an insertion of a G nucleotide at the target site in the pyr4 gene. (The consensus sequence in this alignment is the same as SEQ ID NO:82.) The middle alignment shows that the T4 4.4 clone (second sequence in the alignment; SEQ ID NO:85) has a deletion of an A nucleotide at the target site in the pyr4 gene. (The consensus sequence in this alignment is the same as SEQ ID NO:85.) The bottom alignment shows that the pyr4 gene sequence in the T4 4.3 clone (second sequence in the alignment; SEQ ID NO: 86) diverges abruptly at the target site. (The consensus sequence in this alignment is SEQ ID NO:87; spaces in the consensus sequence in FIG. 13 are represented by "N" in SEQ ID NO:87.) Further alignment analysis (not shown) confirmed that the T4 4.3 clone has a deletion of 988 base pairs at the target site for the introduced Cas9/guide RNA complex.

DETAILED DESCRIPTION

[049] The present disclosure includes compositions and methods that find use in modifying the DNA sequence at a target site in the genome of a fungal cell. The methods employ a functional guide RNA/Cas endonuclease complex which recognizes a desired target site and introduces a double strand break at the site. Repair of this double-strand break can introduce modifications to the DNA sequence at the target site.

[050] Before the present compositions and methods are described in greater detail, it is to be understood that the present compositions and methods are not limited to particular embodiments described, and as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present compositions and methods will be limited only by the appended claims.

[051] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the present compositions and methods. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the present compositions and methods, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the present compositions and methods. [052] Certain ranges are presented herein with numerical values being preceded by the term "about." The term "about" is used herein to provide literal support for the exact number that it precedes, as well as a number that is near to or approximately the number that the term precedes. In determining whether a number is near to or approximately a specifically recited number, the near or approximating unrequited number may be a number which, in the context in which it is presented, provides the substantial equivalent of the specifically recited number. For example, in connection with a numerical value, the term "about" refers to a range of -10% to +10% of the numerical value, unless the term is otherwise specifically defined in context. In another example, the phrase a "pH value of about 6" refers to pH values of from 5.4 to 6.6, unless the pH value is specifically defined otherwise.

[053] The headings provided herein are not limitations of the various aspects or embodiments of the present compositions and methods which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the specification as a whole. [054] The present document is organized into a number of sections for ease of reading; however, the reader will appreciate that statements made in one section may apply to other sections. In this manner, the headings used for different sections of the disclosure should not be construed as limiting.

[055] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present compositions and methods belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present compositions and methods, representative illustrative methods and materials are now described. [056] All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference and are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present compositions and methods are not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.

[057] In accordance with this detailed description, the following abbreviations and definitions apply. Note that the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an enzyme" includes a plurality of such enzymes, and reference to "the dosage" includes reference to one or more dosages and equivalents thereof known to those skilled in the art, and so forth.

[058] It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as "solely," "only" and the like in connection with the recitation of claim elements, or use of a "negative" limitation.

[059] As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present compositions and methods described herein. Any recited method can be carried out in the order of events recited or in any other order which is logically possible.

Definitions

[060] As used herein, a polypeptide referred to as a "Cas endonuclease" or having "Cas endonuclease activity" relates to a CRISPR associated (Cas) polypeptide encoded by a Cas gene where the Cas protein is capable of cutting a target DNA sequence when functionally coupled with one or more guide polynucleotides (see, e.g., US Patent 8697359 entitled "CRISPR-Cas systems and methods for altering

expression of gene products"). Variants of Cas endonucleases that retain guide polynucleotide directed endonuclease activity are also included in this definition. The Cas endonucleases employed in the donor DNA insertion methods detailed herein are endonucleases that introduce double-strand breaks into the DNA at the target site. A Cas endonuclease is guided by the guide polynucleotide to recognize and cleave a specific target site in double stranded DNA, e.g., at a target site in the genome of a cell.

[061] As used herein, the term "guide polynucleotide" relates to a polynucleotide sequence that can form a complex with a Cas endonuclease and enables the Cas endonuclease to recognize and cleave a DNA target site. The guide polynucleotide can be a single molecule or a double molecule. The guide polynucleotide sequence can be a RNA sequence, a DNA sequence, or a combination thereof (a RNA-DNA combination sequence). Optionally, the guide polynucleotide can comprise at least one nucleotide, phosphodiester bond or linkage modification such as, but not limited, to Locked Nucleic Acid (LNA), 5-methyl dC, 2,6-Diaminopurine, 2'-Fluoro A, 2'-Fluoro U, 2'-O-Methyl RNA, phosphorothioate bond, linkage to a cholesterol molecule, linkage to a polyethylene glycol molecule, linkage to a spacer 18 (hexaethylene glycol chain) molecule, or 5' to 3' covalent linkage resulting in circularization. A guide polynucleotide that solely comprises ribonucleic acids is also referred to as a "guide RNA". [062] The guide polynucleotide can be a double molecule (also referred to as duplex guide polynucleotide) comprising a first nucleotide sequence domain (referred to as Variable Targeting domain or VT domain) that is complementary to a nucleotide sequence in a target DNA and a second nucleotide sequence domain (referred to as Cas endonuclease recognition domain or CER domain) that interacts with a Cas endonuclease polypeptide. The CER domain of the double molecule guide

polynucleotide comprises two separate molecules that are hybridized along a region of complementarity. The two separate molecules can be RNA, DNA, and/or RNA-DNA- combination sequences. In some embodiments, the first molecule of the duplex guide polynucleotide comprising a VT domain linked to a CER domain is referred to as "crDNA" (when composed of a contiguous stretch of DNA nucleotides) or "crRNA" (when composed of a contiguous stretch of RNA nucleotides), or "crDNA-RNA" (when composed of a combination of DNA and RNA nucleotides). The crNucleotide can comprise a fragment of the crRNA naturally occurring in Bacteria and Archaea. In one embodiment, the size of the fragment of the crRNA naturally occurring in Bacteria and Archaea that is present in a crNucleotide disclosed herein can range from, but is not limited to, 2, 3, 4, 5, 6, 7, 8, 9,10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20 or more nucleotides. In some embodiments the second molecule of the duplex guide

polynucleotide comprising a CER domain is referred to as "tracrRNA" (when composed of a contiguous stretch of RNA nucleotides) or "tracrDNA" (when composed of a contiguous stretch of DNA nucleotides) or "tracrDNA-RNA" (when composed of a combination of DNA and RNA nucleotides). In certain embodiments, the RNA that guides the RNA/Cas9 endonuclease complex is a duplexed RNA comprising a duplex crRNA-tracrRNA. [063] The guide polynucleotide can also be a single molecule comprising a first nucleotide sequence domain (referred to as Variable Targeting domain or VT domain) that is complementary to a nucleotide sequence in a target DNA and a second nucleotide domain (referred to as Cas endonuclease recognition domain or CER domain) that interacts with a Cas endonuclease polypeptide. By "domain" it is meant a contiguous stretch of nucleotides that can be RNA, DNA, and/or RNA-DNA-combination sequence. The VT domain and / or the CER domain of a single guide polynucleotide can comprise a RNA sequence, a DNA sequence, or a RNA-DNA-combination sequence. In some embodiments the single guide polynucleotide comprises a crNucleotide (comprising a VT domain linked to a CER domain) linked to a

tracrNucleotide (comprising a CER domain), wherein the linkage is a nucleotide sequence comprising a RNA sequence, a DNA sequence, or a RNA-DNA combination sequence. The single guide polynucleotide being comprised of sequences from the crNucleotide and tracrNucleotide may be referred to as "single guide RNA" (when composed of a contiguous stretch of RNA nucleotides) or "single guide DNA" (when composed of a contiguous stretch of DNA nucleotides) or "single guide RNA-DNA"

(when composed of a combination of RNA and DNA nucleotides). In one embodiment of the disclosure, the single guide RNA comprises a crRNA or crRNA fragment and a tracrRNA or tracrRNA fragment of the type II CRISPR/Cas system that can form a complex with a type II Cas endonuclease, wherein the guide RNA/Cas endonuclease complex can direct the Cas endonuclease to a fungal cell genomic target site, enabling the Cas endonuclease to introduce a double strand break into the genomic target site.

[064] One aspect of using a single guide polynucleotide versus a duplex guide polynucleotide is that only one expression cassette needs to be made to express the single guide polynucleotide in a target cell. [065] The term "variable targeting domain" or "VT domain" is used interchangeably herein and includes a nucleotide sequence that is complementary to one strand

(nucleotide sequence) of a double strand DNA target site. The % complementation between the first nucleotide sequence domain (VT domain ) and the target sequence is at least 50%, 51 %, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61 %, 62%, 63%, 63%, 65%, 66%, 67%, 68%, 69%, 70%, 71 %, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or is 100% complementary. The VT domain can be at least 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotides in length. In some embodiments, the VT domain comprises a contiguous stretch of 12 to 30 nucleotides. The VT domain can be composed of a DNA sequence, a RNA sequence, a modified DNA sequence, a modified RNA sequence, or any combination thereof. [066] The term "Cas endonuclease recognition domain" or "CER domain" of a guide polynucleotide is used interchangeably herein and includes a nucleotide sequence (such as a second nucleotide sequence domain of a guide polynucleotide), that interacts with a Cas endonuclease polypeptide. The CER domain can be composed of a DNA sequence, a RNA sequence, a modified DNA sequence, a modified RNA sequence (see for example modifications described herein), or any combination thereof.

[067] The nucleotide sequence linking the crNucleotide and the tracrNucleotide of a single guide polynucleotide can comprise a RNA sequence, a DNA sequence, or a RNA-DNA combination sequence. In one embodiment, the nucleotide sequence linking the crNucleotide and the tracrNucleotide of a single guide polynucleotide can be at least 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, 50, 51 , 52, 53, 54, 55, 56, 57, 58, 59, 60, 61 , 62, 63, 64, 65, 66, 67, 68, 69, 70, 71 , 72, 73, 74, 75, 76, 77, 78, 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 , 92, 93, 94, 95, 96, 97, 98, 99 or 100 nucleotides in length. In another embodiment, the nucleotide sequence linking the crNucleotide and the tracrNucleotide of a single guide

polynucleotide can comprise a tetraloop sequence, such as, but not limiting to a GAAA tetraloop sequence.

[068] Nucleotide sequence modification of the guide polynucleotide, VT domain and/or CER domain can be selected from, but not limited to, the group consisting of a 5' cap, a 3' polyadenylated tail, a riboswitch sequence, a stability control sequence, a sequence that forms a dsRNA duplex, a modification or sequence that targets the guide

polynucleotide to a subcellular location, a modification or sequence that provides for tracking , a modification or sequence that provides a binding site for proteins , a Locked Nucleic Acid (LNA), a 5-methyl dC nucleotide, a 2,6-Diaminopurine nucleotide, a 2'- Fluoro A nucleotide, a 2'-Fluoro U nucleotide; a 2'-O-Methyl RNA nucleotide, a phosphorothioate bond, linkage to a cholesterol molecule, linkage to a polyethylene glycol molecule, linkage to a spacer 18 molecule, a 5' to 3' covalent linkage, or any combination thereof. These modifications can result in at least one additional beneficial feature, wherein the additional beneficial feature is selected from the group of a modified or regulated stability, a subcellular targeting, tracking, a fluorescent label, a binding site for a protein or protein complex, modified binding affinity to complementary target sequence, modified resistance to cellular degradation, and increased cellular permeability.

[069] As used herein, the term "guide polynucleotide/Cas endonuclease system" (and equivalents) includes a complex of a Cas endonuclease and a guide polynucleotide (single or double) that is capable of introducing a double strand break into a DNA target sequence. The Cas endonuclease unwinds the DNA duplex in close proximity of the genomic target site and cleaves both DNA strands upon recognition of a target sequence by a guide RNA, but only if the correct protospacer-adjacent motif (PAM) is appropriately oriented at the 3' end of the target sequence.

[070] The terms "functional fragment", "fragment that is functionally equivalent", "functionally equivalent fragment", and the like, are used interchangeably and refer to a portion or subsequence of a parent biological sequence, e.g., a polypeptide that retains the qualitative enzymatic activity of the parent polypeptide, or a polynucleotide that retains the main function of the parent polynucleotide. For example, a functional fragment of a Cas endonuclease retains the ability to create a double-strand break with a guide polynucleotide. It is noted here that a functional fragment may have altered quantitative enzymatic activity as compared to the parent polypeptide. Other examples include a functional fragment of a gene promoter which retains the ability to promote transcription, a functional fragment of an intron which retains the ability to facilitate transcription, and a functional fragment of an enzyme-encoding gene sequence which encodes a functional fragment of an enzyme.

[071] The terms "functional variant ", "variant that is functionally equivalent",

"functionally equivalent variant", and the like are used interchangeably and refer to a variant of a parent polypeptide that retains the qualitative enzymatic activity of the parent polypeptide. For example, a functional variant of a Cas endonuclease retains the ability to create a double-strand break with a guide polynucleotide. It is noted here that a functional variant may have altered quantitative enzymatic activity as compared to the parent polypeptide. [072] Fragments and variants can be obtained via any convenient method, including site-directed mutagenesis and synthetic construction.

[073] The term "genome" as it applies to fungal cells encompasses not only

chromosomal DNA found within the nucleus, but organelle DNA found within subcellular components (e.g., mitochondria) of the cell. [074] A "codon-modified gene" or "codon-preferred gene" or "codon-optimized gene" is a gene having its frequency of codon usage designed to mimic the frequency of preferred codon usage of the host cell. The nucleic acid changes made to codon- optimize a gene are "synonymous", meaning that they do not alter the amino acid sequence of the encoded polypeptide of the parent gene. However, both native and variant genes can be codon-optimized for a particular host cell, and as such no limitation in this regard is intended.

[075] "Coding sequence" refers to a polynucleotide sequence which codes for a specific amino acid sequence. "Regulatory sequences" refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA

processing or stability, or translation of the associated coding sequence. Regulatory sequences may include, but are not limited to: promoters, translation leader sequences, 5' untranslated sequences, 3' untranslated sequences, introns, polyadenylation target sequences, RNA processing sites, effector binding sites, and stem-loop structures. [076] "Promoter" refers to a DNA sequence capable of controlling the expression of a coding sequence or functional RNA. The promoter sequence consists of proximal and more distal upstream elements, the latter elements often referred to as enhancers. An "enhancer" is a DNA sequence that can stimulate promoter activity, and may be an innate element of the promoter or a heterologous element inserted to enhance the level or tissue-specificity of a promoter. Promoters may be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, and/or comprise synthetic DNA segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental conditions. It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, DNA fragments of some variation may have identical promoter activity. As is well-known in the art, promoters can be categorized according to their strength and/or the conditions under which they are active, e.g., constitutive promoters, strong promoters, weak promoters, inducible/repressible promoters, tissue-specific/developmentally regulated promoters, cell-cycle dependent promoters, etc.

[077] "RNA transcript" refers to the product resulting from RNA polymerase-catalyzed transcription of a DNA sequence. "Messenger RNA" or "mRNA" refers to the RNA that is without introns and that can be translated into protein by the cell. "cDNA" refers to a DNA that is complementary to, and synthesized from, a mRNA template using the enzyme reverse transcriptase. "Sense" RNA refers to RNA transcript that includes the mRNA and can be translated into protein within a cell or in vitro. "Antisense RNA" refers to an RNA transcript that is complementary to all or part of a target primary transcript or mRNA, and that, under certain conditions, blocks the expression of a target gene (see, e.g., U.S. Patent No. 5,107,065). The complementarity of an antisense RNA may be with any part of the specific gene transcript, i.e., at the 5' non-coding sequence, 3' non-coding sequence, introns, or the coding sequence. "Functional RNA" refers to antisense RNA, ribozyme RNA, or other RNA that may not be translated into a polypeptide but yet has an effect on cellular processes. The terms "complement" and "reverse complement" are used interchangeably herein with respect to mRNA

transcripts, and are meant to define the antisense RNA of the message.

[078] As used herein, "functionally attached" or "operably linked" means that a regulatory region or functional domain of a polypeptide or polynucleotide sequence having a known or desired activity, such as a promoter, enhancer region, terminator, signal sequence, epitope tag, etc., is attached to or linked to a target (e.g., a gene or polypeptide) in such a manner as to allow the regulatory region or functional domain to control the expression, secretion or function of that target according to its known or desired activity. For example, a promoter is operably linked with a coding sequence when it is capable of regulating the expression of that coding sequence (i.e., the coding sequence is under the transcriptional control of the promoter). [079] Standard recombinant DNA and molecular cloning techniques used herein are well known in the art.

[080] "PCR" or "polymerase chain reaction" is a technique for the synthesis of specific DNA segments and consists of a series of repetitive denaturation, annealing, and extension cycles and is well known in the art.

[081] The term "recombinant," when used in reference to a biological component or composition (e.g., a cell, nucleic acid, polypeptide/enzyme, vector, etc.) indicates that the biological component or composition is in a state that is not found in nature. In other words, the biological component or composition has been modified by human intervention from its natural state. For example, a recombinant cell encompass a cell that expresses one or more genes that are not found in its native parent (i.e., non- recombinant) cell, a cell that expresses one or more native genes in an amount that is different than its native parent cell, and/or a cell that expresses one or more native genes under different conditions than its native parent cell. Recombinant nucleic acids may differ from a native sequence by one or more nucleotides, be operably linked to heterologous sequences (e.g., a heterologous promoter, a sequence encoding a non- native or variant signal sequence, etc.), be devoid of intronic sequences, and/or be in an isolated form. Recombinant polypeptides/enzymes may differ from a native sequence by one or more amino acids, may be fused with heterologous sequences, may be truncated or have internal deletions of amino acids, may be expressed in a manner not found in a native cell (e.g., from a recombinant cell that over-expresses the polypeptide due to the presence in the cell of an expression vector encoding the polypeptide), and/or be in an isolated form. It is emphasized that in some

embodiments, a recombinant polynucleotide or polypeptide/enzyme has a sequence that is identical to its wild-type counterpart but is in a non-native form (e.g., in an isolated or enriched form).

[082] The term "engineered", when used in reference to a biological component or composition (e.g., a cell, nucleic acid, polypeptide/enzyme, vector, etc.) indicates that the biological component or composition is designed by human and is at least not completely derived from or completely identical to biological component or composition in nature, as far as the person who designs the "engineered" biological component or composition is aware at the time of designing. An engineered biological component or composition, e.g., an engineered nucleic acid, may be derived from various parts of different naturally existing biological components or compositions. An engineered biological component or composition may be a recombinant biological component or composition.

[083] The terms "plasmid", "vector" and "cassette" refer to an extra chromosomal element that carries a polynucleotide sequence of interest, e.g., a gene of interest to be expressed in a cell (an "expression vector" or "expression cassette"). Such elements are generally in the form of double-stranded DNA and may be autonomously replicating sequences, genome integrating sequences, phage, or nucleotide sequences, in linear or circular form, of a single- or double-stranded DNA or RNA, derived from any source, in which a number of nucleotide sequences have been joined or recombined into a unique construction which is capable of introducing a polynucleotide of interest into a cell. The polynucleotide sequence of interest may be a gene encoding a polypeptide or functional RNA that is to be expressed in the target cell. Expression cassettes/vectors generally contain a gene with operably linked elements that allow for expression of that gene in a host cell.

[084] The term "expression", as used herein, refers to the production of a functional end-product (e.g., an imRNA, guide RNA, or a protein) in either precursor or mature form.

[085] "Introduced" in the context of inserting a polynucleotide or polypeptide into a cell (e.g., a recombinant DNA construct/expression construct) refers to any method for performing such a task, and includes any means of "transfection", "transformation", "transduction", physical means, or the like, to achieve introduction of the desired biomolecule.

[086] By "introduced transiently", "transiently introduced", "transient introduction", "transiently express" and the like is meant that a biomolecule is introduced into a host cell (or a population of host cells) in a non-permanent manner. With respect to double stranded DNA, transient introduction includes situations in which the introduced DNA does not integrate into the chromosome of the host cell and thus is not transmitted to all daughter cells during growth as well as situations in which an introduced DNA molecule that may have integrated into the chromosome is removed at a desired time using any convenient method (e.g., employing a cre-lox system, by removing positive selective pressure for an episomal DNA construct, by promoting looping out of all or part of the integrated polynucleotide from the chromosome using a selection media, etc.). No limitation in this regard is intended. In general, introduction of RNA (e.g., a guide RNA, a messenger RNA, ribozyme, etc.) or a polypeptide (e.g., a Cas polypeptide) into host cells is considered transient in that these biomolecules are not replicated and

indefinitely passed down to daughter cells during cell growth. With respect to the Cas/guide RNA complex, transient introduction covers situations when either of the components is introduced transiently, as both biomolecules are needed to exert targeted Cas endonuclease activity. Thus, transient introduction of a Cas/guide RNA complex includes embodiments where either one or both of the Cas endonuclease and the guide RNA are introduced transiently. For example, a host cell having a genome- integrated expression cassette for the Cas endonuclease (and thus not transiently introduced) into which a guide RNA is transiently introduced can be said to have a transiently introduced Cas/guide RNA complex (or system) because the functional complex is present in the host cell in a transient manner. In certain embodiments, the introducing step includes: (i) obtaining a parental fungal cell population that stably expresses the Cas endonuclease, and (ii) transiently introducing the guide RNA into the parental fungal cell population. Conversely, the introducing step can include: (i) obtaining a parental fungal cell population that stably expresses the guide RNA, and (ii) transiently introducing the Cas endonuclease into the parental fungal cell population.

[087] "Mature" protein refers to a post-translationally processed polypeptide (i.e., one from which any pre- or propeptides present in the primary translation product have been removed). "Precursor" protein refers to the primary product of translation of imRNA (i.e., with pre- and propeptides still present). Pre- and propeptides may be but are not limited to intracellular localization signals.

[088] "Stable transformation" refers to the transfer of a nucleic acid fragment into a genome of a host organism, including both nuclear and organellar genomes, resulting in genetically stable inheritance (the resulting host cell is sometimes referred to herein as a "stable transformant"). In contrast, "transient transformation" refers to the transfer of a nucleic acid fragment into the nucleus, or other DNA-containing organelle, of a host organism resulting in gene expression without integration or stable inheritance

(sometimes referred to herein as "unstable transformation" , and the resulting host cell sometimes referred to herein as an "unstable transformant"). Host organisms containing the transformed nucleic acid fragments are referred to as "transgenic" organisms. [089] "Fungal cell", "fungi", "fungal host cell", and the like, as used herein includes the phyla Ascomycota, Basidiomycota, Chytridiomycota, and Zygomycota (as defined by Hawksworth et al., In, Ainsworth and Bisby's Dictionary of The Fungi, 8th edition, 1995, CAB International, University Press, Cambridge, UK) as well as the Oomycota (as cited in Hawksworth et al., supra) and all mitosporic fungi (Hawksworth et al., supra). In certain embodiments, the fungal host cell is a yeast cell, where by "yeast" is meant ascosporogenous yeast (Endomycetales), basidiosporogenous yeast, and yeast belonging to the Fungi Imperfecti (Blastomycetes). As such, a yeast host cell includes a Candida, Hansenula, Kluyveromyces, Pichia, Saccharomyces, Schizosaccharomyces, or Yarrowia cell. Species of yeast include, but are not limited to, the following:

Saccharomyces carlsbergensis, Saccharomyces cerevisiae, Saccharomyces

diastaticus, Saccharomyces douglasii, Saccharomyces kluyveri, Saccharomyces norbensis, Saccharomyces oviformis, Kluyveromyces lactis, and Yarrowia lipolytica cell.

[090] The term "filamentous fungal cell" includes all filamentous forms of the

subdivision Eumycotina or Pezizomycotina. Suitable cells of filamentous fungal genera include, but are not limited to, cells of Acremonium, Aspergillus, Chrysosporium, Corynascus, Chaetomium, Fusarium, Gibberella, Humicola, Magnaporthe,

Myceliophthora, Neurospora, Paecilomyces, Penicillium, Scytaldium, Talaromyces, Thermoascus, Thielavia, Tolypocladium, Hypocrea, and Trichoderma. [091] Suitable cells of filamentous fungal species include, but are not limited to, cells of Aspergillus awamori, Aspergillus fumigatus, Aspergillus foetidus, Aspergillus japonicus, Aspergillus nidulans, Aspergillus niger, Aspergillus oryzae, Chrysosporium

lucknowense, Hypocrea jecorina, Fusarium bactridioides, Fusarium cerealis, Fusarium crookwellense, Fusarium culmorum, Fusarium graminearum, Fusarium graminum, Fusarium heterosporum, Fusarium negundi, Fusarium oxysporum, Fusarium

reticulatum, Fusarium roseum, Fusarium sambucinum, Fusarium sarcochroum,

Fusarium sporotrichioides, Fusarium sulphureum, Fusarium torulosum, Fusarium trichothecioides, Fusarium venenatum, Humicola insolens, Humicola lanuginosa, Myceliophthora thermophila, Neurospora crassa, Neurospora intermedia, Penicillium purpurogenum, Penicillium canescens, Penicillium solitum, Penicillium funiculosum, Phanerochaete chrysosporium, Talaromyces flavus, Thielavia terrestris, Trichoderma harzianum, Trichoderma koningii, Trichoderma longibrachiatum, Trichoderma reesei, and Trichoderma viride. [092] The terms "target site", "target sequence", "genomic target site", "genomic target sequence" (and equivalents) are used interchangeably herein and refer to a

polynucleotide sequence in the genome of a fungal cell at which a Cas endonuclease cleavage is desired to promote a genome modification, e.g., modification of the DNA sequence at the target site. The context in which this term is used, however, can slightly alter its meaning. For example, the target site for a Cas endonuclease is generally very specific and can often be defined to the exact nucleotide position, whereas in some cases the target site for a desired genome modification can be defined more broadly than merely the site at which DNA cleavage occurs. The target site can be an endogenous site in the fungal cell genome, or alternatively, the target site can be heterologous to the fungal cell and thereby not be naturally occurring in the genome, or the target site can be found in a heterologous genomic location compared to where it occurs in nature.

[093] As used herein, "nucleic acid" means a polynucleotide and includes a single or a double-stranded polymer of deoxyribonucleotide or ribonucleotide bases. Nucleic acids may also include fragments and modified nucleotides. Thus, the terms

"polynucleotide", "nucleic acid sequence", "nucleotide sequence" and "nucleic acid fragment" are used interchangeably to denote a polymer of RNA and/or DNA that is single- or double-stranded, optionally containing synthetic, non-natural, or altered nucleotide bases. Nucleotides (usually found in their 5'-monophosphate form) are referred to by their single letter designation as follows: "A" for adenosine or

deoxyadenosine (for RNA or DNA, respectively), "C" for cytosine or deoxycytosine, "G" for guanosine or deoxyguanosine, "U" for uridine, "T" for deoxythymidine, "R" for purines (A or G), "Y" for pyrimidines (C or T), "K" for G or T, "H" for A or C or T, "I" for inosine, and "N" for any nucleotide.

[094] The term "derived from" encompasses the terms "originated from," "obtained from," "obtainable from," "isolated from," and "created from," and generally indicates that one specified material find its origin in another specified material or has features that can be described with reference to the another specified material. [095] As used herein, the term "hybridization conditions" refers to the conditions under which hybridization reactions are conducted. These conditions are typically classified by degree of "stringency" of the conditions under which hybridization is measured. The degree of stringency can be based, for example, on the melting temperature (Tm) of the nucleic acid binding complex or probe. For example, "maximum stringency" typically occurs at about Tm - 5°C (5°C below the Tm of the probe); "high stringency" at about 5- 10°C below the Tm; "intermediate stringency" at about 10-20°C below the Tm of the probe; and "low stringency" at about 20-25°C below the Tm. Alternatively, or in addition, hybridization conditions can be based upon the salt or ionic strength

conditions of hybridization, and/or upon one or more stringency washes, e.g.: 6X SSC = very low stringency; 3X SSC = low to medium stringency; 1X SSC = medium stringency; and 0.5X SSC = high stringency. Functionally, maximum stringency conditions may be used to identify nucleic acid sequences having strict identity or near- strict identity with the hybridization probe; while high stringency conditions are used to identify nucleic acid sequences having about 80% or more sequence identity with the probe. For applications requiring high selectivity, it is typically desirable to use relatively stringent conditions to form the hybrids (e.g., relatively low salt and/or high temperature conditions are used). [096] As used herein, the term "hybridization" refers to the process by which a strand of nucleic acid joins with a complementary strand through base pairing, as known in the art. More specifically, "hybridization" refers to the process by which one strand of nucleic acid forms a duplex with, i.e., base pairs with, a complementary strand, as occurs during blot hybridization techniques and PCR techniques. A nucleic acid sequence is considered to be "selectively hybridizable" to a reference nucleic acid sequence if the two sequences specifically hybridize to one another under moderate to high stringency hybridization and wash conditions. Hybridization conditions are based on the melting temperature (Tm) of the nucleic acid binding complex or probe. For example, "maximum stringency" typically occurs at about Tm -5 °C (5 ° below the Tm of the probe); "high stringency" at about 5-10°C below the Tm; "intermediate stringency" at about 10-20°C below the Tm of the probe; and "low stringency" at about 20-25 °C below the Tm. Functionally, maximum stringency conditions may be used to identify sequences having strict identity or near-strict identity with the hybridization probe; while intermediate or low stringency hybridization can be used to identify or detect

polynucleotide sequence homologs.

[097] Intermediate and high stringency hybridization conditions are well known in the art. For example, intermediate stringency hybridizations may be carried out with an overnight incubation at 37 °C in a solution comprising 20% formamide, 5 x SSC (150 imM NaCI, 15 imM trisodium citrate), 50 imM sodium phosphate (pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate and 20 img/mL denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37 - 50 °C. High stringency hybridization conditions may be hybridization at 65 °C and 0.1 X SSC (where 1 X SSC = 0.15 M NaCI, 0.015 M Na citrate, pH 7.0). Alternatively, high stringency hybridization conditions can be carried out at about 42oC in 50% formamide, 5X SSC, 5X Denhardt's solution, 0.5% SDS and 100 μg/mL denatured carrier DNA followed by washing two times in 2X SSC and 0.5% SDS at room temperature and two additional times in 0.1 X SSC and 0.5% SDS at 42oC. And very high stringent hybridization conditions may be hybridization at 68 °C and 0.1 X SSC. Those of skill in the art know how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.

[098] The phrase "substantially similar" or "substantially identical," in the context of at least two nucleic acids or polypeptides, means that a polynucleotide or polypeptide comprises a sequence that has at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or even at least 99% identical to a parent or reference sequence, or does not include amino acid substitutions, insertions, deletions, or modifications made only to circumvent the present description without adding functionality.

[099] "Sequence identity" or "identity" in the context of nucleic acid or polypeptide sequences refers to the nucleic acid bases or amino acid residues in two sequences that are the same when aligned for maximum correspondence over a specified comparison window.

[0100] The term "percentage of sequence identity" refers to the value determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the results by 100 to yield the percentage of sequence identity. Useful examples of percent sequence identities include, but are not limited to, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95%, or any integer percentage from 50% to 100%. These identities can be determined using any of the programs described herein.

[0101] Sequence alignments and percent identity or similarity calculations may be determined using a variety of comparison methods designed to detect homologous sequences including, but not limited to, the MegAlign™ program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, Wl). Within the context of this application it will be understood that where sequence analysis software is used for analysis, that the results of the analysis will be based on the "default values" of the program referenced, unless otherwise specified. As used herein "default values" will mean any set of values or parameters that originally load with the software when first initialized.

[0102] The "Clustal V method of alignment" corresponds to the alignment method labeled Clustal V (described by Higgins and Sharp, (1989) CABIOS 5:151 -153; Higgins et al., (1992) Comput Appl Biosci 8:189-191 ) and found in the MegAlign™ program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, Wl). For multiple alignments, the default values correspond to GAP PENALTY=10 and GAP LENGTH PENALTY=10. Default parameters for pairwise alignments and calculation of percent identity of protein sequences using the Clustal method are KTUPLE=1 , GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5. For nucleic acids these parameters are KTUPLE=2, GAP PENALTY=5, WINDOW=4 and DIAGONALS

SAVED=4. After alignment of the sequences using the Clustal V program, it is possible to obtain a "percent identity" by viewing the "sequence distances" table in the same program.

[0103] The "Clustal W method of alignment" corresponds to the alignment method labeled Clustal W (described by Higgins and Sharp, (1989) CABIOS 5:151 -153; Higgins et al., (1992) Comput Appl Biosci 8:189-191 ) and found in the MegAlign™ v6.1 program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, Wl).

Default parameters for multiple alignment (GAP PENALTY=10, GAP LENGTH

PENALTY=0.2, Delay Divergen Seqs (%)=30, DNA Transition Weight=0.5, Protein Weight Matrix=Gonnet Series, DNA Weight Matrix=IUB ). After alignment of the sequences using the Clustal W program, it is possible to obtain a "percent identity" by viewing the "sequence distances" table in the same program. [0104] Unless otherwise stated, sequence identity/similarity values provided herein refer to the value obtained using GAP Version 10 (GCG, Accelrys, San Diego, CA) using the following parameters: % identity and % similarity for a nucleotide sequence using a gap creation penalty weight of 50 and a gap length extension penalty weight of 3, and the nwsgapdna.cmp scoring matrix; % identity and % similarity for an amino acid sequence using a GAP creation penalty weight of 8 and a gap length extension penalty of 2, and the BLOSUM62 scoring matrix (Henikoff and Henikoff, (1989) Proc. Natl. Acad. Sci. USA 89:10915). GAP uses the algorithm of Needleman and Wunsch, (1970) J Mol Biol 48:443-53, to find an alignment of two complete sequences that maximizes the number of matches and minimizes the number of gaps. GAP considers all possible alignments and gap positions and creates the alignment with the largest number of matched bases and the fewest gaps, using a gap creation penalty and a gap extension penalty in units of matched bases.

[0105] It is well understood by one skilled in the art that many levels of sequence identity are useful in identifying polypeptides from other species or modified naturally or synthetically wherein such polypeptides have the same or similar function or activity. Useful examples of percent identities include, but are not limited to, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95%, or any integer percentage from 50% to 100%. Indeed, any integer amino acid identity from 50% to 100% may be useful in describing the present disclosure, such as 51 %, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61 %, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71 %, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.

[0106] "Gene" includes a nucleic acid fragment that encodes and is capable to express a functional molecule such as, but not limited to, a specific polypeptide (e.g., an enzyme) or a functional RNA molecule (e.g., a guide RNA, an anti-sense RNA, ribozyme, etc.), and includes regulatory sequences preceding (5' non-coding

sequences) and/or following (3' non-coding sequences) the coding sequence. "Native gene" refers to a gene as found in nature with its own regulatory sequences. A recombinant gene refers to a gene that is regulated by a different gene's regulatory sequences which could be from a different organism or the same organism.

[0107] A "mutated gene" is a gene that has been altered through human intervention. Such a "mutated gene" has a sequence that differs from the sequence of the corresponding non-mutated gene by at least one nucleotide addition, deletion, or substitution. In certain embodiments of the disclosure, the mutated gene comprises an alteration that results from a guide polynucleotide/Cas endonuclease system as disclosed herein. A mutated fungal cell is a fungal cell comprising a mutated gene. [0108] As used herein, a "targeted mutation" is a mutation in a native gene that was made by altering a target sequence within the native gene using a method involving a double-strand-break-inducing agent that is capable of inducing a double-strand break in the DNA of the target sequence as disclosed herein or known in the art.

[0109] The term "donor DNA" or "donor nucleic acid sequence" or "donor

polynucleotide" refers to a polynucleotide that contains a polynucleotide sequence of interest that is to be inserted at or near a target site or to replace a region at or near a target site, generally in conjunction with the activity of a Cas/guide polynucleotide complex (where the guide polynucleotide defines the target site, as detailed above). As such, the polynucleotide sequence of interest in the donor DNA may include a novel region to be inserted at or near the target site and/or a modified polynucleotide sequence when compared to the nucleotide sequence to be replaced/edited at or near the target site. In certain embodiments, the donor DNA construct further comprises a first and a second region of homology that flank the polynucleotide sequence of interest. The first and second regions of homology of the donor DNA share homology to a first and a second genomic region, respectively, present in or flanking the target site of the fungal cell genome. By "homology" is meant DNA sequences that are similar. For example, a "region of homology to a genomic region" that is found on the donor DNA is a region of DNA that has a similar sequence to a given "genomic region" in the fungal cell genome. A region of homology can be of any length that is sufficient to promote homologous recombination at the cleaved target site. For example, the region of homology can comprise at least 5-10, 5-15, 5-20, 5-25, 5-30, 5-35, 5-40, 5- 45, 5- 50, 5-55, 5-60, 5-65, 5- 70, 5-75, 5-80, 5-85, 5-90, 5-95, 5-100, 5-200, 5-300, 5- 400, 5-500, 5-600, 5-700, 5-800, 5-900, 5-1000, 5-1 100, 5-1200, 5-1300, 5-1400, 5- 1500, 5-1600, 5-1700, 5-1800, 5-1900, 5-2000, 5-2100, 5-2200, 5-2300, 5-2400, 5- 2500, 5-2600, 5-2700, 5-2800, 5-2900, 5-3000, 5-3100 or more bases in length such that the region of homology has sufficient homology to undergo homologous

recombination with the corresponding genomic region. "Sufficient homology" indicates that two polynucleotide sequences have sufficient structural similarity to act as substrates for a homologous recombination reaction. The structural similarity includes overall length of each polynucleotide fragment, as well as the sequence similarity of the polynucleotides. Sequence similarity can be described by the percent sequence identity over the whole length of the sequences, and/or by conserved regions

comprising localized similarities such as contiguous nucleotides having 100% sequence identity, and percent sequence identity over a portion of the length of the sequences.

[0110] The amount of homology or sequence identity shared by a target and a donor polynucleotide can vary and includes total lengths and/or regions having unit integral values in the ranges of about 1 -20 bp, 20-50 bp, 50-100 bp, 75-150 bp, 100-250 bp, 150-300 bp, 200-400 bp, 250-500 bp, 300-600 bp, 350-750 bp, 400-800 bp, 450-900 bp, 500-1000 bp, 600-1250 bp, 700-1500 bp, 800-1750 bp, 900-2000 bp, 1 -2.5 kb, 1 .5- 3 kb, 2-4 kb, 2.5-5 kb, 3-6 kb, 3.5-7 kb, 4-8 kb, 5-10 kb, or up to and including the total length of the target site. These ranges include every integer within the range, for example, the range of 1 -20 bp includes 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19 and 20 bp. The amount of homology can also described by percent sequence identity over the full aligned length of the two polynucleotides which includes percent sequence identity of about at least 50%, 55%, 60%, 65%, 70%, 71 %, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%.

Sufficient homology includes any combination of polynucleotide length, global percent sequence identity, and optionally conserved regions of contiguous nucleotides or local percent sequence identity, for example sufficient homology can be described as a region of 75-150 bp having at least 80% sequence identity to a region of the target locus. Sufficient homology can also be described by the predicted ability of two polynucleotides to specifically hybridize under high stringency conditions, see, for example, Sambrook et al., (1989) Molecular Cloning: A Laboratory Manual, (Cold

Spring Harbor Laboratory Press, NY); Current Protocols in Molecular Biology, Ausubel et al., Eds (1994) Current Protocols, (Greene Publishing Associates, Inc. and John Wiley & Sons, Inc); and, Tijssen (1993) Laboratory Techniques in Biochemistry and Molecular Biology-Hybridization with Nucleic Acid Probes, (Elsevier, New York). [0111 ] A "phenotypic marker" is a screenable or selectable marker that includes visual markers and selectable markers whether it is a positive or negative selectable marker. Any phenotypic marker can be used. Specifically, a selectable or screenable marker comprises a DNA segment that allows one to identify, select for, or screen for or against a molecule or a cell that contains it, often under particular conditions. These markers can encode an activity, such as, but not limited to, production of RNA, peptide, or protein, or can provide a binding site for RNA, peptides, proteins, inorganic and organic compounds or compositions and the like.

[0112] Examples of selectable markers include, but are not limited to, DNA segments that comprise restriction enzyme sites; DNA segments that encode products which provide resistance against otherwise toxic compounds and antibiotics, such as, chlorimuron ethyl, benomyl, Basta, and hygromycin phosphotransferase (HPT); DNA segments that encode products which are otherwise lacking in the recipient cell (e.g., tRNA genes, auxotrophic markers, dominant heterologous marker-amdS); DNA segments that encode products which can be readily identified (e.g., phenotypic markers such as β-galactosidase, GUS; fluorescent proteins such as green fluorescent protein (GFP), cyan (CFP), yellow (YFP), red (RFP), and cell surface proteins); the generation of new primer sites for PCR (e.g., the juxtaposition of two DNA sequence not previously juxtaposed), the inclusion of DNA sequences not acted upon or acted upon by a restriction endonuclease or other DNA modifying enzyme, chemical, etc.; and, the inclusion of a DNA sequences required for a specific modification (e.g., methylation) that allows its identification.

Methods and compositions for Modifying a Fungal Cell Genome

[0113] Methods are provided employing a guide RNA /Cas endonuclease system for modifying the DNA sequence at a target site in the genome of a fungal cell, e.g., a filamentous fungal cell.

[0114] Aspects of the present disclosure include methods for modifying the DNA sequence at a target site in the genome of a fungal cell by transiently introducing a Cas endonuclease/guide polynucleotide complex into the cell. The Cas endonuclease/ guide polynucleotide complex is capable of introducing a double-strand break at the target site in the genome of the fungal cell, and repair of this break can result in sequence modification (e.g., insertions or deletions).

[0115] Introduction of the Cas endonuclease or guide polynucleotide (or other biomolecule) can be done in any convenient manner, including transfection,

transduction, transformation, electroporation, particle bombardment (biolistic particle delivery), cell fusion techniques, etc. Each of these components can be introduced simultaneously or sequentially as desired by the user. For example, a fungal cell can first be stably transfected with a Cas expression DNA construct followed by introduction of a guide polynucleotide into the stable transfectant (either directly or using a guide polynucleotide expressing DNA construct). This set up may even be advantageous as the user can generate a population of stable Cas transfectant fungal cells into which different guide polynucleotides can be introduced independently (in some cases, more than one guide polynucleotide can be introduced into the same cells should this be desired). In some embodiments, a Cas expressing fungal cell is obtained by the user, and thus the user does not need to introduce a recombinant DNA construct capable of expressing a Cas endonuclease into the cell, but rather only need introduce a guide polynucleotide into the Cas expressing cell.

[0116] In certain embodiments, a guide polynucleotide is introduced into the fungal cell by introducing a recombinant DNA construct that includes an expression cassette (or gene) encoding the guide polynucleotide. In some embodiments, the expression cassette is operably linked to a eukaryotic RNA pol III promoter. These promoters are of particular interest as transcription by RNA pol III does not lead to the addition of a 5' cap structure or polyadenylation that occurs upon transcription by RNA polymerase II from an RNA pol II dependent promoter. In certain embodiments, the RNA pol III promoter is a filamentous fungal cell U6 polymerase III promoter (e.g., SEQ ID NO:11 and functional variants thereof, e.g., SEQ ID NO:12). [0117] When a double-strand break is induced in the genomic DNA of a host cell (e.g., by the activity of a Cas endonuclease/guide RNA complex at a target site, the complex having double-strand endonuclease activity), the cell's DNA repair mechanism is activated to repair the break which, due to its error-prone nature, can produce mutations at double-strand break sites. The most common repair mechanism to bring the broken ends together is the nonhomologous end-joining (NHEJ) pathway (Bleuyard et al., (2006) DNA Repair 5:1 -12). The structural integrity of chromosomes is typically preserved by the repair, but deletions, insertions, or other rearrangements are possible (Siebert and Puchta, (2002) Plant Cell 14:1121 -31 ; Pacher et al., (2007) Genetics 175:21 -9). [0118] Surprisingly, we have found in filamentous fungi that non-homologous insertion of transformed DNA at the double-strand break is highly favored over simple end-joining between the two ends of the chromosomal DNA at a double-strand break. Therefore, in cases where the Cas endonuclease or guide RNA is provided by transformation with an expression cassette containing DNA construct or constructs, those DNA constructs, or fragments thereof, are inserted at the double-strand break at high frequency. This insertion occurs in the absence of homology between DNA sequences on the Cas endonuclease or guide RNA expression constructs and the sequences around the double-strand break.

[0119] DNA taken up by transformation may integrate in a stable fashion in the genome or it may be transiently maintained. Transient maintenance can be recognized by an unstable phenotype. For example, DNA uptake can be recognized by selection for a marker gene present on the transforming DNA. After transformation and selection, the transformants may be grown under non-selective conditions for several generations before transfer back to selective conditions. A stable transformant will be able to grow after transfer back to selective conditions whereas an unstable transformant will be unable to grow after transfer back to selective conditions due to loss of the transforming DNA. We have demonstrated that it is possible to transiently express Cas

endonuclease and/or guide RNA in fungal cells.

[0120] In embodiments where unstable transformants are desired, a plasmid with telomere sequences to encourage autonomous replication can be used. Other types of plasmids that are designed for autonomous replication, such as those with autonomous replication sequences, centromere sequences or other sequences, can also be employed. Surprisingly, in Trichoderma reesei we have found that one can use plasmids with no known origin of replication, autonomous replication sequence, centromere or telomere sequences. By screening those transformants that show an unstable phenotype with respect to the selectable marker, efficient target site gene modification without vector DNA insertion is obtained. [0121] Certain embodiments of the present disclosure include integrating a Cas endonuclease expression cassette and first selectable marker in the genome of a fungus, optionally flanked by repeats to allow subsequent removal (loop-out) of the expression cassette and first selectable marker, to produce a Cas endonuclease expressing host cell. These cells can be employed in numerous ways to obtain a genetic modification of interest, including modification of the DNA sequence at a desired target site.

[0122] For example, a Cas endonuclease expressing host cell can be transformed with a DNA construct including a guide RNA expression cassette containing a second selectable marker. Host cells that are selected for using the second selectable marker will express the guide RNA from this DNA construct, which enables Cas endonuclease activity and targeting to a defined target site of interest in the genome. Screening these host cells for transformants that show an unstable phenotype with respect to the second selectable marker will enable obtaining host cells with a modified site of interest without DNA construct insertion.

[0123] As another example, a Cas endonuclease expressing host cell can be induced to uptake an in vitro synthesized guide RNA to enable Cas endonuclease activity and targeting to a defined site in the genome. In some cases, it will be desirable to induce uptake of both guide RNA and a separate DNA construct bearing a selectable marker gene to allow for selection of those cells that have taken up DNA and, at high

frequency, are expected to have simultaneously taken up guide RNA. As above, screening those transformants that show an unstable phenotype with respect to the selectable marker for the genetic modification of interest without vector DNA insertion is obtained.

[0124] As yet another example, a Cas endonuclease expressing host cell can be used to create a "helper strain" that can provide, in trans, the Cas endonuclease to a "target strain". In brief, a heterokaryon can be created between the helper strain and the target strain, e.g., by fusion of protoplasts from each strain or by anastomosis of hyphae depending on the species of filamentous fungus. Maintenance of the heterokaryon will depend on appropriate nutritional or other marker genes or mutations in each parental strain and growth on suitable selective medium such that the parental strains are unable to grow whereas the heterokaryon, due to complementation, is able to grow. Either at the time of heterokaryon formation or subsequently, a guide RNA is introduced by transfection. The guide RNA may be directly introduced or introduced via a DNA construct having a Cas endonuclease expression cassette and a selectable marker gene. Cas endonuclease is expressed from the gene in the helper strain nucleus and is present in the cytoplasm of the heterokaryon. The Cas endonuclease associates with the guide RNA to create an active complex that is targeted to the desired target site(s) in the genome to induce modification of the DNA sequence. Subsequently, spores are recovered from the heterokaryon and subjected to selection or screening to recover the target strain with modification of the DNA sequence at the target site. In cases in which an expression cassette is used to introduce the guide RNA, heterokaryons are chosen in which the guide RNA expression construct is not stably maintained. [0125] In certain embodiments, the Cas endonuclease is a Cas9 endonuclease (see, e.g., WO 2013141680 entitled "RNA-directed DNA Cleavage by the Cas9-crRNA Complex"). Examples of Cas9 endonucleases include those from Streptococcus sp. (e.g., S. pyogenes, S. mutans, and S. thermophilus), Campylobacter sp. (e.g., C.

jejuni), Neisseria sp. (e.g., N. meningitides), Francisella sp. (e.g., F. novicida), and Pasteurella sp. (e.g., P. multocida) (see, e.g., Cas9 endonucleases described in

Fonfara et al., Nucleic Acids Res., 2013, pages 1 -14: incorporated herein by reference). In some embodiments, the Cas endonuclease is encoded by an optimized Cas9 endonuclease gene, e.g., optimized for expression in a fungal cell (e.g., Cas9 encoding genes containing SEQ ID NO:8, e.g., SEQ ID NO:9, as described below).

[0126] In certain instances, the Cas endonuclease gene is operably linked to one or more polynucleotides encoding nuclear localization signals such that the Cas

endonuclease/guide polynucleotide complex that is expressed in the cell is efficiently transported to the nucleus. Any convenient nuclear localization signal may be used, e.g., a polynucleotide encoding an SV40 nuclear localization signal present upstream of and in-frame with the Cas codon region and a polynucleotide encoding a nuclear localization signal derived from the T. reesei blr2 (blue light regulator 2) gene present downstream and in frame with the Cas codon region. Other nuclear localization signals can be employed. [0127] In certain embodiments of the disclosure, the guide polynucleotide is a guide RNA that includes a crRNA region (or crRNA fragment) and a tracrRNA region (or tracrRNA fragment) of the type II CRISPR/Cas system that can form a complex with a type II Cas endonuclease. As indicated above, the guide RNA/Cas endonuclease complex can direct the Cas endonuclease to a fungal cell genomic target site, enabling the Cas endonuclease to introduce a double strand break into the genomic target site. In some cases, the RNA that guides the RNA/ Cas9 endonuclease complex is a duplex that includes a crRNA and a separate tracrRNA. In other instances, the guide RNA is a single RNA molecule that includes both a crRNA region and a tracrRNA region

(sometimes referred to herein as a fused guide RNA). One advantage of using a fused guide RNA versus a duplexed crRNA-tracrRNA is that only one expression cassette needs to be made to express the fused guide RNA.

[0128] Host cells employed in the methods disclosed herein may be any fungal host cells are from the phyla Ascomycota, Basidiomycota, Chytridiomycota, and Zygomycota (as defined by Hawksworth et al., In, Ainsworth and Bisby's Dictionary of The Fungi, 8th edition, 1995, CAB International, University Press, Cambridge, UK) as well as the Oomycota (as cited in Hawksworth et al., supra) and all mitosporic fungi (Hawksworth et al., supra). In certain embodiments, the fungal host cells are yeast cells, e.g., Candida, Hansenula, Kluyveromyces, Pichia, Saccharomyces, Schizosaccharomyces, or Yarrowia cell. Species of yeast include, but are not limited to, the following:

Saccharomyces carlsbergensis, Saccharomyces cerevisiae, Saccharomyces

diastaticus, Saccharomyces douglasii, Saccharomyces kluyveri, Saccharomyces norbensis, Saccharomyces oviformis, Kluyveromyces lactis, and Yarrowia lipolytica cell. In additional embodiments, the fungal cells are filamentous fungal cells including but not limited to species of Trichoderma, Penicillium, Aspergillus, Humicola,

Chrysosporium, Fusarium, Neurospora, Myceliophthora, Hypocrea, and Emericella. For example, the filamentous fungi T. reesei and A. niger find use in aspects of the disclosed methods. [0129] Virtually any site in a fungal cell genome may be targeted using the disclosed methods, so long as the target site includes the required protospacer adjacent motif, or PAM. In the case of the S. pyogenes Cas9, the PAM has the sequence NGG (5' to 3'; where N is A, G, C or T), and thus does not impose significant restrictions on the selection of a target site in the genome. Other known Cas9 endonucleases have different PAM sites (see, e.g., Cas9 endonuclease PAM sites described in Fonfara et al., Nucleic Acids Res., 2013, pages 1 -14: incorporated herein by reference).

[0130] The length of the target site can vary, and includes, for example, target sites that are at least 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30 or more nucleotides in length. It is further possible that the target site can be palindromic, that is, the sequence on one strand reads the same in the opposite direction on the complementary strand. The cleavage site can be within the target sequence or the cleavage site could be outside of the target sequence. In another variation, the cleavage could occur at nucleotide positions immediately opposite each other to produce a blunt end cut or, in other cases, the incisions could be staggered to produce single-stranded overhangs, also called "sticky ends", which can be either 5' overhangs, or 3' overhangs.

[0131] In some cases, active variant target sequences in the genome of the fungal cell can also be used, meaning that the target site is not 100% identical to the relevant sequence in the guide polynucleotide (within the crRNA sequence of the guide polynucleotide). Such active variants can comprise at least 65%, 70%, 75%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the given target site, wherein the active variant target sequences retain biological activity and hence are capable of being recognized and cleaved by a Cas

endonuclease. Assays to measure the double-strand break of a target site by an endonuclease are known in the art and generally measure the overall activity and specificity of the agent on DNA substrates containing recognition sites.

[0132] Target sites of interest include those located within a region of a gene of interest. Non-limiting examples of regions within a gene of interest include an open reading frame, a promoter, a transcriptional regulatory element, a translational regulatory element, a transcriptional terminator sequence, an imRNA splice site, a protein coding sequence, an intron site, and an intron enhancing motif.

[0133] In certain embodiments, modification of the genome of the fungal cell results in a phenotypic effect that can be detected and, in many instances, is a desired outcome of the user. Non-limiting examples include acquisition of a selectable cell growth phenotype (e.g., resistance to or sensitivity to an antibiotic, gain or loss of an

auxotrophic characteristic, increased or decreased rate of growth, etc.), expression of a detectable marker (e.g., fluorescent marker, cell-surface molecule, chromogenic enzyme, etc.), and the secretion of an enzyme whose activity can be detected in culture supernatant.

[0134] In some instances, the genomic modification in the fungal cells is detected directly using any convenient method, including sequencing, PCR, Southern blot, restriction enzyme analysis, and the like, including combinations of such methods. [0135] In some embodiments, specific genes are targeted for modification using the disclosed methods, including genes encoding enzymes, e.g., acetyl esterases, aminopeptidases, amylases, arabinases, arabinofuranosidases, carboxypeptidases, catalases, cellulases, chitinases, cutinase, deoxyribonucleases, epimerases, esterases, a-galactosidases, β-galactosidases, a-glucanases, glucan lysases, endo- β- glucanases, glucoamylases, glucose oxidases, a-glucosidases, β-glucosidases, glucuronidases, hemicellulases, hexose oxidases, hydrolases, invertases, isomerases, laccases, lipases, lyases, mannosidases, oxidases, oxidoreductases, pectate lyases, pectin acetyl esterases, pectin depolymerases, pectin methyl esterases, pectinolytic enzymes, peroxidases, phenoloxidases, phytases, polygalacturonases, proteases, rhamno-galacturonases, ribonucleases, transferases, transport proteins,

transglutaminases, xylanases, hexose oxidases, and combinations thereof.

[0136] There are numerous variations for implementing the methods described herein. For example, instead of having the Cas expression cassette present as an exogenous sequence in the fungal host cell, this cassette can be integrated into the genome of the fungal host cell. Generating this parental cell line would allow a user to simply introduce a desired guide RNA (e.g., as a guide RNA expression vector) which would then target the genomic site of interest as detailed elsewhere herein. In some of these embodiments, the integrated Cas gene can be designed to include polynucleotide repeats flanking it for subsequent loop-out /removal from the genome if needed.

[0137] Non-limiting examples or embodiments of compositions and methods disclosed herein are as follows:

1 . A method for modifying the DNA sequence at a target site in the genome of a filamentous fungal cell, the method comprising:

a) introducing into a population of filamentous fungal cells a Cas

endonuclease and a guide RNA, wherein the Cas endonuclease and guide RNA are capable of forming a complex that enables the Cas endonuclease to introduce a double-strand break at a target site in the genome of the fungal cells; and

b) identifying at least one fungal cell from the population that has a

modification of the DNA sequence at the target site,

wherein the Cas endonuclease, the guide RNA, or both are introduced

transiently into the population of fungal cells.

2. The method of embodiment 1 , wherein the modification of the DNA sequence at said target site is selected from the group consisting of a deletion of one or more nucleotides, an insertion of one or more nucleotides, a substitution of one or more nucleotides, and any combination thereof.

3. The method of embodiment 1 or 2, wherein introducing the Cas

endonuclease into the population of fungal cells is achieved using a method selected from the group consisting of transfection, transduction, transformation, electroporation, particle bombardment (biolistic particle delivery), and cell fusion techniques.

4. The method of any preceding embodiment, wherein introducing the guide RNA into the population of fungal cells is achieved using a method selected from the group consisting of transfection, transduction, transformation,

electroporation, particle bombardment (biolistic particle delivery), and cell fusion techniques.

5. The method of any preceding embodiment, wherein the identifying step comprises culturing the population of fungal cells from step (a) under conditions to select for or screen for the modification of the DNA sequence at the target site.

6. The method of any preceding embodiment, wherein the identifying step comprises culturing the population of cells from step (a) under conditions to screen for unstable transformants.

7. The method of any preceding embodiment, wherein the Cas

endonuclease is a Cas9 endonuclease or variant thereof.

8. The method of embodiment 7, wherein the Cas9 endonuclease or variant thereof comprises a full length Cas9 or a functional fragment thereof from a species selected from the group consisting of: Streptococcus sp., S. pyogenes, S. mutans, S. thermophilus, Campylobacter sp., C. jejuni, Neisseria sp., N. meningitides, Francisella sp., F. novicida, and Pasteurella sp., P. multocida.

9. The method of embodiment 8, wherein the Cas9 endonuclease or variant thereof comprises an amino acid sequence that has at least 70% identity to any one of SEQ ID NOs:1 to 7 or a functional fragment thereof.

10. The method of any preceding embodiment, wherein the introducing step comprises introducing a DNA construct comprising an expression cassette for the Cas endonuclease into the fungal cells. 1 1 . The method of any preceding embodiment, wherein the introducing step comprises introducing a DNA construct comprising an expression cassette for the guide RNA into the fungal cells.

12. The method of any one of embodiments 1 to 9 and 1 1 , wherein the introducing step comprises directly introducing the Cas endonuclease into the fungal cells.

13. The method of any one of embodiments 1 to 10 and 12, wherein the introducing step comprises directly introducing the guide RNA into the fungal cells.

14. The method of embodiment 10, wherein the expression cassette for the Cas endonuclease comprises a Cas coding sequence that is optimized for expression in the fungal cell.

15. The method of embodiment 14, wherein the Cas coding sequence is a Cas9 coding sequence comprising a polynucleotide sequence that is at least 70% identical to SEQ ID NO:8 or a functional fragment thereof.

16. The method of any preceding embodiment, wherein the Cas

endonuclease is operably linked to a nuclear localization signal.

17. The method of embodiment 1 1 , wherein the expression cassette for the guide RNA comprises a RNA polymerase III dependent promoter functional in a Euascomycete or Pezizomycete, and wherein the promoter is operably linked to the DNA encoding the guide RNA.

18. The method of embodiment 17, wherein the promoter is derived from a Trichoderma U6 snRNA gene.

19. The method of embodiment 17 or 18, wherein the promoter comprises a nucleotide sequence with at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 1 1 or 12 or a functional fragment thereof.

20. The method of embodiment 19, wherein the promoter comprises the sequence of SEQ ID NO: 1 1 or 12.

21 . The method of any one of embodiments 1 1 and 17-20, wherein the expression cassette for the guide RNA comprises a guide RNA-encoding DNA with an intron sequence from a Trichoderma U6 snRNA gene.

22. The method of embodiment 21 , wherein the intron sequence derived from Trichoderma U6 snRNA gene comprises a nucleotide sequence with at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 90 or a functional fragment thereof.

23. The method of embodiment 22, wherein the intron sequence derived from Trichoderma U6 snRNA gene comprises the sequence of SEQ ID NO: 90.

24. The method of any preceding embodiment, wherein the filamentous fungal cell is a Eumycotina or Pezizomycotina fungal cell.

25. The method of any preceding embodiment, wherein filamentous fungal cell is selected from the group consisting of Trichoderma, Penicillium,

Aspergillus, Humicola, Chrysosporium, Fusarium, Myceliophthora, Neurospora, Hypocrea, and Emericella.

26. The method of any preceding embodiment, wherein the target site is located within a region of a gene of interest selected from the group consisting of: an open reading frame, a promoter, a regulatory sequence, a terminator sequence, a regulatory element sequence, a splice site, a coding sequence, a polyubiquitination site, an intron site, and an intron enhancing motif.

27. The method of any one of embodiments 1 , 2, 4-9, 1 1 , 13, and 16-19, wherein the introducing step comprises: (i) obtaining a parental fungal cell population that stably expresses the Cas endonuclease, and (ii) transiently introducing the guide RNA into the parental fungal cell population.

28. The method of any one of embodiments 1 -3, 5-10, 12, and 14-19, wherein the introducing step comprises: (i) obtaining a parental fungal cell population that stably expresses the guide RNA, and (ii) transiently introducing the Cas endonuclease into the parental fungal cell population.

29. The method of any preceding embodiment, wherein the modification of the DNA sequence at the target site is not caused by a homologous

recombination.

30. The method of any preceding embodiment, wherein the method does not involve introducing a donor DNA into the population of fungal cells.

31 . A recombinant fungal cell produced by the method of any preceding embodiment.

32. An engineered nucleic acid encoding a Cas endonuclease or variant thereof, wherein the Cas endonuclease or variant thereof comprises an amino acid sequence that has at least 70%, 75%, 80%, 85%, 90%, or 95% identity to any one of SEQ ID NOs:1 to 7 or a functional fragment thereof, and wherein the nucleic acid comprises a polynucleotide sequence that is at least 70% 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:8 or a functional fragment thereof.

33. The engineered nucleic acid of embodiment 32, wherein the nucleic acid comprises the sequence of SEQ ID NO:8.

34. An engineered nucleic acid encoding a guide RNA which enables a Cas endonuclease to introduce a double-strand break at a target site in the genome of a filamentous fungal cell, wherein the nucleic acid encoding the guide RNA comprises a RNA polymerase III dependent promoter functional in a Euascomycete or Pezizomycete, and the promoter is derived from a Trichoderma U6 snRNA gene

35. The engineered nucleic acid of embodiment 34, wherein the promoter comprises a nucleotide sequence with at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 1 1 or 12 or a functional fragment thereof.

36. An engineered nucleic acid encoding a guide RNA which enables a Cas endonuclease to introduce a double-strand break at a target site in the genome of a filamentous fungal cell, wherein the nucleic acid encoding the guide RNA comprises a guide RNA-encoding DNA with an intron sequence derived from a Trichoderma U6 snRNA gene.

37. The engineered nucleic acid of embodiment 36, wherein the intron sequence derived from Trichoderma U6 snRNA gene comprises a nucleotide sequence with at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 100% identity to SEQ ID NO: 90 or a functional fragment thereof.

38. The engineered nucleic acid of embodiment 34 or 36, wherein the nucleic acid encoding the guide RNA comprises both a promoter derived from a

Trichoderma U6 snRNA gene and an intron sequence derived from a

Trichoderma U6 snRNA gene, wherein the promoter comprises a nucleotide sequence with at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 1 1 or 12 or a functional fragment thereof, and wherein the intron sequence derived from Trichoderma U6 snRNA gene comprises a nucleotide sequence with at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 90 or a functional fragment thereof.

EXAMPLES

[0138] In the following Examples, unless otherwise stated, parts and percentages are by weight and degrees are Celsius. It should be understood that these Examples, while indicating embodiments of the disclosure, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can make various changes and modifications of the disclosure to adapt it to various usages and

conditions. Such modifications are also intended to fall within the scope of the appended claims.

Section A: Introduction of Cas/quide RNA by Expression Vectors

Example 1 : Identification of T. reesei U6 snRNA gene

[0139]An RNA polymerase III directed promoter is desired for production of guide RNA in T. reesei without the addition of a 5' cap structure or polyadenylation that would result from the use of a RNA polymerase II dependent promoter. However, no RNA

polymerase III dependent promoter that is functional in T. reesei has been described. Known RNA polymerase III dependent promoters from other species were considered to be tested for their ability to function in T. reeesi including the 5' upstream regions from the Saccharomyces cerevisiae snr52 gene, the human U6 snRNA gene, or the corn U6 snRNA gene.

[0140] More desirable was to identify a native T. reesei sequence that would function as an RNA polymerase III dependent promoter. The DNA sequence encoding the human U6 small nuclear RNA (snRNA; GenBank accession number M14486) was used to search the T. reesei v2 genome sequence (www.jgi.doe.gov) using the BLAST algorithm. A short region of T. reesei DNA sequence was identified with similarity to the human sequence. Examination of the surrounding DNA sequence and comparison with the U6 genes of yeasts, particularly Schizosaccharomyces pombe (Marck et al., 2006, Nucleic Acids Research 34:1816-1835), allowed a number of features of the T. reesei U6 gene to be putatively identified (SEQ ID NO:22, shown below). The start of the transcribed sequence and the terminator were identified as were an upstream TATA box. An intron apparently interrupts the transcribed region and possible A-box and B- box promoter elements can be recognized within the transcribed region, the latter within the intron. (see FIG. 1 ).

AAAAAACACTAGTAAGTACTTACTTATGTATTATTAACTACTTTAGCTAACTTCTGCA GTACTACCTAAGAGGCTAGGGGTAGTTTTATAGCAGACTTATAGCTATTATTTTTAT TT AGT AA AGTG CTTTT AAAGT AAG GTCTTTTTT AT AG C ACTTTTT ATTT ATT ATA AT AT ATATTATATAATAATTTTAAGCCTGGAATAGTAAAGAGGCTTATATAATAATTTATAG TAATAAAAGCTTAGCAGCTGTAATATAATTCCTAAAGAAACAGCATGAAATGGTATT ATGTAAGAGCTATAGTCTAAAGGCACTCTGCTGGATAAAAATAGTGGCTATAAGTC TGCTGCAAAACTACCCCCAACCTCGTAGGTATATAAGTACTGTTTGATGGTAGTCT ATCGCCTTCGGGCATTTGGTCAATTTATAACGATACAGGTTCGTTTCGGCTTTTCC TCGGAACCCCCAGAGGTCATCAGTTCGAATCGCTAACAGGTCAACAGAGAAGATT AGCATGGCCCCTGCACTAAGGATGACACGCTCACTCAAAGAGAAGCTAAACATTTT TTTTCTCTTCCAAGTCGTGATGGTTATCTTTTTGCTTAGAGAATCTATTCTTGTGGA CGATTAGTATTGGTAAATCCCTGCTGCACATTGCGGCGGATGGTCTCAACGGCAT AATACCCCATTCGTGATGCAGCGGTGATCTTCAATATGTAGTGTAATACGTTGCAT ACACCACCAGGTTCGGTGCCTCCTGTATGTACAGTACTGTAGTTCGACTCCTCCG CGCAGGTGGAAACGATTCCCTAGTGGGCAGGTATTTTGGCGGGGTCAAGAA (SEQ ID NO:22)

Example 2: sgRNA sequences to target T. reesei genes

[0141] It has been shown that a single guide RNA (sgRNA) molecule can interact with the Streptococcus pyogenes Cas9 protein to target this endonuclease in vivo to a specific locus in a eukaryote genome (REFS). The sgRNA is a hybrid molecule designed as a fusion between the tracrRNA and crRNA observed naturally to be components of the Streptococcus pyogenes type II CRISPR-Cas system (Gasiunas et al. (2012) Proc. Natl. Acad. Sci. USA 109:E2579-86, Jinek et al. (2012) Science

337:816-21 , Mali et al. (2013) Science 339:823-26, and Cong et al. (2013) Science

339:819-23). The first 20 nucleotides of the sgRNA are complementary to the target site in the genome. An additional sequence (PAM, protospacer adjacent motif) is also required to be present at the target site in the genome adjacent to the sgRNA- complementary region. In the case of the S. pyogenes Cas9 the PAM has the sequence NGG (where N is A, G, C or T).

[0142] The sequence of sgRNA used in these experiments is shown below where the 20 nucleotides designed to be complementary to the target site are shown as N residues (SEQ ID NO:23) (N = A, G, C, or U).

NNNNNNNNNNNNNNNNNNNNGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGG CUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGGUGC

[0143] sgRNAs were designed to target different loci in the T. reesei genome. The sequence of an sgRNA (called gAd3A TS1 ) to target the T. reesei ad3A gene

(Phosphoribosylamidoimidazole-succinocarboxamide synthase) at a site designated as target site 1 (TS1 ) is shown below (SEQ ID NO:24). The 20 nucleotide region that is complementary to the T. reesei genome sequence is shown in lower case. guccucgagcaaaaggugccGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGU CCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGGUGC

[0144]The sequence of an sgRNA (called gTrGA TS2) to target the T. reesei glal (glucoamylase) gene at a site designated as target site 2 (TS2) is shown below (SEQ ID NO:25). The 20 nucleotide region that is complementary to the T. reesei genome sequence is shown in lower case. guucagugcaauaggcgucuGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGU CCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGGUGC

[0145] The sequence of an sgRNA (called gTrGA TSU ) to target the T. reesei glal (glucoamylase) gene at a site designated as target site 11 (TS11 ) is shown below (SEQ ID NO:26). The 20 nucleotide region that is complementary to the T. reesei genome sequence is shown in lower case. gccaauggcgacggcagcacGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGU CCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGGUGC [0146]The sequence of an sgRNA (called gPyr2 TS6) to target the T. reesei pyr2

(orotate phosphoribosyltransferase) gene at a site designated as target site 6 (TS6) is shown below (SEQ ID NO:27). The 20 nucleotide region that is complementary to the T. reesei genome sequence is shown in lower case. gcacagcgggaugcccuuguGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGU CCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGGUGC

Example 3: Cas9 DNA and protein sequences for expression in T. reesei

[0147]A codon optimized Streptococcus pyogenes Cas9-encoding gene, including NLS sequences, was designed, synthesized and tested for expression in T. reesei (SEQ ID NO:9). The encoded protein (SEQ ID NO:10) has an N- terminal SV40 nuclear localization signal (NLS; SEQ ID NO: 19) and a C-terminal NLS derived from the T.

reesei blr2 (blue light regulator 2) gene (SEQ ID NO:20; both are underlined in SEQ ID NO:10 below). SEQ ID NO:9

atggcaccgaagaagaagcgcaaggtgatggacaagaagtacagcatcggcctcgacatcggcaccaactcggtgg gctgggccgtcatcacggacgaatataaggtcccgtcgaagaagttcaaggtcctcggcaatacagaccgccacagca tcaagaaaaacttgatcggcgccctcctgttcgatagcggcgagaccgcggaggcgaccaggctcaagaggaccgcc aggagacggtacactaggcgcaagaacaggatctgctacctgcaggagatcttcagcaacgagatggcgaaggtgg acgactccttcttccaccgcctggaggaatcattcctggtggaggaggacaagaagcatgagcggcacccaatcttcgg caacatcgtcgacgaggtggcctaccacgagaagtacccgacaatctaccacctccggaagaaactggtggacagca cagacaaggcggacctccggctcatctaccttgccctcgcgcatatgatcaagttccgcggccacttcctcatcgagggc gacctgaacccggacaactccgacgtggacaagctgttcatccagctcgtgcagacgtacaatcaactgttcgaggaga accccataaacgctagcggcgtggacgccaaggccatcctctcggccaggctctcgaaatcaagaaggctggagaac cttatcgcgcagttgccaggcgaaaagaagaacggcctcttcggcaaccttattgcgctcagcctcggcctgacgccga acttcaaatcaaacttcgacctcgcggaggacgccaagctccagctctcaaaggacacctacgacgacgacctcgaca acctcctggcccagataggagaccagtacgcggacctcttcctcgccgccaagaacctctccgacgctatcctgctcagc gacatccttcgggtcaacaccgaaattaccaaggcaccgctgtccgccagcatgattaaacgctacgacgagcaccatc aggacctcacgctgctcaaggcactcgtccgccagcagctccccgagaagtacaaggagatcttcttcgaccaatcaaa aaacggctacgcgggatatatcgacggcggtgccagccaggaagagttctacaagttcatcaaaccaatcctggagaa gatggacggcaccgaggagttgctggtcaagctcaacagggaggacctcctcaggaagcagaggaccttcgacaac ggctccatcccgcatcagatccacctgggcgaactgcatgccatcctgcggcgccaggaggacttctacccgttcctgaa ggataaccgggagaagatcgagaagatcttgacgttccgcatcccatactacgtgggcccgctggctcgcggcaactcc cggttcgcctggatgacccggaagtcggaggagaccatcacaccctggaactttgaggaggtggtcgataagggcgct agcgctcagagcttcatcgagcgcatgaccaacttcgataaaaacctgcccaatgaaaaagtcctccccaagcactcgc tgctctacgagtacttcaccgtgtacaacgagctcaccaaggtcaaatacgtcaccgagggcatgcggaagccggcgtt cctgagcggcgagcagaagaaggcgatagtggacctcctcttcaagaccaacaggaaggtgaccgtgaagcaattaa aagaggactacttcaagaaaatagagtgcttcgactccgtggagatctcgggcgtggaggatcggttcaacgcctcactc gg cacgtatcacg acctcctcaagatcattaaag acaagg acttcctcgacaacg agg agaacg agg acatcctcgag gacatcgtcctcaccctgaccctgttcgaggaccgcgaaatgatcgaggagaggctgaagacctacgcgcacctgttcg acgacaaggtcatgaaacagctcaagaggcgccgctacactggttggggaaggctgtcccgcaagctcattaatggca tcagggacaagcagagcggcaagaccatcctggacttcctcaagtccgacgggttcgccaaccgcaacttcatgcagc tcattcacgacgactcgctcacgttcaaggaagacatccagaaggcacaggtgagcgggcagggtgactccctccacg aacacatcgccaacctggccggctcgccggccattaaaaagggcatcctgcagacggtcaaggtcgtcgacgagctc gtgaaggtgatgggccggcacaagcccgaaaatatcgtcatagagatggccagggagaaccagaccacccaaaaa gggcagaagaactcgcgcgagcggatgaaacggatcgaggagggcattaaagagctcgggtcccagatcctgaag gagcaccccgtggaaaatacccagctccagaatgaaaagctctacctctactacctgcagaacggccgcgacatgtac gtggaccaggagctggacattaatcggctatcggactacgacgtcgaccacatcgtgccgcagtcgttcctcaaggacg atagcatcgacaacaaggtgctcacccggtcggataaaaatcggggcaagagcgacaacgtgcccagcgaggaggt cgtgaagaagatgaaaaactactggcgccagctcctcaacgcgaaactgatcacccagcgcaagttcgacaacctga cgaaggcggaacgcggtggcttgagcgaactcgataaggcgggcttcataaaaaggcagctggtcgagacgcgcca gatcacgaagcatgtcgcccagatcctggacagccgcatgaatactaagtacgatgaaaacgacaagctgatccggg aggtgaaggtgatcacgctgaagtccaagctcgtgtcggacttccgcaaggacttccagttctacaaggtccgcgagatc aacaactaccaccacgcccacgacgcctacctgaatgcggtggtcgggaccgccctgatcaagaagtacccgaagct ggagtcggagttcgtgtacggcgactacaaggtctacgacgtgcgcaaaatgatcgccaagtccgagcaggagatcgg caaggccacggcaaaatacttcttctactcgaacatcatgaacttcttcaagaccgagatcaccctcgcgaacggcgag atccgcaagcgcccgctcatcgaaaccaacggcgagacgggcgagatcgtctgggataagggccgggatttcgcgac ggtccgcaaggtgctctccatgccgcaagtcaatatcgtgaaaaagacggaggtccagacgggcgggttcagcaagg agtccatcctcccgaagcgcaactccgacaagctcatcgcgaggaagaaggattgggacccgaaaaaatatggcggc ttcgacagcccgaccgtcgcatacagcgtcctcgtcgtggcgaaggtggagaagggcaagtcaaagaagctcaagtcc gtgaaggagctgctcgggatcacgattatggagcggtcctccttcgagaagaacccgatcgacttcctagaggccaagg gatataaggaggtcaagaaggacctgattattaaactgccgaagtactcgctcttcgagctggaaaacggccgcaaga ggatgctcgcctccgcaggcgagttgcagaagggcaacgagctcgccctcccgagcaaatacgtcaatttcctgtacctc gctagccactatgaaaagctcaagggcagcccggaggacaacgagcagaagcagctcttcgtggagcagcacaag cattacctggacgagatcatcgagcagatcagcgagttctcgaagcgggtgatcctcgccgacgcgaacctggacaag gtgctgtcggcatataacaagcaccgcgacaaaccaatacgcgagcaggccgaaaatatcatccacctcttcaccctca ccaacctcggcgctccggcagccttcaagtacttcgacaccacgattgaccggaagcggtacacgagcacgaaggag gtgctcgatgcgacgctgatccaccagagcatcacagggctctatgaaacacgcatcgacctgagccagctgggcgga gacaagaagaagaagctcaagctctag

SEQ ID NO:10

MAPKKKRKVMDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGA

LLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEE

DKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLI

EGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLP

GEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADL

FLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEI

FFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNG

SIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRK

SEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKV

KYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDR

FNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKV MKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFK

EDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMA

RENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRD

MYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKM

KNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSR

MNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTAL

IKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEI

RKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRN

SDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSF

EKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYV

NFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSA

YNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITG

LYETRIDLSQLGGDKKKKLKL

Example 4: Construction of Cas9 expression vectors

[0148] The synthetic DNA sequence encoding Cas9 shown above was inserted into pENTR/D-TOPO so that it would be between flanking attl_1 and attl_2 sites to enable transfer by Gateway cloning (InVitrogen) into suitable expression vectors. A Gateway compatible expression vector, pTrex2gHyg, was available that comprises the following features; the promoter region from the T. reeesi pkil (pyruvate kinase) gene and terminator region from the T. reesei cbhl (cellobiohydrolase I) gene separated by Gateway cloning sites, a bacterial hygromycin phosphotransferase gene functionally linked to the Neurospora crassa cpd (cross pathway control 1 ) promoter region and the Aspergillus nidulans trpC (trifunctional protein with glutamine amido transferase, indoleglycerolphosphate synthase and phosphoribosylanthranilate isomerase activity) terminator region, and bacterial vector sequences for selection and maintenance in E. coli. The cas9 gene was cloned into pTrex2gHyg using the Gateway cloning procedure (InVitrogen) to give pTrex2gHyg MoCas (see FIG. 2).

Example 5: Construction of sgRNA expression vectors

[0149] Synthetic DNA sequences were obtained that encode the gAd3A TS1 sgRNA flanked by different putative RNA polymerase III dependent promoters and terminators. Each of these synthetic DNA sequences also had restriction enzyme recognition sites (EcoRI and BamHI) at either end. [0150] The following sequence encodes the gAd3A TS1 sgRNA (underlined) with the Saccharomyces cerevisiae snr52 promoter and S. cerevisiae sup4 terminator (denoted gAd3A TS1 -1 ; SEQ ID NO:28):

gaattcggatccTCTTTGAAAAGATAATGTATGATTATGCTTTCACTCATATTTATACAGA AACTTGATGTTTTCTTTCGAGTATATACAAGGTGATTACATGTACGTTTGAAGTACA ACTCTAGATTTTGTAGTGCCCTCTTGGGCTAGCGGTAAAGGTGCGCATTTTTTCAC ACCCTACAATGTTCTGTTCAAAAGATTTTGGTCAAACGCTGTAGAAGTGAAAGTTG GTGCGCATGTTTCGGCGTTCGAAACTTCTCCGCAGTGAAAGATAAATGATCqtcctcq aqcaaaaqqtqccGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATC AACTTGAAAAAGTGGCACCGAGTCGGTGGTGCTTTTTTTGTTTTTTATGTCTqaattcq gatcc

[0151] The following sequence encodes the gAd3A TS1 sgRNA (underlined) with the T. reesei U6 promoter and terminator (denoted gAd3A TS1 -2; SEQ ID NO:29): gaattcggatccAAAAAACACTAGTAAGTACTTACTTATGTATTATTAACTACTTTAGCTA ACTTCTGCAGTACTACCTAAGAGGCTAGGGGTAGTTTTATAGCAGACTTATAGCTA TTATTTTTATTTAGTAAAGTGCTTTTAAAGTAAGGTCTTTTTTATAGCACTTTTTATTT ATTATAATATATATTATATAATAATTTTAAGCCTGGAATAGTAAAGAGGCTTATATAA TAATTTATAGTAATAAAAGCTTAGCAGCTGTAATATAATTCCTAAAGAAACAGCATG AA ATG GT ATTATGT AAG AG CT AT AGTCT AAAG G C ACTCTG CTG G ATA AA AAT AGTG GCTATAAGTCTGCTGCAAAACTACCCCCAACCTCGTAGGTATATAAGTACTGTTTG ATGGTAGTCTATCqtcctcqaqcaaaaqqtqccGTTTTAGAGCTAGAAATAGCAAGTTAAAA TAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGGTGCTTTTTT TTCTCTTgaattcggatcc

[0152] The following sequence encodes the gAd3A TS1 sgRNA (underlined) with the T. reesei U6 promoter, terminator and an intron (in italics) (denoted gAd3A TS1 -3; SEQ ID NO:30): gaattcggatccAAAAAACACTAGTAAGTACTTACTTATGTATTATTAACTACTTTAGCTA ACTTCTGCAGTACTACCTAAGAGGCTAGGGGTAGTTTTATAGCAGACTTATAGCTA TTATTTTTATTTAGTAAAGTGCTTTTAAAGTAAGGTCTTTTTTATAGCACTTTTTATTT ATTATAATATATATTATATAATAATTTTAAGCCTGGAATAGTAAAGAGGCTTATATAA TAATTTATAGTAATAAAAGCTTAGCAGCTGTAATATAATTCCTAAAGAAACAGCATG AA ATG GT ATTATGT AAG AG CT AT AGTCT AAAG G C ACTCTG CTG G ATA AA AAT AGTG GCTATAAGTCTGCTGCAAAACTACCCCCAACCTCGTAGGTATATAAGTACTGTTTG ATGGTAGTCTATCqtcctcqaqcaaaaqqtqccGTTTTAGAGCTAGAGrrCGrrrCGGCrrr TCCTCGGAACCCCCAGAGGTCATCAGTTCGAATCGCTAACAGAA1 AGCAAGTT AAA ATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGGTGCTTTTT TTTCTCTTgaattcggatcc

[0153] Plasmid p219M (FIG. 3) is an E. coli vector containing the T. reesei pyr4

(orotidine monophosphate decarboxylase) gene including its native promoter and terminator. This vector was digested with EcoRI and BamHI and the ends were dephosphorylated. Each of the above synthetic DNA molecules was digested with EcoRI and BamHI and ligated with the cut p219M to create a series of vectors containing an sgRNA expression cassette and the pyr4 gene. Each vector was designated by the name of the sgRNA that it encoded (for example, p219M gAd3A TS1 - 1 incorporates the gAd3A expression cassette with the S. cerevisiae snr52 promoter and sup4 terminator).

[0154] Guide RNA expression cassettes with a shorter T. reesei U6 promoter region were obtained as synthetic DNA. An example is provided here that includes the sequence for an sgRNA targeting the T. reesei glal gene at TS11 (SEQ ID NO:31 ;

intron sequence is underlined).

AATTCCTAAAGAAACAGCATGAAATGGTATTATGTAAGAGCT AT AGTCT AAAGGCA CTCTGCTGGATAAAAATAGTGGCTATAAGTCTGCTGCAAAACTACCCCCAACCTCG TAGGTATATAAGTACTGTTTGATGGTAGTCTATCgccaatggcgacggcagcacGTTTTAGA GCTAGAGTTCGTTTCGGCTTTTCCTCGGAACCCCCAGAGGTCATCAGTTCGAATC GCTAACAGAAT AGCAAGTT AAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGG CACCGAGTCGGTGGTGCTTTTTTTTCTCTT

[0155] The above gRNA expression cassette was amplified by PCR using primers gRNA fwd aflll (5'- cgtcagcttaagaattcctaaagAAACAGCATGAAATGG; SEQ ID NO:32) and gRNA rev sfil (5'- cgtcagggccacgtgggccAAGAGAAAAAAAAGCACCACCGACTCGG; SEQ ID NO:33). These primers add an aflll to the 5' end and an sfil site to the 3' end of the guide RNA expression cassette. The PCR product was purified using a Qiagen PCR Purification Kit according to the manufacturer's directions. The PCR product was then digested with Sfil and Aflll and cleaned again on a Qiagen PCR Purification Kit. Plasmid pTrex2g/Hyg MoCas was digested with Sfil and Aflll and dephosphorylated using the Roche Rapid alkaline phosphatase kit (Roche Diagnostics Corp., IN). The digested plasmid and PCR product were finally ligated using the Roche Rapid DNA ligase kit to create

pTrex2g/Hyg MoCas gTrGA TS11 B. Other sgRNA expression cassettes were inserted into pTrex2g/Hyg MoCas in a similar manner.

Example 6: Cas9-mediated gene inactivation in Trichoderma reesei

[0156] A series of experiments are described below in which a Trichoderma reesei strain is either co-transformed with two separate expression vectors, one for production of Cas9 and one for production of gRNA, or is transformed with a single vector for expression of both Cas9 and gRNA. These experiments demonstrate that the 5' upstream region from the T. reesei U6 gene promotes gRNA transcription only when the U6 intron is also present within the gRNA transcribed region. The experiments also demonstrate that targeted gene inactivation can occur with high efficiency in T. reesei transformants.

Inactivation of the ad3A gene

[0157] A strain of Trichoderma reesei derived from the publicly available strain RL-P37 in which the genes (cbhl , cbh2, egl1 , and egl2) encoding the four major secreted cellulases were deleted was used. This strain also lacked a functional pyr4 gene.

Biolistic transformation (as described in US20060003408A1 ) was used to co-transform with a mixture of equal amounts of pTrex2gHyg MoCas and either p219M gAd3ATS1 -1 , p219M gAd3ATS1 -2 or p219M gAd3ATS1 -3. Transformants were selected on agar plates with Vogel's minimal medium containing 2% glucose, 100 mg/L hygromycin B and 200 mg/L adenine. After selection on the first plates transformant colonies were picked to fresh plates of the same selective medium. During growth on the second plate it was possible to distinguish between stable and unstable hygromycin-resistant transformants. Stable transformants grew more rapidly, the colonies had a smooth outline and the mycelium was more dense. Unstable transformants grew slower, had less dense mycelium and colonies had a ragged irregular outline. After growth on the second plate transformants were transferred to Vogel's medium with glucose, without hygromycin and with 14mg/L adenine to screen for those which exhibited a red/brown color indicating that they were adenine auxotrophs. Five stable and 23 unstable transformants were obtained with p219M gAd3ATS1 -1 and all were adenine prototrophs. Eleven stable and 38 unstable transformants were obtained with p219M gAd3ATS1 -2 and all 11 stable and 29 of the unstable transformants were adenine prototrophs. Nineteen stable and 2 unstable transformants were obtained with p219M gAd3ATS1 -3 and all were adenine auxotrophs. Clearly, adenine auxotrophs were only obtained with gAd3ATS1 -3 that utilizes the T. reesei U6 promoter, intron and terminator to control transcription of sgAd3A TS1 . Adenine auxotrophy indicates targeted Cas9 cleavage at the native T. reesei ad3A locus. It can be concluded that Cas9-mediated gene inactivation is efficient because all transformants with gAd3ATS1 -3 that were tested were adenine auxotrophs.

[0158] In order to determine the mutations at the ad3A locus in co-transformants with pTrex2gHyg MoCas and p219M gAd3ATS1 -3 genomic DNA was extracted from 10 stable adenine auxotrophic transformants. This DNA was used as template for PCR using several different primer pairs designed to generate products that spanned the Cas9 target site or were upstream or downstream of the target site. PfuUltra II Fusion HS DNA polymerase (Agilent Technologies) was used for the PCR according to the manufacturer's directions. In each case, the extension time was that suggested by the manufacturer for the expected size of the PCR product as described below. The sizes of the PCR products were evaluated by agarose gel electrophoresis. [0159] A PCR product of the expected size (872 bp) was obtained in all transformants using Ad3 5' fwd + Ad3 5' rev primers (5'- tgaacacagccaccgacatcagc [SEQ ID NO:34] and 5'- gctggtgagggtttgtgctattg [SEQ ID NO:35] respectively) that amplify a region on the 5' side of the TS1 target site.

[0160] A PCR product of the expected size (1214 bp) was obtained in all transformants using Ad3 5' fwd + Ad3a 5005 rev primers (5'- tgaacacagccaccgacatcagc [SEQ ID NO:34] and 5'- gattgcttgggaggaggacat [SEQ ID NO:36] respectively) that amplify a region on the 5' side of the TS1 target site.

[0161] A PCR product of the expected size (904 bp) was obtained in all transformants using Ad3 3' fwd + Ad3 3' rev primers (5'- cgaggccactgatgaagttgttc [SEQ ID NO:37] and 5'- cagttttccaaggctgccaacgc [SEQ ID NO:38] respectively) that amplify a region on the 3' side of the TS1 target site.

[0162] A PCR product of the expected size (757 bp) was obtained in all transformants using Ad3a 5003 fwd + Ad3mid rev primers (5'- ctgatcttgcaccctggaaatc [SEQ ID NO:39] and 5'- ctctctatcatttgccaccctcc [SEQ ID NO:40] respectively) that amplify a region on the 3' side of the TS1 target site.

[0163] The above PCR results demonstrated that the genomic DNA preparations were of a quality sufficient to obtain PCR products from either upstream or downstream of the Cas9 target site.

[0164] No PCR product could be obtained for any transformants using Adfrag fwd + Adfrag rev primers (5'- ctccattcaccctcaattctcc [SEQ ID NO:41 ] and 5'- gttcccttggcggtgcttggatc [SEQ ID NO:42] respectively) spanning the TS1 target site in ad3A. The expected size for this PCR product presuming no large size change caused by Cas9 activity was approximately 764 bp.

[0165] No PCR product could be obtained for any transformants using Adfrag fwd + Ad3 3' rev primers (5'- ctccattcaccctcaattctcc [SEQ ID NO:41 ] and 5'- cagttttccaaggctgccaacgc [SEQ ID NO:38] respectively) spanning the TS1 target site in ad3A. The expected size for this PCR product presuming no large size change caused by Cas9 activity was approximately 2504 bp.

[0166] No PCR product could be obtained for any transformants using Ad3a 2k fwd + Ad3a 2k rev primers (5'- caatagcacaaaccctcaccagc [SEQ ID NO:43] and 5'- gaacaacttcatcagtggcctcg [SEQ ID NO:44] respectively) spanning the TS1 target site in ad3A. The expected size for this PCR product presuming no large size change caused by Cas9 activity was approximately 1813 bp.

[0167] Five of the transformants also gave no PCR product using Adfrag fwd + Ad3 mid rev primers (5'- ctccattcaccctcaattctcc [SEQ ID NO:41 ] and 5'- ctctctatcatttgccaccctcc [SEQ ID NO:40] respectively) spanning the TS1 target site. The expected size for this PCR product presuming no large size change caused by Cas9 activity was

approximately 1438 bp.

[0168] Based on published data, Cas9-mediated inactivation of genes typically involves error-prone repair of a double-strand break in the DNA at the target site. The end result is small deletions or insertions (indels) at the target site. The above results from PCR analysis were surprising in that it was not possible to obtain a PCR product of the expected size that spanned the target site suggesting that inactivation of ad3A was not due to small insertions or deletions (indels) at the target site. Instead, these data are consistent with the possibilities that inactivation of ad3A was caused by a chromosomal rearrangement or large insertion at the target site. Inactivation of the glucoamylase (GA) gene

[0169] A strain of Trichoderma reesei derived from the publicly available strain RL-P37 in which the genes (cbhl , cbh2, egl1 , and egl2) encoding the four major secreted cellulases were deleted was used. This strain also lacked a functional pyr4 gene. This strain was co-transformed using the biolistic method with a mixture of equal amounts of pTrex2gHyg MoCas and p219M gTrGA TS2. Transformants were selected on agar plates with Vogel's minimal medium containing 1 % glucose, 100 ug/ml hygromycin B and 2 mg/ml uridine. After selection on the first plates transformant colonies were picked to fresh plates of the same selective medium. During growth on the second plate it was possible to distinguish between stable and unstable hygromycin-resistant transformants. Seventeen stable and 4 unstable transformants were obtained. These transformants were transferred to Vogel's agar plates without glucose and with 1 % insoluble starch to screen for presence or absence of secreted glucoamylase. Colonies able to secrete glucoamylase grow well and sporulate. Colonies unable to secrete glucoamylase grow with very sparse mycelium and are clearly distinguishable.

Fourteen of the 17 stable transformants were unable to secrete glucoamylase and all 4 of the unstable transformants did not secrete glucoamylase.

[0170] In order to determine the mutations at the glal (glucoamylase) locus in co- transformants with pTrex2gHyg MoCas and p219M gTrGA TS2 genomic DNA was extracted from 5 stable glucoamylase non-producing transformants. This DNA was used as template for PCR using different primer pairs designed to generate products that spanned the Cas9 target site or were upstream or downstream of the target site. PfuUltra II Fusion HS DNA polymerase (Agilent Technologies) was used for the PCR according to the manufacturer's directions. In each case, the extension time was that suggested by the manufacturer for the expected size of the PCR product as described below. The sizes of the PCR products were evaluated by agarose gel electrophoresis.

[0171] No PCR product could be obtained for any transformants using glaA + glaB primers (5'- ccgttagttgaagatccttgccg [SEQ ID NO:45] and 5'- gtcgaggatttgcttcatacctc [SEQ ID NO:46] respectively) spanning the TS2 target site in glal . The expected size for this PCR product presuming no large size change caused by Cas9 activity was approximately 1371 bp. [0172] A band of the expected size (364 bp) was obtained in all transformants using glaA + glaJ primers (5'- ccgttagttgaagatccttgccg [SEQ ID NO:45] and 5'- tgccgactttgtccagtgattcg [SEQ ID NO:47] respectively) that amplify a region on the 5' side of the TS2 target site. [0173] A band of the expected size (520 bp) was obtained in 4 of the transformants using glaK + glaB primers (5'- ttacatgtggacgcgagatagcg [SEQ ID NO:48] and 5'- gtcgaggatttgcttcatacctc [SEQ ID NO:46] respectively) that amplify a region on the 3' side of the TS2 target site. One of the transformants gave no PCR product with this primer pair. [0174] A separate experiment intended to demonstrate inactivation of the glal gene by targeted Cas9 action was performed using a strain of T. reesei derived from RL-P37 and having an inactive pyr4 gene. Protoplasts of this strain were transformed with pTrex2gHyg MoCas gTrGA TSU using a polyethylene glycol-mediated procedure (as described below). Transformants were selected on agar plates of Vogel's minimal medium with 2% glucose, 2 mg/ml uridine, 1 .1 M sorbitol and 100 ug/ml hygromycin B. After selection on the first plates transformant colonies were picked to fresh plates of the same selective medium without sorbitol. During growth on the second plate it was possible to distinguish between stable and unstable hygromycin-resistant

transformants. Transformants were transferred to Vogel's agar plates without glucose and with 1 % insoluble starch to screen for presence or absence of secreted

glucoamylase. Five stable transformants, designated B#1 , B#2, B#4, B#5 and B#6, which did not secrete glucoamylase were selected for further analysis. Genomic DNA was extracted from each of these transformants.

[0175] PCR was performed using genomic DNA as template and primers glal repF and glal repR (5'- gtgtgtctaatgcctccaccac [SEQ ID NO:49] and 5'- gatcgtgctagcgctgctgttg [SEQ ID NO:50] respectively) that generate a product of 983 bp from the wild-type glal locus spanning the TS11 target site. The PCR conditions included gradually reducing the primer annealing temperature with each PCR cycle and a long extension time to determine if there had been a large insertion at the target site. The specific PCR conditions were as follows.

Step 1 : 94C for 1 minute

Step 2: 94C for 25 seconds

Step 3: 63C for 30 seconds (temperature reduced by 0.2C per cycle) Step 4: 70C for 8 minutes

Steps 2-4 repeated 24 more times

Step 5: Hold at 4C [0176] A clear PCR product of greater than 12 kb was obtained from two of the transformants (B#1 and B#6) suggesting an increase of greater than 11 kb in the DNA region spanning the target site. The other three transformants gave only non-specific PCR products that appeared as low intensity bands on agarose gel electrophoresis. Sequence analysis of the >12 kb PCR product from B#6 demonstrated that DNA derived from plasmid pTrex2gHyg MoCas gTrGA TSU was inserted at the TS11 target site.

[0177] PCR was performed using genomic DNA samples B#2, B#4, and B#5 and primer pair 1553R and 1555F (5'- CCGTGATGGAGCCCGTCTTCT [SEQ ID NO:51 ] and 5'- CGCGGTGAGTTCAGGCTTTTTC [SEQ ID NO:52] respectively). Primer 1553R binds to the glal gene on the 3' side of target site 11 . Primer 1555F binds near the start codon of the hygromycin phosphotransferase (hygB) gene on the plasmid pTrex2gHyg MoCas gTrGA TSU . The same PCR conditions were used as above. PCR products of 4.5 kb and 6.5 were obtained for transformants B#4 and B#5 respectively. PCR products should only be obtained if the plasmid with the hygB gene had inserted into the glal gene. Presumably, the inserted plasmid DNA in transformants B#4, and B#5 was so large that it was not possible to obtain a PCR product using primers glal repF and glal repR.

[0178] Taken together, the PCR data demonstrated that stable hygromycin-resistant transformants with glucoamylase inactivation have arisen through insertion of large segments of the Cas9 and guide RNA expression vector at the target site in the glal gene.

Inactivation of the pyr2 gene

[0179] Transformants of T. reesei strains QM6a or RL-P37 were generated by PEG- mediated transformation of protoplasts with derivatives of plasmid pTrex2gHyg MoCas that included guide RNA expression cassettes targeting different positions within the T. reesei pyr2 gene. Inactivation of this gene confers uridine auxotrophy and resistance to 5-fluoroorotic acid (FOA). Transformants were initially selected on medium containing hygromycin B. Upon transfer to fresh agar plates containing hygromycin B they were scored as stable or unstable. Transformants were then transferred to agar plates of Vogel's minimal medium with 2 mg/ml uridine and 1 .2 mg/ml FOA. The ability to grow in the presence of FOA is indicative of uridine auxotrophy due to Cas9-mediated inactivation of the pyr2 gene.

[0180] Genomic DNA was extracted from some of the FOA resistant hygromycin stable and unstable transformants for PCR analysis. The primers used for this analysis were pyr2F (5'-gtataagagcaggaggagggag [SEQ ID NO:53]) and pyr2R (5'- gaacgcctcaatcagtcagtcg [SEQ ID NO:54]) designed to amplify a region of the pyr2 locus spanning the target sites and approximately 0.8kb in length.

[0181] Among the QM6a transformants shown to be FOA resistant 18 stable and 5 unstable hygromycin resistant transformants were tested using the PCR protocol with an extension time sufficient to amplify the region of the pyr2 locus presuming the size to be similar to that in a wild-type strain. None of the stable transformants gave a PCR product with this short extension time whereas 2 of the unstable transformants did give a PCR product. DNA sequence analysis of these two PCR products showed that one had a single nucleotide deletion and the other had a 111 nucleotide deletion at the expected target site.

[0182] Among the RL-P37 transformants shown to be FOA resistant 4 stable and 2 unstable hygromycin resistant transformants were tested using the PCR protocol with a short extension time. None of the stable transformants gave a PCR product with this short extension time whereas both of the unstable transformants did give a PCR product. DNA sequence analysis of these two PCR products showed that one had a single nucleotide deletion and the other had an insertion of 134 nucleotides at the expected target site. This insertion consisted of two small fragments of the pTrex2gHyg vector.

[0183] A different 6 stable hygromycin resistant RL-P37 transformants were analyzed using the PCR protocol described earlier designed to enable amplification of the region of the pyr2 locus presuming a large DNA fragment was inserted at the target site in the pyr2 locus. All 6 transformants gave a large PCR product (between approximately 5 kb and >12 kb depending on the transformant) with this long extension time protocol. DNA sequence analysis of 5 of these PCR products showed that pTrex2gHyg vector DNA, or fragments thereof, was integrated in all cases. [0184] Taken together, these data show that repair of a double strand break caused by Cas9 predominantly involves integration of large vector fragments in stable

transformants. This can be a very efficient method of gene inactivation. This also demonstrates that a DNA fragment or vector bearing a functional gene and having no sequence homology with the target site can integrate in a site-specific manner at the target site following Cas9 cleavage and double strand break formation. In contrast, small deletions or insertions (indels) are associated with inactivation of a gene by Cas9 in unstable transformants. This is the method of choice for gene inactivation if vector integration is undesirable.

Example 7: Expression of cas9 and sgRNA using expression vector with telomeres

[0185] A version of the Cas9 and guide RNA expression vector pTrex2gHyg MoCAS gPyr2 TS6 was constructed that contained Trichoderma reesei telomere sequences (shown in FIG. 6). The DNA sequence shown below (SEQ ID NO:55) was inserted into the vector. The underlined regions contain the repeated telomere sequences, each reading in towards center of this fragment. The central portion is a bacterial kanamycin resistance gene with promoter and terminator that enables selection in E. coli to ensure maintenance of the telomere repeats. In Trichoderma, a vector with telomeres is expected to linearize with the telomere sequences at each end and should be maintained autonomously at low copy number although occasional integration into the chromosomal DNA can also occur. tcaqqaaataqctttaaqtaqcttattaaqtattaaaattatatatatttttaatataactatatttctttaataaataqqtattttaaq ctttatatataaatataataataaaataatatattatataqctttttattaataaataaaataqctaaaaatataaaaaaaataq ctttaaaatacttatttttaattaqaattttatatatttttaatatataaqatcttttacttttttataaqcttcctaccttaaattaaattttta cttttttttactattttactatatcttaaataaaqqctttaaaaatataaaaaaaatcttcttatatattataaqctataaqqattatat atatatttttttttaatttttaaaqtaaqtattaaaqctaqaattaaaqttttaattttttaaqqctttatttaaaaaaaqqcaqtaata qcttataaaaqaaatttctttttcttttatactaaaaqtactttttttttaataaqqttaqqqttaqqqtttactcacaccqaccatcc caaccacatcttaqqqttaqqqttaqqqttaqqqttaqqqttaqqqttaqqqttaqqqtaaqqqtttaaacaaaq ccacgtt gtgtctcaaaatctctgatgttacattgcacaagataaaaatatatcatcatgaacaataaaactgtctgcttacataaacag taatacaaggggtgttatgagccatattcaacgggaaacgtcttgctcgaggccgcgattaaattccaacatggatgctga tttatatgggtataaatgggctcgcgataatgtcgggcaatcaggtgcgacaatctatcgattgtatgggaagcccgatgcg ccagagttgtttctgaaacatggcaaaggtagcgttgccaatgatgttacagatgagatggtcagactaaactggctgacg gaatttatgcctcttccgaccatcaagcattttatccgtactcctgatgatgcatggttactcaccactgcgatccccgggaaa acagcattccaggtattagaagaatatcctgattcaggtgaaaatattgttgatgcgctggcagtgttcctgcgccggttgca ttcgattcctgtttgtaattgtccttttaacagcgatcgcgtatttcgtctcgctcaggcgcaatcacgaatgaataacggtttggt tgatgcgagtgattttgatgacgagcgtaatggctggcctgttgaacaagtctggaaagaaatgcataagcttttgccattct caccggattcagtcgtcactcatggtgatttctcacttgataaccttatttttgacgaggggaaattaataggttgtattgatgttg gacgagtcggaatcgcagaccgataccaggatcttgccatcctatggaactgcctcggtgagttttctccttcattacagaa acggctttttcaaaaatatggtattgataatcctgatatgaataaattgcagtttcatttgatgctcgatgagtttttctaatcaga attggttaattggttgtaacactggcagagcattacgctgacttgacgggacggcggctttgttgaataaatcgaacttttgct gagttgaaggatcagatcacgcatcttcccgacaacgcagaccgttccgtggcaaagcaaaagttcaaaatcaccaact ggtccacctacaacaaagctctcatcaaccgtggctccctcactttctggctggatgatggggcgattcaggcctggtatga g tcag caacaccttcttcacg agg cag acctcag cqqtttaaacctaaccctaaccctaaccctaaccctaaccctaacc ctaaccctaaccctaaccctaaccctaaccctaaccctaaccctaacctaaccctaatqqqqtcqatctqaaccqaqqat qaqqqttctataqactaatctacaqqccqtacatqqtqtqattqcaqatqcqacqqqcaaqqtqtacaqtqtccaqaaqq aqqaqaqcqqcataqqtattqtaataqaccaqctttacataataatcqcctqttqctactqactqatqaccttcttccctaac caqtttcctaattaccactqcaqtqaqqataaccctaactcqctctqqqqttattattatactqattaqcaqqtqqcttatataqt qctqaaqtactataaqaqtttctqcqqqaqqaqqtqqaaqqactataaactqqacacaqttaqqqataqaqtqatqaca aqacctqaatqttatcctccqqtqtqqtataqcqaattqqctqaccttqcaqatqqtaatqqtttaqqcaqqqtttttqcaqaq qqqqacqaqaacqcqttctqcqatttaacqqctqctqccqccaaqctttacqqttctctaatqqqcqqccqc (SEQ ID NO:55) [0186] This vector was inserted into T. reesei strain RL-P37 by PEG-mediated

transformation of protoplasts. Transformants were selected for hygromycin resistance and transferred to fresh agar plates with hygromycin. The majority of transformants showed an unstable hygromycin resistance phenotype. Individual transformed colonies were transferred to minimal medium agar plates containing 2 mg/ml uridine and 1 .2 mg/ml 5-fluoroorotic acid to select for those that were able to grow and thus had a Pyr- minus phenotype. Eight out of 142 (6%) of the unstable transformants were Pyr-minus. Analysis by PCR of the pyr2 locus and sequencing of three of these transformants showed that two had small deletions at the target site (1 bp and 27 bp respectively) and one had a 1 bp deletion combined with an insertion of 68 bp derived from the bacterial vector portion of pTrex2gHyg MoCAS gPyr2 TS6. The other 5 transformants did not give a PCR product despite using PCR conditions designed to amplify large DNA fragments [PCR conditions: Step 1 : 94°C for 1 minute; Step 2: 94°C for 25 seconds; Step 3: 63C for 30 seconds (temperature reduced by 0.2C per cycle); Step 4: 70 °C for 8 minutes; Steps 2-4 repeated 24 more times; Step 5: Hold at 4°C. Polymerase:

PfuUltra II Fusion HS DNA polymerase (Agilent Technologies)].

[0187] These results demonstrate that expression of Cas9 and guide RNA from an autonomously replicating vector enables Cas9 targeting to a specific locus (pyr2 in this case). The resulting gene inactivation can occur without insertion of vector DNA at the target site.

Section B: Direct Introduction of Cas and/or guide RNA Example 8: Heterologous expression of CRISP R SpyCas9 in E.coli

[0188] E. coli codon-optimized Streptococcus pyogenes Cas9 (SpyCas9) gene was synthesized and inserted into the expression vector pET30a at Ncol and Hindlll sites by Generay (Shanghai, China), resulting in the plasmid pET30a-SpyCas9 (FIG. 7). As indicated in the plasmid map in FIG. 8A, the full coding sequence of the expression cassette contains, in 5' to 3' orientation, a sequence encoding an N-terminal His6 tag / thrombin / S*Tag™ / enterokinase region (SEQ ID NO:13; includes a start codon methionine), a sequence encoding an SV40 nuclear localization signal (SEQ ID

NO:14), a sequence encoding the SpyCas9 (SEQ ID NO:15), and a sequence encoding the BLR nuclear localization signal (SEQ ID NO:16) all in operable linkage. This entire coding sequence is shown in SEQ ID NO:17. The amino acid sequence of the N- terminal His6 tag / thrombin / S*Tag™ / enterokinase region encoded by SEQ ID NO:13 is shown in SEQ ID NO:18 (including the methionine at position 1 ), the amino acid sequence of the SV40 nuclear localization signal encoded by SEQ ID NO:14 is shown in SEQ ID NO:19, the amino acid sequence of the SpyCas9 encoded by SEQ ID NO:15 is shown in SEQ ID NO:1 , and the amino acid sequence of the BLR nuclear localization signal encoded by SEQ ID NO:16 is shown in SEQ ID NO:20. The amino acid sequence encoded by SEQ ID NO:17 is shown in SEQ ID NO:21 .

[0189] The pET30a-SpyCas9 plasmid was transformed into Rosetta2 (De3)plysS E. coli strain (Novagen®, EMD Biosciences, Inc., Merck KGaA, Darmstadt, Germany) and the transformation products were spread on Luria Agar plates supplemented with 34ppm Chloramphenicol and 50ppm Kanamycin. Colonies were picked and cultivated for 24 hours in a 250ml shake flask with 25 ml of the Invitrogen MagicMedia™ E.coli

Expression Medium (Thermo Fisher Scientific Inc., Grand Island, NY). Example 9: Purification of SpyCas9

[0190] For purification of SpyCas9, a combination of affinity, hydrophobic interaction and size exclusion chromatographic steps were applied. Briefly, SpyCas9 expressing E. coli cells (Rosetta2 (De3)plysS, as described above) were cultured in a 250ml shake flask with 25 ml MagicMedia™ for 24 hours and harvested by centrifugation. Cells (approximately 40 grams) were pelleted and resuspended in 400 ml lysis buffer (20mM HEPES, pH7.5, 500mM NaCI, 0.1 % Triton X-1 00, 1 mM DTT and 1 mM TCEP, protease inhibitor cocktail purchased from Roche) and lysed via ultra-sonicator (35% power, 20 min, 2s on/3s off) (SCIENT2-II D, Ningbo Scientz Biotechnology Co., LTD). The lysate was cleared by centrifugation at 20000g for 40 min.

[0191 ] Approximately 400 ml of clarified lysate was incubated with 5 ml Ni-NTA resin (GE Healthcare) overnight at A- C with shaking at 30 rpm/min using a Rolling Incubator (Kylin-Bell Lab. Instruments Co., Ltd. Haimen, China). After centrifugation, the resin was transferred to a XK26/20 column (GE Healthcare) and connected to AKTA Explorer system (GE Healthcare). After being washed extensively with equilibration buffer (20 mM HEPES, pH 7.5, 300 mM NaCI, 0.1 % Triton X-1 00) followed by wash buffer (25 mM imidazole in equilibration buffer), the target protein was eluted with250 mM imidazole in equilibration buffer. [0192] To the active fraction collected from the affinity step, ammonium sulfate was added to a final concentration of 0.8 M and loaded onto a 20 ml phenyl-Sepharose HP column (GE Healthcare). The column was eluted with a gradient of 0.8 M to 0.0 M ammonium sulfate in 50 mM HEPES buffer pH 7.5 and the flow through was collected.

[0193] Finally, the protein was further purified by size exclusion chromatography on a Superdex 200 1 6/60 column (GE Healthcare) in 20 mM HEPES pH7.5, 1 50 mM KCI and 1 0% glycerol. The fraction with the highest purity were pooled and concentrated via Amicon 30 KDa membrane filter (Millipore). The final protein sample was stored at - 20^QC freezer in the 40% glycerol until use.

Example 10: Guide RNA Design and Expression Vector Cloning

[0194] We used the Cas9 Target Finder to identify viable target sites. Target sequences with an appropriate PAM site were identified on the sense or antisense strand of the xyrl gene of Trichoderma reesei (Transcription factor Xylanase regulator 1 involved in Xylan degradation (Protein ID 122208)) as well as the pyr4 gene of Trichoderma reesei (orotidine-5'-monophosphate decarboxylase (Protein ID 74020)). Using this program, we identified all 20-nucleotide long target sequences followed by a 3-nucleotide PAM sequence (NGG) that matches the sequence pattern GGN18NGG or GN19NGG. Basic local alignment search tool (BLAST) was performed using the Trichoderma reesei genome sequence database (genome.jgi-psf.org/Trire2/Trire2.home) to check for uniqueness of the 20-nt sequence and to avoid off target effects. The following sequences were used to generate in vitro guide RNA expression constructs in the pSM1 guide plasmid (shown in FIG. 8A) for two xyrl specific target sites (xyrl Ta and xyrl Tc) and for one pyr4 specific target site (pyr4 TS2). The target sequences with the associated PAM sites as well as the oligos used for annealing and cloning into the pSM1 guide plasmid at the BSA1 restriction sites are shown:

XvM Ta

(1 ) Target sequence (5'-3', PAM bold underlined):

GCAGCACCTCGCACAGCATGCGG (SEQ ID NO:56)

(2) oligo 1 : TAGGCAGCACCTCGCACAGCATG (SEQ ID NO:57)

(3) oligo 2: AAACCATGCTGTGCGAGGTGCT (SEQ ID NO:58)

Xyrl Tc

(1 ) Target sequence (5'-3', PAM bold underlined):

GCTGCCAGGAAGAATTCAACGGG (SEQ ID NO:59)

(2) oligo 1 : TAGGCTGCCAGGAAGAATTCAAC (SEQ ID NO:60)

(3) oligo 2: AAACGTTGAATTCTTCCTGGCA (SEQ ID NO:61 )

Pyr4 TS2

(1 ) Target sequence (5'-3', PAM bold underlined):

GCTCAAGACGCACTACGACATGG (SEQ ID NO:62)

(2) oligo 1 : TAGGCTCAAGACGCACTACGACA (SEQ ID NO:63)

(3) oligo 2: AAACTGTCGTAGTGCGTCTTGAGC (SEQ ID NO:64)

[0195] The sequences below show the template sequence derived from the respective pSM1 guide plasmid constructs for transcription of each of the three guide RNAs (i.e., for the xyrl Ta, xyrl Tc and pyr4 TS2 target sites above). Each sequence below shows the 17 promoter (bold), the VT domain (shown in uppercase), the CER domain (shown in lowercase), and a transcriptional terminator (bold underline).

Xyr1 Ta (SEQ ID NO:65)

taatacgactcactataggGCAGCACCTCGCACAGCATGgttttagagctagaaatagcaagtt aaaataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggtgctttttacg

Xyr1 Tc (SEQ ID NO:66)

taatacgactcactataggGCTGCCAGGAAGAATTCAACgttttagagctagaaatagcaagtta aaataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggtgctttttacg

Pyr4 TS2 (SEQ ID NO:67)

taatacgactcactatagg G CTC AAG ACG C ACTACG AC Ag ttttagag ctag aaatag caagtta aaataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggtgctttttacg Example 11: In vitro DNA Cleavage assay

[0196] Guide RNAs were produced in vitro from templates for xyrl Ta and xyrl Tc using the MEGAshortscript™ 17 transcription kit from Thermo Fisher according to the manufacturer's instructions. In vitro transcription was carried out at 37^QC for at least 5 hours. Transcribed guide RNAs were purified using MEGAclear™ Transcription Clean- Up kit from Thermo Fisher. The RNA concentration was measured with NanoDrop™ (Thermo Fisher). Denaturing urea- PAGE gel (10%) was used to confirm the quality of the guide RNA produced (data not shown).

[0197] Purified Cas9 protein (200ng) was incubated with: (1 ) 300 ng substrate DNA alone (substrate DNA is plasmid pXA3 [shown in FIG. 9A] linearized with Ndel ; pXA3 contains the xyrl gene [SEQ ID NO:89] that has the 20bp target sequence and appropriately spaced PAM site for both of the xyrl guide RNAs)(2) 300ng substrate DNA in the presence of 100ng in vitro synthesized xyrl Ta guide RNA; and (3) 300ng substrate DNA in the presence of 100ng in vitro synthesized xyrl Tc guide RNA. The reactions were carried out in NEB buffer 3 in a reaction volume of 20ul for 1 h at 37 °C. (1 X NEB3 Buffer Components consists of 10OmM NaCI, 50mM Tris-HCI, 10mM

MgCI21 OmM MgCI2, 1 mM DTT, pH 7.9 at 25 °C.)

[0198] As shown in FIG. 9B, each of the xyrl specific guide RNA with purified SpyCas9 can successfully cut substrate DNA into the expected fragments(Lanes 3 and 4), confirming the function of the synthesized guide RNA/Cas9 complex. Lane 1 shows molecular weight markers; Lane 2 shows Ndel-linearized plasmid pXA3 substrate in the absence of Cas9 and guide RNA; Lane 3 shows cleavage of linearized plasmid pXA3 substrate in the presence of Cas9 and a guide RNA with the xyrl Ta VT domain; Lane 4 shows cleavage of the linearized plasmid pXA3 substrate in the presence of Cas9 and a guide RNA with the xyrl Tc VT domain. Positions of the linearized plasmid pXA3 substrate and products are indicated at the right.

Example 12: guide RNA introduction into Cas9-expressing fungal cells

Methods

(i) Protoplast preparation

[0199] For protoplast preparation, 5 x 1 08 spores of the desired T. reesei strain are inoculated into 50 ml germination medium (recipe described in US Patent No.

8,679,815) in a 250 ml shake flask with 4 baffles and incubated at 27°C for 17 hours at 170 rpm. The myceiia are recovered by transferring the liquid volume into 50 ml conical tubes and spinning at 3000 rpm for 10 minutes. The supernatant is decanted and the mycelial pellets are washed twice using 1 .2 M MgSO4 -10 imM Na-phosphate buffer and resuspended in 15 ml lysing enzyme buffer (lysing Enzyme from Trichoderma harzianum (Sigma catalog #L1412)) dissolved in 1 .2 M MgSO4 - 10 imM Na-phosphate buffer (pH 5.8), 50 mg/ml). The cell suspension is transferred into a 250 ml shake flask with 4 baffles and shaken at room temperature for at least 2 hours at 200 rpm. The protoplasts are harvested by filtration through Miracloth (Calbiochem Art. No. 475855) folded in a glass funnel into a Greiner tube. 0.6 M Sorbitol - 0.1 M Tris-HCI buffer is added carefully on top of the filtered protoplasts. The protoplasts are collected by centrifugation for 15 minutes at 4000 rpm. The middle phase containing the protoplasts is transferred into a new tube and added at least an equal volume of 1 .2 M Sorbitol - 10 mM Tris-HCI buffer. The protoplasts are collected by centrifugation for 5 minutes at 4000 rpm, and washed two times with 1 .2M sorbitol-10mM Tris-HCI buffer. The pellet is resuspended into at least 1 ml 1 .2 M Sorbitol - 10 mM Tris-HCI pH 7.5 - 10 mM CaCI2 buffer and the number of protoplasts counted under a microscope. The protoplast suspension is diluted using 4 parts of 1 .2 M Sorbitol - 10 mM Tris-HCI - 10 mM CaCI2 and 1 part of 25% PEG6000 - 50 mM CaCI2 - 10mM Tris-HCI until 5 x 108 per ml for use in subsequent transformation. (ii)Transformation

[0200] The desired cargo (e.g., a DNA construct, guide RNA, Cas9/guide RNA complex, etc.) is added to 200 μΙ_ protoplast (~1 ^χ 1 08) and kept on ice for 30 min. After

incubation, protoplasts are added to cooled molten sorbitol/Vogel agar (1 .1 M sorbitol of minimal Vogel agar) to be as the top layer of the minimal Vogel plate (Davis et al., (1 970) Methods in Enzymology 1 7A, pp. 79-143 and Davis, Rowland, NEUROSPORA, CONTRIBUTIONS OF A MODEL ORGANISM, Oxford University Press, (2000)). The plates are incubated at 30 ° C for a week. The detailed steps are described in US Patent No. 8,679,815 (incorporated herein by reference).

Experimental

[0201 ] Protoplasts of a Trichoderma reesei strain having an inactivated pyr2 gene (encoding orotate phosphoribosyl transferase, Protein ID 21435) (strain T4 mpg1 Apyr2) was transformed as described above with a DNA construct containing an expression cassette for Cas9 under the control of the pyruvate kinase (pki) promoter and an expression cassette for the pyr2 gene from T. reesei under the control of the its native promoter. A transformant with the Cas9-pyr2 cassette integrated into the genome and constitutively expressing the Cas9 gene was identified by selecting for cells having a functional pyr2 gene (growth without uridine supplementation on Vogels media).

[0202] Twenty (20) ug of in vitro synthesized Pyr4 TS2 guide RNA as described above (with target site 5'GCTCAAGACGCACTACGACA3', SEQ ID NO:92) was introduced into the Cas9 expressing T. reesei cells by the protoplast transformation method described above. Analysis of the pyr4 gene from isolated strains that are resistant to FOA and require uridine for growth by sequencing and alignment showed the presence of changes to the DNA sequence at the pyr4 gene target site. Sequence changes included insertions of a few nucleotides (1 -2 nucleotides; clones T4 4-3, T4 4-11 , T4 4- 1 8, T4 4-1 9, T4 4-4, and T4 4-7) as well as larger insertions (68 nucleotides, clone T4 4-20) (FIG. 1 0). This demonstrates that direct, transient introduction of guide RNA into a Cas-expressing fungal host cell can be used to modify the DNA sequence at a desired target site in the genome of the cell. Example 13: In vivo SpyCas9/guide RNA uptake experiment

[0203]To form the Cas9/guide RNA complex in vitro, purified Cas9 protein 20 μg was mixed with Pyr4 TS2 guide RNA 20 μg in 20mM Hepes, 100mM NaCI, 5mM MgCI2, 0.1 mM EDTA pH6.5 (final volume is 40 μΙ_), and incubated at room temperature from 15-30 minutes to allow for complex formation. The Cas9/guide RNA complex was transformed into T. reesei protoplasts as described above and grown on Vogel's Uridine FOA plates.

[0204] PCR analysis of the isolated strains from this transformation is shown in FIGS. 11 A and B. FIG. 11 A shows agarose gel analysis of pyr4 specific PCR products (encompassing the target site) of two isolated strains (P37 2.2. and P37 4.1 ; both resistant to FOA and that require uridine for growth). Strain P37 2.2 (Lane 2) showed a PCR product that is of lower molecular weight than the T4 4.1 clone (Lane 3; which is equivalent to the control, shown in FIG. 11 B, Lane 2), indicating a large deletion in the pyr4 gene. FIG. 11 B shows similar PCR/agarose gel analysis as in FIG. 11 A, and includes analysis of P37 strains 4.1 , 4.2, 4.3, and 4.4 (all of which are resistant to FOA and require uridine for growth). Strain 4.3 (Lane 5) showed PCR product of the pyr4 gene that is of lower molecular weight than the control (C+; Lane 2), indicating a large deletion in the pyr4 gene.

[0205] Sequence analysis of the pyr4 genes derived from clones T4 2.2 (shown in FIG. 11 A) and T4 2.4 (not shown in FIG. 11 A or 11 B) is shown in FIG. 12. Note that the wild type pyr4 sequence is the first sequence (top) in the alignments. This analysis shows that the T4 2.2 clone (top alignment) has a deletion of 61 1 base pairs at the target site of the introduced Cas9/guide RNA complex. The sequence corresponding to the VT domain sequence of the guide RNA is boxed and the PAM site is circled. The bottom alignment shows a 1 base pair insertion in the pyr4 gene at the target site of the isolated T4 2.4 strain (a "G" residue). The sequence corresponding to the VT domain sequence of the guide RNA is indicated with a line over the alignment and the PAM site is circled.

[0206] FIG. 13 shows sequence analysis of the pyr4 genes derived from clones P37 4.1 and 4.2 (top alignment), 4.3 (bottom alignment) and 4.4 (middle alignment) (which were shown in FIG. 11 B). The wild type pyr4 sequence is the first sequence (top) in all alignments and a consensus is shown on the bottom of all alignments. The top alignment shows that the P37 4.1 clone (third sequence in the alignment) has an insertion of a T nucleotide while the P37 4.2 clone (second sequence in the alignment) has an insertion of a G nucleotide at the target site in the pyr4 gene. The middle alignment shows that the P37 4.4 clone (second sequence in the alignment) has a deletion of an A nucleotide at the target site in the pyr4 gene. The bottom alignment shows that the pyr4 gene sequence in the P37 4.3 clone (second sequence in the alignment) diverges abruptly at the target site. Further alignment analysis (not shown) confirmed that the P37 4.3 clone has a deletion of 988 base pairs at the target site of the introduced Cas9/guide RNA complex.

[0207] This demonstrates that direct, transient introduction of a Cas9/guide RNA complex into a fungal host cell can be used to modify the DNA sequence at a desired target site in the genome of the cell.

[0208] Although the foregoing compositions and methods have been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings herein that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

[0209] Accordingly, the preceding merely illustrates the principles of the present compositions and methods. It will be appreciated that those skilled in the art will be able to devise various arrangements which, although not explicitly described or shown herein, embody the principles of the present compositions and methods and are included within its spirit and scope. Furthermore, all examples and conditional language recited herein are principally intended to aid the reader in understanding the principles of the present compositions and methods and the concepts contributed by the inventors to furthering the art, and are to be construed as being without limitation to such specifically recited examples and conditions. Moreover, all statements herein reciting principles, aspects, and embodiments of the present compositions and methods as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents and equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure. The scope of the present compositions and methods, therefore, is not intended to be limited to the exemplary embodiments shown and described herein. Sequences:

SEQ ID NO:1

Streptococcus pyogenes Cas9, no NLS (encoded by SEQ ID NO:8 and SEQ ID NO:15)

MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETA

EATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPI

FGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDN

SDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLF

GNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLS

DAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKN

GYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHL

GELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITP

WNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEG

MRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLG

TYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKR

RRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQ

VSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQ

KGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELD

INRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLL

NAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDEN

DKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLES

EFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETN

GETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKK

DWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLE

AKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHY

EKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPI

REQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQ

LGGD

SEQ ID NO:2

Streptococcus thermophilus LMD-9 Cas9

MTKPYSIGLDIGTNSVGWAVTTDNYKVPSKKMKVLGNTSKKYIKKNLLGVLLFDSGITA EGRRLKRTARRRYTRRRNRILYLQEIFSTEMATLDDAFFQRLDDSFLVPDDKRDSKYPI FGNLVEEKAYHDEFPTIYHLRKYLADSTKKADLRLVYLALAHMIKYRGHFLIEGEFNSK NNDIQKNFQDFLDTYNAIFESDLSLENSKQLEEIVKDKISKLEKKDRILKLFPGEKNSGIF SEFLKLIVGNQADFRKCFNLDEKASLHFSKESYDEDLETLLGYIGDDYSDVFLKAKKLY

DAILLSGFLTVTDNETEAPLSSAMIKRYNEHKEDLALLKEYIRNISLKTYNEVFKDDTKN

GYAGYIDGKTNQEDFYVYLKKLLAEFEGADYFLEKIDREDFLRKQRTFDNGSIPYQIHL

QEMRAILDKQAKFYPFLAKNKERIEKILTFRIPYYVGPLARGNSDFAWSIRKRNEKITPW

NFEDVIDKESSAEAFINRMTSFDLYLPEEKVLPKHSLLYETFNVYNELTKVRFIAESMRD

YQFLDSKQKKDIVRLYFKDKRKVTDKDIIEYLHAIYGYDGIELKGIEKQFNSSLSTYHDLL

NIINDKEFLDDSSNEAIIEEIIHTLTIFEDREMIKQRLSKFENIFDKSVLKKLSRRHYTGWG

KLSAKLINGIRDEKSGNTILDYLIDDGISNRNFMQLIHDDALSFKKKIQKAQIIGDEDKGNI

KEVVKSLPGSPAIKKGILQSIKIVDELVKVMGGRKPESIVVEMARENQYTNQGKSNSQQ

RLKRLEKSLKELGSKILKENIPAKLSKIDNNALQNDRLYLYYLQNGKDMYTGDDLDIDRL

SNYDIDHIIPQAFLKDNSIDNKVLVSSASNRGKSDDVPSLEVVKKRKTFWYQLLKSKLIS

QRKFDNLTKAERGGLSPEDKAGFIQRQLVETRQITKHVARLLDEKFNNKKDENNRAVR

TVKIITLKSTLVSQFRKDFELYKVREINDFHHAHDAYLNAVVASALLKKYPKLEPEFVYG

DYPKYNSFRERKSATEKVYFYSNIMNIFKKSISLADGRVIERPLIEVNEETGESVWNKE

SDLATVRRVLSYPQVNVVKKVEEQNHGLDRGKPKGLFNANLSSKPKPNSNENLVGAK

EYLDPKKYGGYAGISNSFTVLVKGTIEKGAKKKITNVLEFQGISILDRINYRKDKLNFLLE

KGYKDIELIIELPKYSLFELSDGSRRMLASILSTNNKRGEIHKGNQIFLSQKFVKLLYHAK

RISNTINENHRKYVENHKKEFEELFYYILEFNENYVGAKKNGKLLNSAFQSWQNHSIDE

LCSSFIGPTGSERKGLFELTSRGSAADFEFLGVKIPRYRDYTPSSLLKDATLIHQSVTGL

YETRIDLAKLGEG

SEQ ID NO:3

Streptococcus mutans UA159 Cas9

MKKPYSIGLDIGTNSVGWAVVTDDYKVPAKKMKVLGNTDKSHIEKNLLGALLFDSGNT

AEDRRLKRTARRRYTRRRNRILYLQEIFSEEMGKVDDSFFHRLEDSFLVTEDKRGERH

PIFGNLEEEVKYHENFPTIYHLRQYLADNPEKVDLRLVYLALAHIIKFRGHFLIEGKFDTR

NNDVQRLFQEFLAVYDNTFENSSLQEQNVQVEEILTDKISKSAKKDRVLKLFPNEKSN

GRFAEFLKLIVGNQADFKKHFELEEKAPLQFSKDTYEEELEVLLAQIGDNYAELFLSAK

KLYDSILLSGILTVTDVGTKAPLSASMIQRYNEHQMDLAQLKQFIRQKLSDKYNEVFSD

VSKDGYAGYIDGKTNQEAFYKYLKGLLNKIEGSGYFLDKIEREDFLRKQRTFDNGSIPH

QIHLQEMRAIIRRQAEFYPFLADNQDRIEKLLTFRIPYYVGPLARGKSDFAWLSRKSAD

KITPWNFDEIVDKESSAEAFINRMTNYDLYLPNQKVLPKHSLLYEKFTVYNELTKVKYK

TEQGKTAFFDANMKQEIFDGVFKVYRKVTKDKLMDFLEKEFDEFRIVDLTGLDKENKV

FNASYGTYHDLCKILDKDFLDNSKNEKILEDIVLTLTLFEDREMIRKRLENYSDLLTKEQ VKKLERRHYTGWGRLSAELIHGIRNKESRKTILDYLIDDGNSNRNFMQLINDDALSFKE

EIAKAQVIGETDNLNQVVSDIAGSPAIKKGILQSLKIVDELVKIMGHQPENIVVEMAREN

QFTNQGRRNSQQRLKGLTDSIKEFGSQILKEHPVENSQLQNDRLFLYYLQNGRDMYT

GEELDIDYLSQYDIDHIIPQAFIKDNSIDNRVLTSSKENRGKSDDVPSKDVVRKMKSYW

SKLLSAKLITQRKFDNLTKAERGGLTDDDKAGFIKRQLVETRQITKHVARILDERFNTET

DENNKKIRQVKIVTLKSNLVSNFRKEFELYKVREINDYHHAHDAYLNAVIGKALLGVYP

QLEPEFVYGDYPHFHGHKENKATAKKFFYSNIMNFFKKDDVRTDKNGEIIWKKDEHIS

NIKKVLSYPQVNIVKKVEEQTGGFSKESILPKGNSDKLIPRKTKKFYWDTKKYGGFDSP

IVAYSILVIADIEKGKSKKLKTVKALVGVTIMEKMTFERDPVAFLERKGYRNVQEENIIKL

PKYSLFKLENGRKRLLASARELQKGNEIVLPNHLGTLLYHAKNIHKVDEPKHLDYVDKH

KDEFKELLDVVSNFSKKYTLAEGNLEKIKELYAQNNGEDLKELASSFINLLTFTAIGAPA

TFKFFDKNIDRKRYTSTTEILNATLIHQSITGLYETRIDLNKLGGD

SEQ ID NO:4

Campylobacter jejuni Cas9

MARILAFDIGISSIGWAFSENDELKDCGVRIFTKVENPKTGESLALPRRLARSARKRLAR

RKARLNHLKHLIANEFKLNYEDYQSFDESLAKAYKGSLISPYELRFRALNELLSKQDFA

RVILHIAKRRGYDDIKNSDDKEKGAILKAIKQNEEKLANYQSVGEYLYKEYFQKFKENS

KEFTNVRNKKESYERCIAQSFLKDELKLIFKKQREFGFSFSKKFEEEVLSVAFYKRALK

DFSHLVGNCSFFTDEKRAPKNSPLAFMFVALTRIINLLNNLKNTEGILYTKDDLNALLNE

VLKNGTLTYKQTKKLLGLSDDYEFKGEKGTYFIEFKKYKEFIKALGEHNLSQDDLNEIAK

DITLIKDEIKLKKALAKYDLNQNQIDSLSKLEFKDHLNISFKALKLVTPLMLEGKKYDEAC

NELNLKVAINEDKKDFLPAFNETYYKDEVTNPVVLRAIKEYRKVLNALLKKYGKVHKINI

ELAREVGKNHSQRAKIEKEQNENYKAKKDAELECEKLGLKINSKNILKLRLFKEQKEFC

AYSGEKIKISDLQDEKMLEIDHIYPYSRSFDDSYMNKVLVFTKQNQEKLNQTPFEAFGN

DSAKWQKIEVLAKNLPTKKQKRILDKNYKDKEQKNFKDRNLNDTRYIARLVLNYTKDYL

DFLPLSDDENTKLNDTQKGSKVHVEAKSGMLTSALRHTWGFSAKDRNNHLHHAIDAVI

IAYANNSIVKAFSDFKKEQESNSAELYAKKISELDYKNKRKFFEPFSGFRQKVLDKIDEI

FVSKPERKKPSGALHEETFRKEEEFYQSYGGKEGVLKALELGKIRKVNGKIVKNGDMF

RVDIFKHKKTNKFYAVPIYTMDFALKVLPNKAVARSKKGEIKDWILMDENYEFCFSLYK

DSLILIQTKDMQEPEFVYYNAFTSSTVSLIVSKHDNKFETLSKNQKILFKNANEKEVIAKS

IGIQNLKVFEKYIVSALGEVTKAEFRQREDFKK SEQ ID NO:5

Neisseria meningitides Cas9

MAAFKPNSINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRVFERAEVPKTGDSLAM

ARRLARSVRRLTRRRAHRLLRTRRLLKREGVLQAANFDENGLIKSLPNTPWQLRAAAL

DRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVAGNAHALQTGDFRT

PAELALNKFEKESGHIRNQRSDYSHTFSRKDLQAELILLFEKQKEFGNPHVSGGLKEGI

ETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTKLNNLRILEQGS

ERPLTDTERATLMDEPYRKSKLTYAQARKLLGLEDTAFFKGLRYGKDNAEASTLMEM

KAYHAISRALEKEGLKDKKSPLNLSPELQDEIGTAFSLFKTDEDITGRLKDRIQPEILEAL

LKHISFDKFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEI

RNPVVLRALSQARKVINGVVRRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDR

EKAAAKFREYFPNFVGEPKSKDILKLRLYEQQHGKCLYSGKEINLGRLNEKGYVEIDHA

LPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFP

RSKKQRILLQKFDEDGFKERNLNDTRYVNRFLCQFVADRMRLTGKGKKRVFASNGQI

TNLLRGFWGLRKVRAENDRHHALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTID

KETGEVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTLEKLRTLLAEKLSSR

PEAVHEYVTPLFVSRAPNRKMSGQGHMETVKSAKRLDEGVSVLRVPLTQLKLKDLEK

MVNREREPKLYEALKARLEAHKDDPAKAFAEPFYKYDKAGNRTQQVKAVRVEQVQKT

GVWVRNHNGIADNATMVRVDVFEKGDKYYLVPIYSWQVAKGILPDRAVVQGKDEED

WQLIDDSFNFKFSLHPNDLVEVITKKARMFGYFASCHRGTGNINIRIHDLDHKIGKNGIL

EGIGVKTALSFQKYQIDELGKEIRPCRLKKRPPVR

SEQ ID NO:6

Francisella tularensis subsp. novicida Cas9

MNFKILPIAIDLGVKNTGVFSAFYQKGTSLERLDNKNGKVYELSKDSYTLLMNNRTARR

HQRRGIDRKQLVKRLFKLIWTEQLNLEWDKDTQQAISFLFNRRGFSFITDGYSPEYLNI

VPEQVKAILMDIFDDYNGEDDLDSYLKLATEQESKISEIYNKLMQKILEFKLMKLCTDIKD

DKVSTKTLKEITSYEFELLADYLANYSESLKTQKFSYTDKQGNLKELSYYHHDKYNIQE

FLKRHATINDRILDTLLTDDLDIWNFNFEKFDFDKNEEKLQNQEDKDHIQAHLHHFVFA

VNKIKSEMASGGRHRSQYFQEITNVLDENNHQEGYLKNFCENLHNKKYSNLSVKNLV

NLIGNLSNLELKPLRKYFNDKIHAKADHWDEQKFTETYCHWILGEWRVGVKDQDKKD

GAKYSYKDLCNELKQKVTKAGLVDFLLELDPCRTIPPYLDNNNRKPPKCQSLILNPKFL

DNQYPNWQQYLQELKKLQSIQNYLDSFETDLKVLKSSKDQPYFVEYKSSNQQIASGQ

RDYKDLDARILQFIFDRVKASDELLLNEIYFQAKKLKQKASSELEKLESSKKLDEVIANS QLSQILKSQHTNGIFEQGTFLHLVCKYYKQRQRARDSRLYIMPEYRYDKKLHKYNNTG

RFDDDNQLLTYCNHKPRQKRYQLLNDLAGVLQVSPNFLKDKIGSDDDLFISKWLVEHI

RGFKKACEDSLKIQKDNRGLLNHKINIARNTKGKCEKEIFNLICKIEGSEDKKGNYKHGL

AYELGVLLFGEPNEASKPEFDRKIKKFNSIYSFAQIQQIAFAERKGNANTCAVCSADNA

HRMQQIKITEPVEDNKDKIILSAKAQRLPAIPTRIVDGAVKKMATILAKNIVDDNWQNIKQ

VLSAKHQLHIPIITESNAFEFEPALADVKGKSLKDRRKKALERISPENIFKDKNNRIKEFA

KGISAYSGANLTDGDFDGAKEELDHIIPRSHKKYGTLNDEANLICVTRGDNKNKGNRIF

CLRDLADNYKLKQFETTDDLEIEKKIADTIWDANKKDFKFGNYRSFINLTPQEQKAFRH

ALFLADENPIKQAVIRAINNRNRTFVNGTQRYFAEVLANNIYLRAKKENLNTDKISFDYF

GIPTIGNGRGIAEIRQLYEKVDSDIQAYAKGDKPQASYSHLIDAMLAFCIAADEHRNDGS

IGLEIDKNYSLYPLDKNTGEVFTKDIFSQIKITDNEFSDKKLVRKKAIEGFNTHRQMTRD

GIYAENYLPILIHKELNEVRKGYTWKNSEEIKIFKGKKYDIQQLNNLVYCLKFVDKPISIDI

QISTLEELRNILTTNNIAATAEYYYINLKTQKLHEYYIENYNTALGYKKYSKEMEFLRSLA

YRSERVKIKSIDDVKQVLDKDSNFIIGKITLPFKKEWQRLYREWQNTTIKDDYEFLKSFF

NVKSITKLHKKVRKDFSLPISTNEGKFLVKRKTWDNNFIYQILNDSDSRADGTKPFIPAF

DISKNEIVEAIIDSFTSKNIFWLPKNIELQKVDNKNIFAIDTSKWFEVETPSDLRDIGIATIQ

YKIDNNSRPKVRVKLDYVIDDDSKINYFMNHSLLKSRYPDKVLEILKQSTIIEFESSGFNK

TIKEMLGMKLAGIYNETSNN

SEQ ID NO:7

Pasteurella multocida Cas9

MQTTNLSYILGLDLGIASVGWAVVEINENEDPIGLIDVGVRIFERAEVPKTGESLALSRR

LARSTRRLIRRRAHRLLLAKRFLKREGILSTIDLEKGLPNQAWELRVAGLERRLSAIEW

GAVLLHLIKHRGYLSKRKNESQTNNKELGALLSGVAQNHQLLQSDDYRTPAELALKKF

AKEEGHIRNQRGAYTHTFNRLDLLAELNLLFAQQHQFGNPHCKEHIQQYMTELLMWQ

KPALSGEAILKMLGKCTHEKNEFKAAKHTYSAERFVWLTKLNNLRILEDGAERALNEEE

RQLLINHPYEKSKLTYAQVRKLLGLSEQAIFKHLRYSKENAESATFMELKAWHAIRKAL

ENQGLKDTWQDLAKKPDLLDEIGTAFSLYKTDEDIQQYLTNKVPNSVINALLVSLNFDK

FIELSLKSLRKILPLMEQGKRYDQACREIYGHHYGEANQKTSQLLPAIPAQEIRNPVVLR

TLSQARKVINAIIRQYGSPARVHIETGRELGKSFKERREIQKQQEDNRTKRESAVQKFK

ELFSDFSSEPKSKDILKFRLYEQQHGKCLYSGKEINIHRLNEKGYVEIDHALPFSRTWD

DSFNNKVLVLASENQNKGNQTPYEWLQGKINSERWKNFVALVLGSQCSAAKKQRLLT

QVIDDNKFIDRNLNDTRYIARFLSNYIQENLLLVGKNKKNVFTPNGQITALLRSRWGLIK

ARENNNRHHALDAIVVACATPSMQQKITRFIRFKEVHPYKIENRYEMVDQESGEIISPH FPEPWAYFRQEVNIRVFDNHPDTVLKEMLPDRPQANHQFVQPLFVSRAPTRKMSGQ

GHMETIKSAKRLAEGISVLRIPLTQLKPNLLENMVNKEREPALYAGLKARLAEFNQDPA

KAFATPFYKQGGQQVKAIRVEQVQKSGVLVRENNGVADNASIVRTDVFIKNNKFFLVPI

YTWQVAKGILPNKAIVAHKNEDEWEEMDEGAKFKFSLFPNDLVELKTKKEYFFGYYIG

LDRATGNISLKEHDGEISKGKDGVYRVGVKLALSFEKYQVDELGKNRQICRPQQRQ

PVR

SEQ ID NO:8

Filamentous fungal cell codon optimized Streptococcus pyogenes Cas9-encoding gene; no NLS

atggacaagaagtacagcatcggcctcgacatcggcaccaactcggtgggctgggccgtcatcacggacgaatataa ggtcccgtcgaagaagttcaaggtcctcggcaatacagaccgccacagcatcaagaaaaacttgatcggcgccctcct gttcgatagcggcgagaccgcggaggcgaccaggctcaagaggaccgccaggagacggtacactaggcgcaaga acaggatctgctacctgcaggagatcttcagcaacgagatggcgaaggtggacgactccttcttccaccgcctggagga atcattcctggtggaggaggacaagaagcatgagcggcacccaatcttcggcaacatcgtcgacgaggtggcctacca cgagaagtacccgacaatctaccacctccggaagaaactggtggacagcacagacaaggcggacctccggctcatct accttgccctcgcgcatatgatcaagttccgcggccacttcctcatcgagggcgacctgaacccggacaactccgacgtg gacaagctgttcatccagctcgtgcagacgtacaatcaactgttcgaggagaaccccataaacgctagcggcgtggacg ccaaggccatcctctcggccaggctctcgaaatcaagaaggctggagaaccttatcgcgcagttgccaggcgaaaaga agaacggcctcttcggcaaccttattgcgctcagcctcggcctgacgccgaacttcaaatcaaacttcgacctcgcggag gacgccaagctccagctctcaaaggacacctacgacgacgacctcgacaacctcctggcccagataggagaccagta cgcggacctcttcctcgccgccaagaacctctccgacgctatcctgctcagcgacatccttcgggtcaacaccgaaattac caaggcaccgctgtccgccagcatgattaaacgctacgacgagcaccatcaggacctcacgctgctcaaggcactcgt ccgccagcagctccccgagaagtacaaggagatcttcttcgaccaatcaaaaaacggctacgcgggatatatcgacgg cggtgccagccaggaagagttctacaagttcatcaaaccaatcctggagaagatggacggcaccgaggagttgctggt caagctcaacagggaggacctcctcaggaagcagaggaccttcgacaacggctccatcccgcatcagatccacctgg gcgaactgcatgccatcctgcggcgccaggaggacttctacccgttcctgaaggataaccgggagaagatcgagaag atcttgacgttccgcatcccatactacgtgggcccgctggctcgcggcaactcccggttcgcctggatgacccggaagtcg gaggagaccatcacaccctggaactttgaggaggtggtcgataagggcgctagcgctcagagcttcatcgagcgcatg accaacttcgataaaaacctgcccaatgaaaaagtcctccccaagcactcgctgctctacgagtacttcaccgtgtacaa cgagctcaccaaggtcaaatacgtcaccgagggcatgcggaagccggcgttcctgagcggcgagcagaagaaggc gatagtggacctcctcttcaagaccaacaggaaggtgaccgtgaagcaattaaaagaggactacttcaagaaaataga gtgcttcgactccgtggagatctcgggcgtggaggatcggttcaacgcctcactcggcacgtatcacgacctcctcaagat cattaaagacaaggacttcctcgacaacgaggagaacgaggacatcctcgaggacatcgtcctcaccctgaccctgttc gaggaccgcgaaatgatcgaggagaggctgaagacctacgcgcacctgttcgacgacaaggtcatgaaacagctca agaggcgccgctacactggttggggaaggctgtcccgcaagctcattaatggcatcagggacaagcagagcggcaag accatcctggacttcctcaagtccgacgggttcgccaaccgcaacttcatgcagctcattcacgacgactcgctcacgttc aaggaagacatccagaaggcacaggtgagcgggcagggtgactccctccacgaacacatcgccaacctggccggct cgccggccattaaaaagggcatcctgcagacggtcaaggtcgtcgacgagctcgtgaaggtgatgggccggcacaag cccgaaaatatcgtcatagagatggccagggagaaccagaccacccaaaaagggcagaagaactcgcgcgagcg gatgaaacggatcgaggagggcattaaagagctcgggtcccagatcctgaaggagcaccccgtggaaaatacccag ctccagaatgaaaagctctacctctactacctgcagaacggccgcgacatgtacgtggaccaggagctggacattaatc ggctatcggactacgacgtcgaccacatcgtgccgcagtcgttcctcaaggacgatagcatcgacaacaaggtgctcac ccggtcggataaaaatcggggcaagagcgacaacgtgcccagcgaggaggtcgtgaagaagatgaaaaactactg gcgccagctcctcaacgcgaaactgatcacccagcgcaagttcgacaacctgacgaaggcggaacgcggtggcttga gcgaactcgataaggcgggcttcataaaaaggcagctggtcgagacgcgccagatcacgaagcatgtcgcccagatc ctggacagccgcatgaatactaagtacgatgaaaacgacaagctgatccgggaggtgaaggtgatcacgctgaagtcc aagctcgtgtcggacttccgcaaggacttccagttctacaaggtccgcgagatcaacaactaccaccacgcccacgacg cctacctgaatgcggtggtcgggaccgccctgatcaagaagtacccgaagctggagtcggagttcgtgtacggcgacta caaggtctacgacgtgcgcaaaatgatcgccaagtccgagcaggagatcggcaaggccacggcaaaatacttcttcta ctcgaacatcatgaacttcttcaagaccgagatcaccctcgcgaacggcgagatccgcaagcgcccgctcatcgaaac caacggcgagacgggcgagatcgtctgggataagggccgggatttcgcgacggtccgcaaggtgctctccatgccgca agtcaatatcgtgaaaaagacggaggtccagacgggcgggttcagcaaggagtccatcctcccgaagcgcaactccg acaagctcatcgcgaggaagaaggattgggacccgaaaaaatatggcggcttcgacagcccgaccgtcgcatacag cgtcctcgtcgtggcgaaggtggagaagggcaagtcaaagaagctcaagtccgtgaaggagctgctcgggatcacgat tatggagcggtcctccttcgagaagaacccgatcgacttcctagaggccaagggatataaggaggtcaagaaggacct gattattaaactgccgaagtactcgctcttcgagctggaaaacggccgcaagaggatgctcgcctccgcaggcgagttgc agaagggcaacgagctcgccctcccgagcaaatacgtcaatttcctgtacctcgctagccactatgaaaagctcaaggg cagcccggaggacaacgagcagaagcagctcttcgtggagcagcacaagcattacctggacgagatcatcgagcag atcagcgagttctcgaagcgggtgatcctcgccgacgcgaacctggacaaggtgctgtcggcatataacaagcaccgc gacaaaccaatacgcgagcaggccgaaaatatcatccacctcttcaccctcaccaacctcggcgctccggcagccttca agtacttcgacaccacgattgaccggaagcggtacacgagcacgaaggaggtgctcgatgcgacgctgatccaccag agcatcacagggctctatgaaacacgcatcgacctgagccagctgggcggagac

SEQ ID NO:9

Filamentous fungal cell codon optimized Streptococcus pyogenes Cas9-encoding gene; with N- and C-terminal NLS sequences atggcaccgaagaagaagcgcaaggtgatggacaagaagtacagcatcggcctcgacatcggcaccaactcggtgg gctgggccgtcatcacggacgaatataaggtcccgtcgaagaagttcaaggtcctcggcaatacagaccgccacagca tcaagaaaaacttgatcggcgccctcctgttcgatagcggcgagaccgcggaggcgaccaggctcaagaggaccgcc aggagacggtacactaggcgcaagaacaggatctgctacctgcaggagatcttcagcaacgagatggcgaaggtgg acgactccttcttccaccgcctggaggaatcattcctggtggaggaggacaagaagcatgagcggcacccaatcttcgg caacatcgtcgacgaggtggcctaccacgagaagtacccgacaatctaccacctccggaagaaactggtggacagca cagacaaggcggacctccggctcatctaccttgccctcgcgcatatgatcaagttccgcggccacttcctcatcgagggc gacctgaacccggacaactccgacgtggacaagctgttcatccagctcgtgcagacgtacaatcaactgttcgaggaga accccataaacgctagcggcgtggacgccaaggccatcctctcggccaggctctcgaaatcaagaaggctggagaac cttatcgcgcagttgccaggcgaaaagaagaacggcctcttcggcaaccttattgcgctcagcctcggcctgacgccga acttcaaatcaaacttcgacctcgcggaggacgccaagctccagctctcaaaggacacctacgacgacgacctcgaca acctcctggcccagataggagaccagtacgcggacctcttcctcgccgccaagaacctctccgacgctatcctgctcagc gacatccttcgggtcaacaccgaaattaccaaggcaccgctgtccgccagcatgattaaacgctacgacgagcaccatc aggacctcacgctgctcaaggcactcgtccgccagcagctccccgagaagtacaaggagatcttcttcgaccaatcaaa aaacggctacgcgggatatatcgacggcggtgccagccaggaagagttctacaagttcatcaaaccaatcctggagaa gatggacggcaccgaggagttgctggtcaagctcaacagggaggacctcctcaggaagcagaggaccttcgacaac ggctccatcccgcatcagatccacctgggcgaactgcatgccatcctgcggcgccaggaggacttctacccgttcctgaa ggataaccgggagaagatcgagaagatcttgacgttccgcatcccatactacgtgggcccgctggctcgcggcaactcc cggttcgcctggatgacccggaagtcggaggagaccatcacaccctggaactttgaggaggtggtcgataagggcgct agcgctcagagcttcatcgagcgcatgaccaacttcgataaaaacctgcccaatgaaaaagtcctccccaagcactcgc tgctctacgagtacttcaccgtgtacaacgagctcaccaaggtcaaatacgtcaccgagggcatgcggaagccggcgtt cctgagcggcgagcagaagaaggcgatagtggacctcctcttcaagaccaacaggaaggtgaccgtgaagcaattaa aagaggactacttcaagaaaatagagtgcttcgactccgtggagatctcgggcgtggaggatcggttcaacgcctcactc gg cacgtatcacg acctcctcaagatcattaaag acaagg acttcctcgacaacg agg agaacg agg acatcctcgag gacatcgtcctcaccctgaccctgttcgaggaccgcgaaatgatcgaggagaggctgaagacctacgcgcacctgttcg acgacaaggtcatgaaacagctcaagaggcgccgctacactggttggggaaggctgtcccgcaagctcattaatggca tcagggacaagcagagcggcaagaccatcctggacttcctcaagtccgacgggttcgccaaccgcaacttcatgcagc tcattcacgacgactcgctcacgttcaaggaagacatccagaaggcacaggtgagcgggcagggtgactccctccacg aacacatcgccaacctggccggctcgccggccattaaaaagggcatcctgcagacggtcaaggtcgtcgacgagctc gtgaaggtgatgggccggcacaagcccgaaaatatcgtcatagagatggccagggagaaccagaccacccaaaaa gggcagaagaactcgcgcgagcggatgaaacggatcgaggagggcattaaagagctcgggtcccagatcctgaag gagcaccccgtggaaaatacccagctccagaatgaaaagctctacctctactacctgcagaacggccgcgacatgtac gtggaccaggagctggacattaatcggctatcggactacgacgtcgaccacatcgtgccgcagtcgttcctcaaggacg atagcatcgacaacaaggtgctcacccggtcggataaaaatcggggcaagagcgacaacgtgcccagcgaggaggt cgtgaagaagatgaaaaactactggcgccagctcctcaacgcgaaactgatcacccagcgcaagttcgacaacctga cgaaggcggaacgcggtggcttgagcgaactcgataaggcgggcttcataaaaaggcagctggtcgagacgcgcca gatcacgaagcatgtcgcccagatcctggacagccgcatgaatactaagtacgatgaaaacgacaagctgatccggg aggtgaaggtgatcacgctgaagtccaagctcgtgtcggacttccgcaaggacttccagttctacaaggtccgcgagatc aacaactaccaccacgcccacgacgcctacctgaatgcggtggtcgggaccgccctgatcaagaagtacccgaagct ggagtcggagttcgtgtacggcgactacaaggtctacgacgtgcgcaaaatgatcgccaagtccgagcaggagatcgg caaggccacggcaaaatacttcttctactcgaacatcatgaacttcttcaagaccgagatcaccctcgcgaacggcgag atccgcaagcgcccgctcatcgaaaccaacggcgagacgggcgagatcgtctgggataagggccgggatttcgcgac ggtccgcaaggtgctctccatgccgcaagtcaatatcgtgaaaaagacggaggtccagacgggcgggttcagcaagg agtccatcctcccgaagcgcaactccgacaagctcatcgcgaggaagaaggattgggacccgaaaaaatatggcggc ttcgacagcccgaccgtcgcatacagcgtcctcgtcgtggcgaaggtggagaagggcaagtcaaagaagctcaagtcc gtgaaggagctgctcgggatcacgattatggagcggtcctccttcgagaagaacccgatcgacttcctagaggccaagg gatataaggaggtcaagaaggacctgattattaaactgccgaagtactcgctcttcgagctggaaaacggccgcaaga ggatgctcgcctccgcaggcgagttgcagaagggcaacgagctcgccctcccgagcaaatacgtcaatttcctgtacctc gctagccactatgaaaagctcaagggcagcccggaggacaacgagcagaagcagctcttcgtggagcagcacaag cattacctggacgagatcatcgagcagatcagcgagttctcgaagcgggtgatcctcgccgacgcgaacctggacaag gtgctgtcggcatataacaagcaccgcgacaaaccaatacgcgagcaggccgaaaatatcatccacctcttcaccctca ccaacctcggcgctccggcagccttcaagtacttcgacaccacgattgaccggaagcggtacacgagcacgaaggag gtgctcgatgcgacgctgatccaccagagcatcacagggctctatgaaacacgcatcgacctgagccagctgggcgga gacaagaagaagaagctcaagctctag

SEQ ID NO:10

Streptococcus pyogenes Cas9 with N- and C-terminal NLS sequences (encoded by SEQ ID NO:9)

MAPKKKRKVMDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGA

LLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEE

DKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLI

EGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLP

GEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADL

FLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEI

FFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNG

SIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRK

SEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKV

KYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDR FNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKV MKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFK EDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMA RENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRD MYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKM KNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSR MNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTAL IKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEI RKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRN SDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSF EKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYV NFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSA YNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITG LYETRIDLSQLGGDKKKKLKL

SEQ ID N0:1 1

Full U6 gene promoter sequence (not including transcription start site)

AAAAAACACTAGTAAGTACTTACTTATGTATTATTAACTACTTTAGCTAACTTCTGCA

GTACTACCTAAGAGGCTAGGGGTAGTTTTATAGCAGACTTATAGCTATTATTTTTAT TT AGT AA AGTG CTTTT AAAGT AAG GTCTTTTTT AT AG C ACTTTTT ATTT ATT ATA AT AT ATATTATATAATAATTTTAAGCCTGGAATAGTAAAGAGGCTTATATAATAATTTATAG TAATAAAAGCTTAGCAGCTGTAATATAATTCCTAAAGAAACAGCATGAAATGGTATT ATGTAAGAGCTATAGTCTAAAGGCACTCTGCTGGATAAAAATAGTGGCTATAAGTC TGCTGCAAAACTACCCCCAACCTCGTAGGTATATAAGTACTGTTTGATGGTAGTCT ATC

SEQ ID NO:12

Truncated/shorter U6 gene promoter sequence (not including transcription start site) AATTCCTAAAGAAACAGCATGAAATGGTATTATGTAAGAGCTATAGTCTAAAGGCA CTCTGCTGGATAAAAATAGTGGCTATAAGTCTGCTGCAAAACTACCCCCAACCTCG TAGGTATATAAGTACTGTTTGATGGTAGTCTATC SEQ ID NO:13

N-terminal His6 tag / thrombin / S*Tag™ / enterokinase region polynucleotide sequence (with start codon); encodes SEQ ID NO:18

atgcaccatcatcatcatcattcttctggtctggtgccacgcggttctggtatgaaagaaaccgctgctgctaaattcgaacg ccagcacatggacagcccagatctgggtaccgacgacgacgacaaggccatggcc

SEQ ID NO:14

SV40 NLS coding sequence (encodes SEQ ID NO:19)

ccaaaaaag aaacg caagg tt

SEQ ID NO:15

E. coli codon-optimized Cas9 gene (no stop codon)

atggataaaaaatacagcattggtctggatatcggaaccaacagcgttgggtgggcagtaataacagatgaatacaaa gtgccgtcaaaaaaatttaaggttctggggaatacagatcgccacagcataaaaaagaatctgattggggcattgctgttt gattcgggtgagacagctgaggccacgcgtctgaaacgtacagcaagaagacgttacacacgtcgtaaaaatcgtattt gctacttacaggaaattttttctaacgaaatggccaaggtagatgatagtttcttccatcgtctcgaagaatcttttctggttgag gaagataaaaaacacgaacgtcaccctatctttggcaatatcgtggatgaagtggcctatcatgaaaaataccctacgatt tatcatcttcgcaagaagttggttgatagtacggacaaagcggatctgcgtttaatctatcttgcgttagcgcacatgatcaa atttcgtggtcatttcttaattgaaggtgatctgaatcctgataactctgatgtggacaaattgtttatacaattagtgcaaaccta taatcagctgttcgaggaaaaccccattaatgcctctggagttgatgccaaagcgattttaagcgcgagactttctaagtcc cggcgtctggagaatctgatcgcccagttaccaggggaaaagaaaaatggtctgtttggtaatctgattgccctcagtctgg ggcttaccccgaacttcaaatccaattttgacctggctgaggacgcaaagctgcagctgagcaaagatacttatgatgatg acctcgacaatctgctcgcccagattggtgaccaatatgcggatctgtttctggcagcgaagaatctttcggatgctatcttgc tgtcggatattctgcgtgttaataccgaaatcaccaaagcgcctctgtctgcaagtatgatcaagagatacgacgagcacc accaggacctgactcttcttaaggcactggtacgccaacagcttccggagaaatacaaagaaatattcttcgaccagtcc aagaatggttacgcgggctacatcgatggtggtgcatcacaggaagagttctataaatttattaaaccaatccttgagaaa atggatggcacggaagagttacttgttaaacttaaccgcgaagacttgcttagaaagcaacgtacattcgacaacggctc catcccacaccagattcatttaggtgaacttcacgccatcttgcgcagacaagaagatttctatcccttcttaaaagacaatc gggagaaaatcgagaagatcctgacgttccgcattccctattatgtcggtcccctggcacgtggtaattctcggtttgcctgg atgacgcgcaaaagtgaggaaaccatcaccccttggaactttgaagaagtcgtggataaaggtgctagcgcgcagtcttt tatagaaagaatgacgaacttcgataaaaacttgcccaacgaaaaagtcctgcccaagcactctcttttatatgagtacttt actgtgtacaacgaactgactaaagtgaaatacgttacggaaggtatgcgcaaacctgcctttcttagtggcgagcagaa aaaagcaattgtcgatcttctctttaaaacgaatcgcaaggtaactgtaaaacagctgaaggaagattatttcaaaaagat cgaatgctttgattctgtcgagatctcgggtgtcgaagatcgtttcaacgcttccttagggacctatcatgatttgctgaagata ataaaagacaaagactttctcgacaatgaagaaaatgaagatattctggaggatattgttttgaccttgaccttattcgaag atagagagatgatcgaggagcgcttaaaaacctatgcccacctgtttgatgacaaagtcatgaagcaattaaagcgccg cagatatacggggtggggccgcttgagccgcaagttgattaacggtattagagacaagcagagcggaaaaactatcct ggatttcctcaaatctgacggatttgcgaaccgcaattttatgcagcttatacatgatgattcgcttacattcaaagaggatatt cagaaggctcaggtgtctgggcaaggtgattcactccacgaacatatagcaaatttggccggctctcctgcgattaagaa ggggatcctgcaaacagttaaagttgtggatgaacttgtaaaagtaatgggccgccacaagccggagaatatcgtgata gaaatggcgcgcgagaatcaaacgacacaaaaaggtcaaaagaactcaagagagagaatgaagcgcattgagga ggggataaaggaacttggatctcaaattctgaaagaacatccagttgaaaacactcagctgcaaaatgaaaaattgtac ctgtactacctgcagaatggaagagacatgtacgtggatcaggaattggatatcaatagactctcggactatgacgtagat cacattgtccctcagagcttcctcaaggatgattctatagataataaagtacttacgagatcggacaaaaatcgcggtaaat cggataacgtcccatcggaggaagtcgttaaaaagatgaaaaactattggcgtcaactgctgaacgccaagctgatcac acagcgtaagtttgataatctgactaaagccgaacgcggtggtcttagtgaactcgataaagcaggatttataaaacggc agttagtagaaacgcgccaaattacgaaacacgtggctcagatcctcgattctagaatgaatacaaagtacgatgaaaa cgataaactgatccgtgaagtaaaagtcattaccttaaaatctaaacttgtgtccgatttccgcaaagattttcagttttacaa ggtccgggaaatcaataactatcaccatgcacatgatgcatatttaaatgcggttgtaggcacggcccttattaagaaatac cctaaactcgaaagtgagtttgtttatggggattataaagtgtatgacgttcgcaaaatgatcgcgaaatcagaacaggaa atcggtaaggctaccgctaaatactttttttattccaacattatgaatttttttaagaccgaaataactctcgcgaatggtgaaat ccgtaaacggcctcttatagaaaccaatggtgaaacgggagaaatcgtttgggataaaggtcgtgactttgccaccgttcg taaagtcctctcaatgccgcaagttaacattgtcaagaagacggaagttcaaacagggggattctccaaagaatctatcct gccgaagcgtaacagtgataaacttattgccagaaaaaaagattgggatccaaaaaaatacggaggctttgattcccct accgtcgcgtatagtgtgctggtggttgctaaagtcgagaaagggaaaagcaagaaattgaaatcagttaaagaactgc tgggtattacaattatggaaagatcgtcctttgagaaaaatccgatcgactttttagaggccaaggggtataaggaagtga aaaaagatctcatcatcaaattaccgaagtatagtctttttgagctggaaaacggcagaaaaagaatgctggcctccgcg ggcgagttacagaagggaaatgagctggcgctgccttccaaatatgttaattttctgtaccttgccagtcattatgagaaact gaagggcagccccgaagataacgaacagaaacaattattcgtggaacagcataagcactatttagatgaaattataga gcaaattagtgaattttctaagcgcgttatcctcgcggatgctaatttagacaaagtactgtcagcttataataaacatcggg ataagccgattagagaacaggccgaaaatatcattcatttgtttaccttaaccaaccttggagcaccagctgccttcaaata tttcgataccacaattgatcgtaaacggtatacaagtacaaaagaagtcttggacgcaaccctcattcatcaatctattactg gattatatgagacacgcattgatctttcacagctgggcggagac

SEQ ID NO:16

BLR2 nuclear localization signal coding sequence (encodes SEQ ID NO:20)

aagaagaaaaaactgaaactg SEQ ID NO:17

The nucleotide sequence of the SpyCas9 synthetic gene in plasmid pET30a- SpyCas9. The oligonucleotides encoding the N-terminal His6 tag, the SV40 nuclear localization signal, and the BLR nuclear localization signal are shown in bold underline, italic underline, and underlined, respectively.

atqcaccatcatcatcatcattcttctqqtctqqtqccacqcqqttctqqtatqaaaqaaaccqctqctqctaaattcqaac qccaqcacatqqacaqcccaqatctqqqtaccqacqacqacqacaaqqccatqqccccaaaaaagaaacgcaag

SLiatggataaaaaatacagcattggtctggatatcggaaccaacagcgttgggtgggcagtaataacagatgaataca aagtgccgtcaaaaaaatttaaggttctggggaatacagatcgccacagcataaaaaagaatctgattggggcattgctg tttgattcgggtgagacagctgaggccacgcgtctgaaacgtacagcaagaagacgttacacacgtcgtaaaaatcgtat ttgctacttacaggaaattttttctaacgaaatggccaaggtagatgatagtttcttccatcgtctcgaagaatcttttctggttga ggaagataaaaaacacgaacgtcaccctatctttggcaatatcgtggatgaagtggcctatcatgaaaaataccctacga tttatcatcttcgcaagaagttggttgatagtacggacaaagcggatctgcgtttaatctatcttgcgttagcgcacatgatca aatttcgtggtcatttcttaattgaaggtgatctgaatcctgataactctgatgtggacaaattgtttatacaattagtgcaaacct ataatcag ctgttcg agg aaaaccccattaatg cctctgg agttg atgccaaag cgattttaagcg cgag actttctaagtc ccggcgtctggagaatctgatcgcccagttaccaggggaaaagaaaaatggtctgtttggtaatctgattgccctcagtctg gggcttaccccgaacttcaaatccaattttgacctggctgaggacgcaaagctgcagctgagcaaagatacttatgatgat gacctcgacaatctgctcgcccagattggtgaccaatatgcggatctgtttctggcagcgaagaatctttcggatgctatctt gctgtcggatattctgcgtgttaataccgaaatcaccaaagcgcctctgtctgcaagtatgatcaagagatacgacgagca ccaccaggacctgactcttcttaaggcactggtacgccaacagcttccggagaaatacaaagaaatattcttcgaccagt ccaagaatggttacgcgggctacatcgatggtggtgcatcacaggaagagttctataaatttattaaaccaatccttgaga aaatggatggcacggaagagttacttgttaaacttaaccgcgaagacttgcttagaaagcaacgtacattcgacaacgg ctccatcccacaccagattcatttaggtgaacttcacgccatcttgcgcagacaagaagatttctatcccttcttaaaagaca atcgggagaaaatcgagaagatcctgacgttccgcattccctattatgtcggtcccctggcacgtggtaattctcggtttgcct ggatgacgcgcaaaagtgaggaaaccatcaccccttggaactttgaagaagtcgtggataaaggtgctagcgcgcagt cttttatagaaagaatgacgaacttcgataaaaacttgcccaacgaaaaagtcctgcccaagcactctcttttatatgagta ctttactgtgtacaacgaactgactaaagtgaaatacgttacggaaggtatgcgcaaacctgcctttcttagtggcgagcag aaaaaagcaattgtcgatcttctctttaaaacgaatcgcaaggtaactgtaaaacagctgaaggaagattatttcaaaaag atcgaatgctttgattctgtcgagatctcgggtgtcgaagatcgtttcaacgcttccttagggacctatcatgatttgctgaagat aataaaagacaaagactttctcgacaatgaagaaaatgaagatattctggaggatattgttttgaccttgaccttattcgaa gatagagagatgatcgaggagcgcttaaaaacctatgcccacctgtttgatgacaaagtcatgaagcaattaaagcgcc gcagatatacggggtggggccgcttgagccgcaagttgattaacggtattagagacaagcagagcggaaaaactatcc tggatttcctcaaatctgacggatttgcgaaccgcaattttatgcagcttatacatgatgattcgcttacattcaaagaggatat tcagaaggctcaggtgtctgggcaaggtgattcactccacgaacatatagcaaatttggccggctctcctgcgattaagaa ggggatcctgcaaacagttaaagttgtggatgaacttgtaaaagtaatgggccgccacaagccggagaatatcgtgata gaaatggcgcgcgagaatcaaacgacacaaaaaggtcaaaagaactcaagagagagaatgaagcgcattgagga ggggataaaggaacttggatctcaaattctgaaagaacatccagttgaaaacactcagctgcaaaatgaaaaattgtac ctgtactacctgcagaatggaagagacatgtacgtggatcaggaattggatatcaatagactctcggactatgacgtagat cacattgtccctcagagcttcctcaaggatgattctatagataataaagtacttacgagatcggacaaaaatcgcggtaaat cggataacgtcccatcggaggaagtcgttaaaaagatgaaaaactattggcgtcaactgctgaacgccaagctgatcac acagcgtaagtttgataatctgactaaagccgaacgcggtggtcttagtgaactcgataaagcaggatttataaaacggc agttagtagaaacgcgccaaattacgaaacacgtggctcagatcctcgattctagaatgaatacaaagtacgatgaaaa cgataaactgatccgtgaagtaaaagtcattaccttaaaatctaaacttgtgtccgatttccgcaaagattttcagttttacaa ggtccgggaaatcaataactatcaccatgcacatgatgcatatttaaatgcggttgtaggcacggcccttattaagaaatac cctaaactcgaaagtgagtttgtttatggggattataaagtgtatgacgttcgcaaaatgatcgcgaaatcagaacaggaa atcggtaaggctaccgctaaatactttttttattccaacattatgaatttttttaagaccgaaataactctcgcgaatggtgaaat ccgtaaacggcctcttatagaaaccaatggtgaaacgggagaaatcgtttgggataaaggtcgtgactttgccaccgttcg taaagtcctctcaatgccgcaagttaacattgtcaagaagacggaagttcaaacagggggattctccaaagaatctatcct gccgaagcgtaacagtgataaacttattgccagaaaaaaagattgggatccaaaaaaatacggaggctttgattcccct accgtcgcgtatagtgtgctggtggttgctaaagtcgagaaagggaaaagcaagaaattgaaatcagttaaagaactgc tgggtattacaattatggaaagatcgtcctttgagaaaaatccgatcgactttttagaggccaaggggtataaggaagtga aaaaagatctcatcatcaaattaccgaagtatagtctttttgagctggaaaacggcagaaaaagaatgctggcctccgcg ggcgagttacagaagggaaatgagctggcgctgccttccaaatatgttaattttctgtaccttgccagtcattatgagaaact gaagggcagccccgaagataacgaacagaaacaattattcgtggaacagcataagcactatttagatgaaattataga gcaaattagtgaattttctaagcgcgttatcctcgcggatgctaatttagacaaagtactgtcagcttataataaacatcggg ataagccgattagagaacaggccgaaaatatcattcatttgtttaccttaaccaaccttggagcaccagctgccttcaaata tttcgataccacaattgatcgtaaacggtatacaagtacaaaagaagtcttggacgcaaccctcattcatcaatctattactg qattatatqaqacacqcattqatctttcacaqctqqqcqqaqacaaqaaqaaaaaactqaaactq

SEQ ID NO:18

N-terminal His6 tag / thrombin / S*Tag™ / enterokinase region amino acid sequence (with start methionine)

Mhhhhhhssglvprgsgmketaaakferqhmdspdlgtddddkama

SEQ ID NO:19

SV40 NLS

PKKKRKV SEQ NO:20

T. reesei blr2 (blue light regulator 2) gene NLS

KKKKLKL

SEQ ID NO:21

The amino acid sequence of the SpyCas9 protein expressed from plasmid pET30a- SpyCas9. The N-terminal His6 tag, the SV40 nuclear localization signal, and the BLR nuclear localization signal are shown in bold underline, italic underline, and underlined, respectively.

mhhhhhhssqlvprqsqmketaaakferqhmdspdlqtddddkamaiD/ / / r/ yrndkkvsiqldiqtnsvqwavit deykvpskkfkvlgntdrhsikknligallfdsgetaeatrlkrtarrrytrrknricylqeifsnemakvddsffhrleesflveed kkherhpifgnivdevayhekyptiyhlrkklvdstdkadlrliylalahmikfrghfliegdlnpdnsdvdklfiqlvqtynqlfe enpinasgvdakailsarlsksrrlenliaqlpgekknglfgnlialslgltpnfksnfdlaedaklqlskdtydddldnllaqigd qyadlflaaknlsdaillsdilrvnteitkaplsasmikrydehhqdltllkalvrqqlpekykeiffdqskngyagyidggasqe efykfikpilekmdgteellvklnredllrkqrtfdngsiphqihlgelhailrrqedfypflkdnrekiekiltfripyyvgplargnsr fawmtrkseetitpwnfeevvdkgasaqsfiermtnfdknlpnekvlpkhsllyeyftvyneltkvkyvtegmrkpaflsge qkkaivdllfktnrkvtvkqlkedyfkkiecfdsveisgvedrfnaslgtyhdllkiikdkdfldneenediledivltltlfedremi eerlktyahlfddkvmkqlkrrrytgwgrlsrklingirdkqsgktildflksdgfanrnfmqlihddsltfkediqkaqvsgqgd slhehianlagspaikkgilqtvkvvdelvkvmgrhkpeniviemarenqttqkgqknsrermkrieegikelgsqilkehp ventqlqneklylyylqngrdmyvdqeldinrlsdydvdhivpqsflkddsidnkvltrsdknrgksdnvpseevvkkmkn ywrqllnaklitqrkfdnltkaergglseldkagfikrqlvetrqitkhvaqildsrmntkydendklirevkvitlksklvsdfrkdf qfykvreinnyhhahdaylnavvgtalikkypklesefvygdykvydvrkmiakseqeigkatakyffysnimnffkteitla ngeirkrplietngetgeivwdkgrdfatvrkvlsmpqvnivkktevqtggfskesilpkrnsdkliarkkdwdpkkyggfds ptvaysvlvvakvekgkskklksvkellgitimerssfeknpidfleakgykevkkdliiklpkyslfelengrkrmlasagelq kgnelalpskyvnflylashyeklkgspedneqkqlfveqhkhyldeiieqisefskrviladanldkvlsaynkhrdkpireq aeniihlftltnlqapaafkyfdttidrkrvtstkevldatlihqsitqlvetridlsqlqqdkkkklkl

SEQ ID NO:22

Putative T. reesei U6 gene

AAAAAACACTAGTAAGTACTTACTTATGTATTATTAACTACTTTAGCTAACTTCTGCA GTACTACCTAAGAGGCTAGGGGTAGTTTTATAGCAGACTTATAGCTATTATTTTTAT TT AGT AA AGTG CTTTT AAAGT AAG GTCTTTTTT AT AG C ACTTTTT ATTT ATT ATA AT AT ATATTATATAATAATTTTAAGCCTGGAATAGTAAAGAGGCTTATATAATAATTTATAG TAATAAAAGCTTAGCAGCTGTAATATAATTCCTAAAGAAACAGCATGAAATGGTATT ATGTAAGAGCTATAGTCTAAAGGCACTCTGCTGGATAAAAATAGTGGCTATAAGTC TGCTGCAAAACTACCCCCAACCTCGTAGGTATATAAGTACTGTTTGATGGTAGTCT ATCGCCTTCGGGCATTTGGTCAATTTATAACGATACAGGTTCGTTTCGGCTTTTCC TCGGAACCCCCAGAGGTCATCAGTTCGAATCGCTAACAGGTCAACAGAGAAGATT AGCATGGCCCCTGCACTAAGGATGACACGCTCACTCAAAGAGAAGCTAAACATTTT TTTTCTCTTCCAAGTCGTGATGGTTATCTTTTTGCTTAGAGAATCTATTCTTGTGGA CGATTAGTATTGGTAAATCCCTGCTGCACATTGCGGCGGATGGTCTCAACGGCAT AATACCCCATTCGTGATGCAGCGGTGATCTTCAATATGTAGTGTAATACGTTGCAT ACACCACCAGGTTCGGTGCCTCCTGTATGTACAGTACTGTAGTTCGACTCCTCCG CGCAGGTGGAAACGATTCCCTAGTGGGCAGGTATTTTGGCGGGGTCAAGAA

SEQ ID NO:23

sequence of sgRNA (N is sequence complementary to target site)

NNNNNNNNNNNNNNNNNNNNGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGG CUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGGUGC

SEQ ID NO:24

sgRNA: gAd3A TS1

guccucgagcaaaaggugccGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGU CCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGGUGC

SEQ ID NO:25

sgRNA: gTrGA TS2

guucagugcaauaggcgucuGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGU CCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGGUGC

SEQ ID NO:26

sgRNA: gTrGA TS1 1

gccaauggcgacggcagcacGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGU CCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGGUGC SEQ ID NO:27

sgRNA: gPyr2 TS6

gcacagcgggaugcccuuguGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGU CCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGGUGC

SEQ ID NO:28

Synthetic DNA: gAd3A TS1 -1 (gAd3A TS1 sgRNA (SEQ ID N0:3) with Saccharomyces cerevisiae snr52 promoter and S. cerevisiae sup4 terminator)

gaattcggatccTCTTTGAAAAGATAATGTATGATTATGCTTTCACTCATATTTATACAGA AACTTGATGTTTTCTTTCGAGTATATACAAGGTGATTACATGTACGTTTGAAGTACA ACTCTAGATTTTGTAGTGCCCTCTTGGGCTAGCGGTAAAGGTGCGCATTTTTTCAC ACCCTACAATGTTCTGTTCAAAAGATTTTGGTCAAACGCTGTAGAAGTGAAAGTTG GTGCGCATGTTTCGGCGTTCGAAACTTCTCCGCAGTGAAAGATAAATGATCgtcctcg agcaaaaggtgccGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATC AACTTGAAAAAGTGGCACCGAGTCGGTGGTGCTTTTTTTGTTTTTTATGTCTgaattcg gatcc

SEQ ID NO:29

Synthetic DNA: gAd3A TS1 -2 (gAd3A TS1 sgRNA (SEQ ID NO:3) with T. reesei U6 promoter and terminator)

gaattcggatccAAAAAACACTAGTAAGTACTTACTTATGTATTATTAACTACTTTAGCTA

ACTTCTGCAGTACTACCTAAGAGGCTAGGGGTAGTTTTATAGCAGACTTATAGCTA

TTATTTTTATTTAGTAAAGTGCTTTTAAAGTAAGGTCTTTTTTATAGCACTTTTTATTT ATTATAATATATATTATATAATAATTTTAAGCCTGGAATAGTAAAGAGGCTTATATAA TAATTTATAGTAATAAAAGCTTAGCAGCTGTAATATAATTCCTAAAGAAACAGCATG AA ATG GT ATTATGT AAG AG CT AT AGTCT AAAG G C ACTCTG CTG G ATA AA AAT AGTG GCTATAAGTCTGCTGCAAAACTACCCCCAACCTCGTAGGTATATAAGTACTGTTTG ATGGTAGTCTATCgtcctcgagcaaaaggtgccGTTTTAGAGCTAGAAATAGCAAGTTAAAA TAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGGTGCTTTTTT TTCTCTTgaattcggatcc SEQ ID NO:30

Synthetic DNA: gAd3A TS1 -3 (gAd3A TS1 sgRNA (SEQ ID NO:3) with T. reesei U6 promoter, terminator and intron)

gaattcggatccAAAAAACACTAGTAAGTACTTACTTATGTATTATTAACTACTTTAGCTA ACTTCTGCAGTACTACCTAAGAGGCTAGGGGTAGTTTTATAGCAGACTTATAGCTA TTATTTTTATTTAGTAAAGTGCTTTTAAAGTAAGGTCTTTTTTATAGCACTTTTTATTT ATTATAATATATATTATATAATAATTTTAAGCCTGGAATAGTAAAGAGGCTTATATAA TAATTTATAGTAATAAAAGCTTAGCAGCTGTAATATAATTCCTAAAGAAACAGCATG AA ATG GT ATTATGT AAG AG CT AT AGTCT AAAG G C ACTCTG CTG G ATA AA AAT AGTG GCTATAAGTCTGCTGCAAAACTACCCCCAACCTCGTAGGTATATAAGTACTGTTTG ATGGTAGTCTATCgtcctcgagcaaaaggtgccGTTTTAGAGCTAGAGTTCGTTTCGGCTTT TCCTCGGAACCCCCAGAGGTCATCAGTTCGAATCGCTAACAGAATAGCAAGTTAAA ATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGGTGCTTTTT TTTCTCTTgaattcggatcc

SEQ ID NO:31

Guide RNA expression cassettes with a shorter T. reesei U6 promoter region were obtained as synthetic DNA. An example is provided here that includes the sequence for an sgRNA targeting the T. reesei glal gene at TS1 1 .

AATTCCTAAAGAAACAGCATGAAATGGTATTATGTAAGAGCT AT AGTCT AAAGGCA CTCTGCTGGATAAAAATAGTGGCTATAAGTCTGCTGCAAAACTACCCCCAACCTCG TAGGTATATAAGTACTGTTTGATGGTAGTCTATCgccaatggcgacggcagcacGTTTTAGA GCTAGAGTTCGTTTCGGCTTTTCCTCGGAACCCCCAGAGGTCATCAGTTCGAATC GCTAACAGAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGG CACCGAGTCGGTGGTGCTTTTTTTTCTCTT

SEQ ID NO:32

Primer: gRNA fwd aflll

cgtcag cttaag A ATTCCT AA AG AA AC AG C ATG A AATG G

SEQ ID NO:33

Primer: gRNA rev sfil

cgtcagggccacgtgggccAAGAGAAAAAAAAGCACCACCGACTCGG SEQ ID NO:34 Primer: Ad3 5' fwd tgaacacagccaccgacatcagc

SEQ ID NO:35

Primer: Ad3 5' rev gctggtgagggtttgtgctattg

SEQ ID NO:36

Primer: Ad3a 5005 rev gattgcttgggaggaggacat

SEQ ID NO:37

Primer: Ad3 3' fwd cgaggccactgatgaagttgttc

SEQ ID NO:38

Primer: Ad3 3' rev

Cagttttccaaggctgccaacgc

SEQ ID NO:39

Primer: Ad3a 5003 fwd ctg atcttg caccctgg aaatc

SEQ ID NO:40

Ad3mid rev

ctctctatcatttg ccaccctcc

SEQ ID NO:41

Primer: Adfrag fwd ctccattcaccctcaattctcc SEQ ID NO:42 Primer: Adfrag rev gttcccttggcggtgcttggatc

SEQ ID NO:43

Primer: Ad3a 2k fwd caatagcacaaaccctcaccagc

SEQ ID NO:44

Ad3a 2k rev

gaacaacttcatcagtggcctcg

SEQ ID NO:45

Primer: glaA

ccgttagttgaagatccttgccg

SEQ ID NO:46

Primer: glaB

gtcgaggatttgcttcatacctc

SEQ ID NO:47

Primer: glaJ

tgccgactttgtccagtgattcg

SEQ ID NO:48

Primer: glaK

ttacatgtggacgcgagatagcg

SEQ ID NO:49

Primer: glal repF gtgtgtctaatgcctccaccac SEQ ID NO:50

Primer: glal repR

gatcgtgctagcgctgctgttg

SEQ ID NO:51

Primer: 1553R

CCGTGATGGAGCCCGTCTTCT

SEQ ID NO:52

Primer: 1555F

CGCGGTGAGTTCAGGCTTTTTC

SEQ ID NO:53

Primer: pyr2F

gtataagagcaggaggagggag

SEQ ID NO:54

Primer: pyr2R

gaacgcctcaatcagtcagtcg

SEQ ID NO:55

Bacterial kanamycin resistance gene (with promoter and terminator) between

Trichoderma reesei telomere sequences

tcaggaaatagctttaagtagcttattaagtattaaaattatatatatttttaatataactatatttctttaataaataggtattttaag ctttatatataaatataataataaaataatatattatatagctttttattaataaataaaatagctaaaaatataaaaaaaatag ctttaaaatacttatttttaattagaattttatatatttttaatatataagatcttttacttttttataagcttcctaccttaaattaaattttta cttttttttactattttactatatcttaaataaaggctttaaaaatataaaaaaaatcttcttatatattataagctataaggattatat atatatttttttttaatttttaaagtaagtattaaagctagaattaaagttttaattttttaaggctttatttaaaaaaaggcagtaata gcttataaaagaaatttctttttcttttatactaaaagtactttttttttaataaggttagggttagggtttactcacaccgaccatcc caaccacatcttagggttagggttagggttagggttagggttagggttagggttagggtaagggtttaaacaaagccacgtt gtgtctcaaaatctctgatgttacattgcacaagataaaaatatatcatcatgaacaataaaactgtctgcttacataaacag taatacaaggggtgttatgagccatattcaacgggaaacgtcttgctcgaggccgcgattaaattccaacatggatgctga tttatatgggtataaatgggctcgcgataatgtcgggcaatcaggtgcgacaatctatcgattgtatgggaagcccgatgcg ccagagttgtttctgaaacatggcaaaggtagcgttgccaatgatgttacagatgagatggtcagactaaactggctgacg gaatttatgcctcttccgaccatcaagcattttatccgtactcctgatgatgcatggttactcaccactgcgatccccgggaaa acagcattccaggtattagaagaatatcctgattcaggtgaaaatattgttgatgcgctggcagtgttcctgcgccggttgca ttcgattcctgtttgtaattgtccttttaacagcgatcgcgtatttcgtctcgctcaggcgcaatcacgaatgaataacggtttggt tgatgcgagtgattttgatgacgagcgtaatggctggcctgttgaacaagtctggaaagaaatgcataagcttttgccattct caccggattcagtcgtcactcatggtgatttctcacttgataaccttatttttgacgaggggaaattaataggttgtattgatgttg gacgagtcggaatcgcagaccgataccaggatcttgccatcctatggaactgcctcggtgagttttctccttcattacagaa acggctttttcaaaaatatggtattgataatcctgatatgaataaattgcagtttcatttgatgctcgatgagtttttctaatcaga attggttaattggttgtaacactggcagagcattacgctgacttgacgggacggcggctttgttgaataaatcgaacttttgct gagttgaaggatcagatcacgcatcttcccgacaacgcagaccgttccgtggcaaagcaaaagttcaaaatcaccaact ggtccacctacaacaaagctctcatcaaccgtggctccctcactttctggctggatgatggggcgattcaggcctggtatga gtcagcaacaccttcttcacgaggcagacctcagcggtttaaacctaaccctaaccctaaccctaaccctaaccctaacc ctaaccctaaccctaaccctaaccctaaccctaaccctaaccctaacctaaccctaatggggtcgatctgaaccgaggat gagggttctatagactaatctacaggccgtacatggtgtgattgcagatgcgacgggcaaggtgtacagtgtccagaagg aggagagcggcataggtattgtaatagaccagctttacataataatcgcctgttgctactgactgatgaccttcttccctaac cagtttcctaattaccactgcagtgaggataaccctaactcgctctggggttattattatactgattagcaggtggcttatatagt gctgaagtactataagagtttctgcgggaggaggtggaaggactataaactggacacagttagggatagagtgatgaca agacctgaatgttatcctccggtgtggtatagcgaattggctgaccttgcagatggtaatggtttaggcagggtttttgcagag ggggacgagaacgcgttctgcgatttaacggctgctgccgccaagctttacggttctctaatgggcggccgc

SEQ ID NO:56

Xyr1 Ta Target sequence (5'-3', PAM bold underlined):

GCAGCACCTCGCACAGCATGCGG

SEQ ID NO:57

XvM Ta (2) oligo 1

TAGGCAGCACCTCGCACAGCATG

SEQ ID NO:58

Xyr1 Ta oligo 2

AAACCATGCTGTGCGAGGTGCT

SEQ ID NO:59

Xyr1 Tc Target sequence (5'-3', PAM bold underlined): GCTGCCAGGAAGAATTCAACGGG

SEQ ID NO:60

Xyr1 Tc oliqo 1

TAGGCTGCCAGGAAGAATTCAAC

SEQ ID NO:61

Xyr1 Tc oliqo 2

AAACGTTGAATTCTTCCTGGCA SEQ ID NO:62

Pyr4 TS2 Target sequence (5'-3', PAM bold underlined)

GCTCAAGACGCACTACGACATGG

SEQ ID NO:63

Pyr4 TS2 oligo 1

TAGGCTCAAGACGCACTACGACA

SEQ ID NO:64

Pyr4 TS2 oligo 2

AAACTGTCGTAGTGCGTCTTGAGC

SEQ ID NO:65

Xyr1 Ta

taatacgactcactataggGCAGCACCTCGCACAGCATGgttttagagctagaaatagcaagttaaaata aggctagtccgttatcaacttgaaaaagtggcaccgagtcggtgctttttacg

SEQ ID NO:66

Xyr1 Tc

taatacgactcactataggGCTGCCAGGAAGAATTCAACgttttagagctagaaatagcaagttaaaataa ggctagtccgttatcaacttgaaaaagtggcaccgagtcggtgctttttacg

SEQ ID NO:67

Pyr4 TS2 taatacgactcactatagg G CTC AAG ACG C ACTACG AC Ag ttttagag ctag aaatag caagttaaaata aggctagtccgttatcaacttgaaaaagtggcaccgagtcggtgctttttacg

SEQ ID NO:68

K21 control T4

tggcccgtcgattgtcgtgctcaagacgcactacgacatggtctcgg

SEQ ID NO:69

T4 4-3

tggcccgtcgattgtcgtgctcaagacgcactacgCGacatggtctcgg

SEQ ID NO:70

T4 4-13

tggcccgtcgattgtcgtgctcaagacgcactacgacatggtctcgg

SEQ ID NO:71

T4 4-1 1

tggcccgtcgattgtcgtgctcaagacgcactacgGacatggtctcgg

SEQ ID NO:72

T4 4-12

tggcccgtcgattgtcgtgctcaagacgcactacgacatggtctcgg

SEQ ID NO:73

T4 4-18

tggcccgtcgattgtcgtgctcaagacgcactacgGacatggtctcgg

SEQ ID NO:74

T4 4-20

tggcccgtcgattgtcgtgctcaagacgcactacgAGCCGACAGGGCGCCTGGCTAAATCCAAGGT CAAGACAGGCTGGTGGTTGTTTAGTGCGAGTCCTCTGacatggtctcgg

SEQ ID NO:75

T4 4-19 tggcccgtcgattgtcgtgctcaagacgcactacgGacatggtctcgg

SEQ ID NO:76

T4 4-4

tggcccgtcgaatgttgtggtcaaggcgcccttcgGacatggtctcgg

SEQ ID NO:77

T4 4-7

tggcccgtcgattgtcgtgctcaagacgcactacgGacatggtctcgg

SEQ ID NO:78

9-96

CCGCTGACGGCTTACCTGTTCAAGCTCATGGACCTCAAGGCGTCCAACCTGTGCC TGAGCGCCGACGTGCCGACAGCGCGCGAGCTGCTGTACCTGGCCGACAAGATTG GCCCGTCGATTGTCGTGCTCAAGACGCACTACGCAGGCCTGCGTCGAGGCCGCC CGGGAGCACAAGGACTTTGTCATG

SEQ ID NO:79

Pyr4 Tr

CCGCTGACGGCTTACCTGTTCAAGCTCATGGACCTCAAGGCGTCCAACCTGTGCC TGAGCGCCGACGTGCCGACAGCGCGCGAGCTGCTGTACCTGGCCGACAAGATTG GCCCGTCGATTGTCGTGCTCAAGACGCACTACGACATGGTCTCGGGCTGGGACTT CCACCCGGAGACGGGCACGGGAGCCCAGCTGGCGTCGCTGGCGCGCAAGCACG GCTTCCTCATCTTCGAGGACCGCAAGTTTGGCGACATTGGCCACACCGTCGAGCT GCAGTACACGGGCGGGTCGGCGCGCATCATCGACTGGGCGCACATTGTCAACGT CAACATGGTGCCCGGCAAGGCGTCGGTGGCCTCGCTGGCCCAGGGCGCCAAGC GCTGGCTCGAGCGCTACCCCTGCGAGGTCAAGACGTCCGTCACCGTCGGCACGC CCACCATGGACTCGTTTGACGACGACGCCGACTCCAGGGACGCCGAGCCCGCCG GCGCCGTCAACGGCATGGGCTCCATTGGCGTCCTGGACAAGCCCATCTACTCGA ACCGGTCCGGCGACGGCCGCAAGGGCAGCATCGTCTCCATCACCACCGTCACCC AGCAGTACGAGTCCGTCTCCTCGCCCCGGTTAACAAAGGCCATCGCCGAGGGCG ACGAGTCGCTCTTCCCGGGCATCGAGGAGGCGCCGCTGAGCCGCGGCCTCCTGA TCCTCGCCCAAATGTCCAGCCAGGGCAACTTCATGAACAAGGAGTACACGCAGGC CTGCGTCGAGGCCGCCCGGGAGCACAAGGACTTTGTCATG SEQ ID NO:80

Query

ctggccgacaagattggcccgtcgattgtcgtgctcaagacgcactacgacatggtctc

SEQ ID N0:81

Subject

ctggccgacaagattggcccgtcgattgtcgtgctcaagacgcactacgGacatggtctc

SEQ ID NO:82

Pyr4 Tr

gacagcgcgcgagctgctgtacctggccgacaagattggcccgtcgattgtcgtgctcaagacgcactacgacatggtct cgggctgggacttccacccgg

SEQ ID NO:83

P37 #13 4.2 rc

gacagcgcgcgagctgctgtacctggccgacaagattggcccgtcgattgtcgtgctcaagacgcactacgGacatggt ctcgggctgggacttccacccgg

SEQ ID NO:84

P37 4.1 #12 rc

gacagcgcgcgagctgctgtacctggccgacaagattggcccgtcgattgtcgtgctcaagacgcactacgTacatggt ctcgggctgggacttccacccgg

SEQ ID NO:85

P37 #15 4.4 rc

gacagcgcgcgagctgctgtacctggccgacaagattggcccgtcgattgtcgtgctcaagacgcactacgcatggtctc gggctgggacttccacccgg

SEQ ID NO:86

P37 #14 4.3

Gacagcgcgcgagctgctgtacctggccgacaagattggcccgtcgattgtcgtgctcaagacgcactacgacatggtc tcgggctgggacttccacccgg SEQ ID NO:87

Consensus (deletion alignment)

Gacagcgcgcgagctgctgtacctggccgacaagattggcccgtcgattgtcgtgctcaagacgcannangnnnngg nnnnnggnngggannncnancngg

SEQ ID NO:88

Wild type pyr4 full coding sequence

Atggcaccacacccgacgctcaaggccaccttcgcggccaggagcgagacggcgacgcacccgctgacggcttacc tgttcaagctcatggacctcaaggcgtccaacctgtgcctgagcgccgacgtgccgacagcgcgcgagctgctgtacctg gccgacaagattggcccgtcgattgtcgtgctcaagacgcactacgacatggtctcgggctgggacttccacccggaga cgggcacgggagcccagctggcgtcgctggcgcgcaagcacggcttcctcatcttcgaggaccgcaagtttggcgaca ttggccacaccgtcgagctgcagtacacgggcgggtcggcgcgcatcatcgactgggcgcacattgtcaacgtcaacat ggtgcccggcaaggcgtcggtggcctcgctggcccagggcgccaagcgctggctcgagcgctacccctgcgaggtca agacgtccgtcaccgtcggcacgcccaccatggactcgtttgacgacgacgccgactccagggacgccgagcccgcc ggcgccgtcaacggcatgggctccattggcgtcctggacaagcccatctactcgaaccggtccggcgacggccgcaag ggcagcatcgtctccatcaccaccgtcacccagcagtacgagtccgtctcctcgccccggttaacaaaggccatcgccg agggcgacgagtcgctcttcccgggcatcgaggaggcgccgctgagccgcggcctcctgatcctcgcccaaatgtcca gccagggcaacttcatgaacaaggagtacacgcaggcctgcgtcgaggccgcccgggagcacaaggactttgtcatg ggcttcatctcgcaggagacgctcaacaccgagcccgacgatgcctttatccacatgacgcccggctgccagctgcccc ccgaagacgaggaccagcagaccaacggatcggtcggtggagacggccagggccagcagtacaacacgccgcac aagctgattggcatcgccggcagcgacattgccattgtgggccggggcatcctcaaggcctcagaccccgtagaggag gcagagcggtaccgatcagcagcgtggaaagcctacaccgagaggctgctgcgatag

SEQ ID NO:89

Xyr1 gene coding sequence

atgttgtccaatcctctccgtcgctattctgcctaccccgacatctcctcggcgtcatttgacccgaactaccatggctcacagt cgcatctccactcgatcaacgtcaacacattcggcaacagccacccctatcccatgcagcacctcgcacagcatgcgga gctttcgagttcacgcatgataagggccagtccggtgcagccaaagcagcgccagggctctcttattgctgccaggaaga attcaacGGGtactgctgggcccattcggcggaggatcagtcgcgcttgtgaccagtgcaaccagcttcgtaccaagtg cgatggcttacacccatgtgcccattgtataggtatgtcccttttcctctacacagtgatgctgcgctcaagcacatgtactgat cgatcttgtttagaattcggccttggatgcgaatatgtccgagagagaaagaagcgtggcaaagcttcgcgcaaggatatt gctgcccagcaagccgcggcggctgcagcacaacactccggccaggtccaggatggtccagaggatcaacatcgca aactctcacgccagcaaagcgaatcttcgcgtggcagcgctgagcttgcccagcctgcccacgacccgcctcatggcca cattgagggctctgtcagctccttcagcgacaatggcctttcccagcatgctgccatgggcggcatggatggcctggaaga tcaccatggccacgtcggagttgatcctgccctgggccgaactcagctggaagcgtcatcagcaatgggcctgggcgca tacggtgaagtccaccccggctatgagagccccggcatgaatggccatgtgatggtgcccccgtcgtatggcgcgcaga ccaccatggccgggtattccggtatctcgtatgctgcgcaagccccgagtccggctacgtatagcagcgacggtaactttc gactcaccggtcacatccatgattacccgctggcaaatgggagctcgccctcatggggagtctcgctggcctcgccttcga accagttccagcttcagctctcgcagcccatcttcaagcaaagcgatttgcgatatcctgtgcttgagcctctgctgcctcac ctgggaaacatcctccccgtgtctttggcgtgcgatctgattgacctgtacttctcctcgtcttcatcagcacagatgcaccca atgtccccatacgttctgggcttcgtcttccggaagcgctccttcttgcaccccacgaacccacgaaggtgccagcccgcg ctgcttgcgagcatgctgtgggtggcggcacagactagcgaagcgtccttcttgacgagcctgccgtcggcgaggagca aggtctgccagaagctgctcgagctgaccgttgggcttcttcagcccctgatccacaccggcaccaacagcccgtctccc aagactagccccgtcgtcggtgctgctgccctgggagttcttggggtggccatgccgggctcgctgaacatggattcactg gccggcgaaacgggtgcttttggggccatagggagccttgacgacgtcatcacctatgtgcacctcgccacggtcgtctc ggccagcgagtacaagggcgccagcctgcggtggtggggtgcggcatggtctctcgccagagagctcaagcttggccg tgagctgccgcctggcaatccacctgccaaccaggaggacggcgagggccttagcgaagacgtggatgagcacgact tgaacagaaacaacactcgcttcgtgacggaagaggagcgcgaagagcgacggcgagcatggtggctcgtttacatc gtcgacaggcacctggcgctctgctacaaccgccccttgtttcttctggacagcgagtgcagcgacttgtaccacccgatg gacgacatcaagtggcaggcaggcaaatttcgcagccacgatgcagggaactccagcatcaacatcgatagctccatg acggacgagtttggcgatagtccccgggcggctcgcggcgcacactacgagtgccgcggtcgtagcatttttggctacttc ttgtccttgatgacaatcctgggcgagattgtcgatgtccaccatgctaaaagccacccccggttcggcgttggattccgctc cgcgcgggattgggacgagcaggttgctgaaatcacccgacacctggacatgtatgaggagagcctcaagaggttcgt ggccaagcatctgccattgtcctcaaaggacaaggagcagcatgagatgcacgacagtggagcggtaacagacatgc aatctccactctcggtgcggaccaacgcgtccagccgcatgacggagagcgagatccaggccagcatcgtggtggctt acagcacccatgtgatgcatgtcctccacatcctccttgcggataagtgggatcccatcaaccttctagacgacgacgactt gtggatctcgtcggaaggattcgtgacggcgacgagccacgcggtatcggctgccgaagctattagccagattctcgagt ttgaccctggcctggagtttatgccattcttctacggcgtctatctcctgcagggttccttcctcctcctgctcatcgccgacaag ctgcaggccgaagcgtctccaagcgtcatcaaggcttgcgagaccattgttagggcacacgaagcttgcgttgtgacgct gagcacagagtatcaggtaagccctatcagttcaaacgtctatcttgctgtgaatcaaagactgacttggacatcagcgca actttagcaaggttatgcgaagcgcgctggctctgattcggggccgtgtgccggaagatttagctgagcagcagcagcga cgacgcgagcttcttgcactataccgatggactggtaacggaaccggtctggccctctaa

SEQ ID NO:90

U6 intron

GTTCGTTTCGGCTTTTCCTCGGAACCCCCAGAGGTCATCAGTTCGAATCGCTAACA G SEQ ID NO:91

U6 gene transcriptional terminator sequence TTTTTTTTCTCTT SEQ ID NO:92

Target Sequence for Pyr4 TS2 guide RNA GCTCAAGACGCACTACGACA

Claims

THAT WHICH IS CLAIMED:

1. A method for modifying the DNA sequence at a target site in the genome of a filamentous fungal cell, the method comprising:

a) introducing into a population of filamentous fungal cells a Cas

endonuclease and a guide RNA, wherein the Cas endonuclease and guide RNA are capable of forming a complex that enables the Cas endonuclease to introduce a double-strand break at a target site in the genome of the fungal cells; and

b) identifying at least one fungal cell from the population that has a modification of the DNA sequence at the target site,

wherein the Cas endonuclease, the guide RNA, or both are introduced transiently into the population of fungal cells.

2. The method of claim 1 , wherein the modification of the DNA sequence at said target site is selected from the group consisting of a deletion of one or more nucleotides, an insertion of one or more nucleotides, a substitution of one or more nucleotides, and any combination thereof.

3. The method of claim 1 or 2, wherein introducing the Cas endonuclease into the population of fungal cells is achieved using a method selected from the group consisting of transfection, transduction, transformation, electroporation, particle bombardment (biolistic particle delivery), and cell fusion techniques.

4. The method of any preceding claim, wherein introducing the guide RNA into the population of fungal cells is achieved using a method selected from the group consisting of transfection, transduction, transformation, electroporation, particle bombardment (biolistic particle delivery), and cell fusion techniques.

5. The method of any preceding claim, wherein the identifying step comprises culturing the population of fungal cells from step (a) under conditions to select for or screen for the modification of the DNA sequence at the target site.

6. The method of any preceding claim, wherein the identifying step comprises culturing the population of cells from step (a) under conditions to screen for unstable transformants.

7. The method of any preceding claim, wherein the Cas endonuclease is a Cas9 endonuclease or variant thereof.

8. The method of claim 7, wherein the Cas9 endonuclease or variant thereof comprises a full length Cas9 or a functional fragment thereof from a species selected from the group consisting of: Streptococcus sp., S. pyogenes, S. mutans, S.

thermophilus, Campylobacter sp., C. jejuni, Neisseria sp., N. meningitides, Francisella sp., F. novicida, and Pasteurella sp., P. multocida.

9. The method of claim 8, wherein the Cas9 endonuclease or variant thereof comprises an amino acid sequence that has at least 70% identity to any one of SEQ ID NOs:1 to 7.

10. The method of any preceding claim, wherein the introducing step comprises introducing a DNA construct comprising an expression cassette for the Cas

endonuclease into the fungal cells.

11. The method of any preceding claim, wherein the introducing step comprises introducing a DNA construct comprising an expression cassette for the guide RNA into the fungal cells.

12. The method of any one of claims 1 to 9 and 1 1 , wherein the introducing step comprises directly introducing the Cas endonuclease into the fungal cells.

13. The method of any one of claims 1 to 10 and 12, wherein the introducing step comprises directly introducing the guide RNA into the fungal cells.

14. The method of claim 10, wherein the expression cassette for the Cas

endonuclease comprises a Cas coding sequence that is optimized for expression in the fungal cell.

15. The method of claim 14, wherein the Cas coding sequence is a Cas9 coding sequence comprising a polynucleotide sequence that is at least 70% identical to SEQ ID NO:8.

16. The method of any preceding claim, wherein the Cas endonuclease is operably linked to a nuclear localization signal.

17. The method of claim 1 1 , wherein the expression cassette for the guide RNA comprises a RNA polymerase III dependent promoter functional in a Euascomycete or Pezizomycete, and wherein the promoter is operably linked to the DNA encoding the guide RNA.

18. The method of claim 17, wherein the promoter is derived from a Trichoderma U6 snRNA gene.

19. The method of claim 17 or 18, wherein the promoter comprises a nucleotide sequence with at least 70% identity to SEQ ID NO: 1 1 or 12.

20. The method of any one of claims 1 1 and 17-19, wherein the expression cassette for the guide RNA comprises a guide RNA-encoding DNA with an intron sequence from a Trichoderma U6 snRNA gene.

21. The method of claim 20, wherein the intron sequence derived from Trichoderma U6 snRNA gene comprises a nucleotide sequence with at least 70% identity to SEQ ID NO: 90.

22. The method of any preceding claim, wherein the filamentous fungal cell is a Eumycotina or Pezizomycotina fungal cell.

23. The method of any preceding claim, wherein filamentous fungal cell is selected from the group consisting of Trichoderma, Penicillium, Aspergillus, Humicola,

Chrysosporium, Fusarium, Myceliophthora, Neurospora, Hypocrea, and Emericella.

24. The method of any preceding claim, wherein the target site is located within a region of a gene of interest selected from the group consisting of: an open reading frame, a promoter, a regulatory sequence, a terminator sequence, a regulatory element sequence, a splice site, a coding sequence, a polyubiquitination site, an intron site, and an intron enhancing motif.

25. The method of any one of claims 1 , 2, 4-9, 1 1 , 1 3, and 1 6-1 9, wherein the introducing step comprises: (i) obtaining a parental fungal cell population that stably expresses the Cas endonuclease, and (ii) transiently introducing the guide RNA into the parental fungal cell population.

26. The method of any one of claims 1 -3, 5-1 0, 1 2, and 14-1 9, wherein the introducing step comprises: (i) obtaining a parental fungal cell population that stably expresses the guide RNA, and (ii) transiently introducing the Cas endonuclease into the parental fungal cell population.

27. The method of any preceding claim, wherein the modification of the DNA sequence at the target site is not caused by a homologous recombination.

28. The method of any preceding claim, wherein the method does not involve introducing a donor DNA into the population of fungal cells.

29. A recombinant fungal cell produced by the method of any preceding claim.

30. An engineered nucleic acid encoding a Cas endonuclease or variant thereof, wherein the Cas endonuclease or variant thereof comprises an amino acid sequence that has at least 70% identity to any one of SEQ ID NOs:1 to 7, and wherein the nucleic acid comprises a polynucleotide sequence that is at least 70% identical to SEQ ID NO:8.

31. An engineered nucleic acid encoding a guide RNA which enables a Cas endonuclease to introduce a double-strand break at a target site in the genome of a filamentous fungal cell, wherein the nucleic acid encoding the guide RNA comprises a RNA polymerase III dependent promoter functional in a Euascomycete or

Pezizomycete, and the promoter is derived from a Trichoderma U6 snRNA gene

32. The engineered nucleic acid of claim 31 , wherein the promoter comprises a nucleotide sequence with at least 70% identity to SEQ ID NO: 1 1 or 1 2.

33. An engineered nucleic acid encoding a guide RNA which enables a Cas endonuclease to introduce a double-strand break at a target site in the genome of a filamentous fungal cell, wherein the nucleic acid encoding the guide RNA comprises a guide RNA-encoding DNA with an intron sequence derived from a Trichoderma U6 snRNA gene.

34. The engineered nucleic acid of claim 33, wherein the intron sequence derived from Trichoderma U6 snRNA gene comprises a nucleotide sequence with at least 70% identity to SEQ ID NO: 90.

35. The engineered nucleic acid of claim 31 or 33, wherein the nucleic acid encoding the guide RNA comprises both a promoter derived from a Trichoderma U6 snRNA gene and an intron sequence derived from a Trichoderma U6 snRNA gene, wherein the promoter comprises a nucleotide sequence with at least 70% identity to SEQ ID NO: 1 1 or 1 2, and wherein the intron sequence derived from Trichoderma U6 snRNA gene comprises a nucleotide sequence with at least 70% identity to SEQ ID NO: 90.